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I. Abstract 
 
Environmental Enteric Dysfunction (EED) is a subclinical condition of the gut 
characterized by changes in gut morphology and function with underlying chronic 
inflammatory responses. EED affects more than two-thirds of young children 
living in low-income settings. EED has been linked with growth faltering in young 
children living in low-income settings, however, the mechanisms by which EED 
impacts growth are not well defined. A proposed pathway suggests that ingestion 
of enteric pathogens and toxins, through contaminated food and water, changes 
gut microbiota composition and function. This results in intestinal inflammation 
and changes in the intestinal epithelium structure.  
There is limited data examining the association between the gut microbiota and 
EED. The present work was nested in a cluster-randomized trial of mass drug 
administration of azithromycin and was carried out to characterize composition 
and diversity of the gut microbiota in rural Malawian children with and without 
signs of EED. The work also tested for associations between the gut microbiota 
and stunting. Proteins were extracted from fecal samples and used for the 
quantification, by ELISA, of neopterin, myeloperoxidase and alpha-1 antitrypsin, 
which are biomarkers of intestinal inflammation and permeability that have been 
proposed as potential proxies of EED. Concentrations of the three biomarkers 
were combined to form a proxy EED score using principal component analysis. 
Total genomic DNA was also extracted from the fecal samples for V4-16SrRNA 
sequencing and for species-specific PCR to determine intestinal carriage of 
bacteria that have previously been shown to be associated with growth in a 
mouse model. 
All three biomarkers decreased with age. Faecalibacterium prausnitzii and Dorea 
formicigenerans were prevalent in over 70% of children while Bifidobacterium 
longum was the least prevalent of the bacteria assayed. No associations were 
found between fecal biomarkers of EED or intestinal bacteria carriage and 
stunting, however, intestinal carriage of D. formicigenerans was associated with 
normal biomarker concentration. Increased fecal microbiota diversity was 
associated with a reduction in neopterin concentration. Increased abundance of 
Succinivibrio was associated with reduced EED scores. Mass treatment with 
azithromycin appeared to have no long-term impact on alpha diversity of fecal 
samples but was weakly associated with increased abundance of Prevotella at 
24-months follow-up. 
A negative correlation between age and the three biomarkers of EED was found 
and confirms trends shown in other children living in similar low-income settings. 
The association between D. formicigenerans and normal biomarker 
concentration suggests a potential beneficial role of the bacterium in gut health. 
An increase in microbiota diversity is potentially associated with reduced 
intestinal inflammation, but larger studies are needed to confirm this. The 
association between Succinivibrio and biomarkers of EED shown here is 
consistent with recent data from another study conducted in Malawi. Succinivibrio 
plays a role in fiber-degradation and metabolites of fiber-degradation have been 
shown to inhibit intestinal colonization by pathogenic bacteria, therefore, further 
studies are needed to investigate the significance of this bacterium in EED. Mass 
treatment with azithromycin may have long-lasting effects on the abundance of 
defined bacterial taxa but not overall microbiota diversity. 
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1. INTRODUCTION 
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1.1 Epidemiology of EED 
 
In recent years, nutritionists have paid more attention to environmental enteric 
dysfunction (EED), a subclinical condition, characterized by impaired nutrition 
and growth1. EED is a disorder of the small intestine characterized by partial villus 
atrophy, reduced absorptive capacity, increased small intestinal permeability and 
prominent inflammatory cell infiltration2,3. EED, formerly known as tropical 
enteropathy, was described in the 1960s after an unusual microscopic 
appearance of the small bowel was reported in adults from low-income countries4-
6 compared to that from apparently healthy adults from Western industrialized 
countries7. Available evidence suggests that EED is more prevalent in low-
income countries. A comparison of test results of intestinal permeability and 
absorptive capacity showed higher levels of intestinal permeability in individuals 
from low-income countries of South-East Asia and Africa compared to high-
income countries of Europe8. EED is acquired during infancy and may persist into 
adulthood however evidence suggests that it is reversible. Expatriates who had 
EED whilst living abroad in India or Pakistan resolved the signs of this condition 
after they emigrated to high income settings9. Similarly, Indians and Pakistanis 
with EED indicators who had moved to the USA showed significant improvements 
in these indicators with increasing periods of residence10. EED continues to be 
prevalent in low and middle-income countries where malnutrition and stunting 
(impaired linear growth) are more prevalent11. In Malawi, approximately two-
thirds of children between 3 and 5 years of age have markedly high intestinal 
permeability typical of EED12. 
 
1.2 EED pathology 
 
The specific cause of EED is still unclear, however, nutrition, enteric pathogens, 
enteric toxins, and the gut microbiome13,14 are some of the factors associated 
with the etiology of EED. The pathogenesis of EED has been linked with ingestion 
of fecal-contaminated food and water as a result of poor sanitary conditions. High 
levels of enteric pathogens found in contaminated food stuffs and toxins produced 
by the ingested microbes can trigger T-cell hyperstimulation resulting in structural 
changes in the intestinal epithelium, which include villus atrophy, crypt 
hyperplasia and increased permeability15-17. These changes in the intestinal 
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epithelium result in malabsorption as shorter villi and deep crypts have fewer 
absorptive cells18. 
 
EED does not have immediate symptoms, nor does it have a commonly accepted 
case definition. Current definitions of EED are based on morphology (short, fused 
expanded villi compared to long slender villi in healthy subjects as shown in 
Figure 1.1.1), gut function based on biochemical tests such as the dual sugar 
intestinal permeability test19, and epithelial architecture (defects in cell adhesion 
that include loss of tight junctions and intestinal permeability).  
 
 
 
Figure 1.1.1 An illustration of the histological appearance of the small intestinal 
mucosa of individuals with or without EED. (A) shows an abnormal EE crypt to villus 
ratio (B) shows a normal crypt to villus ratio (Figure taken from McKay et al14). 
 
Confirmation of a diagnosis of EED requires evidence of the histological features 
of EED in the small intestine, which can be gained by endoscopy or biopsy. These 
are invasive tests that have many logistical challenges and may not be 
considered ethical in asymptomatic participants. The non-invasive dual sugar 
absorption challenge test is therefore more commonly used to diagnose EED. 
The test involves challenging a subject, after a period of fasting, with a solution 
that has a known concentration of lactulose and mannitol 19,20. Lactulose is a large 
sugar that is not normally absorbed by the small intestine while mannitol is a 
smaller sugar that is absorbed by the small intestine in proportion to absorptive 
surface area. Both sugars are excreted in urine a few hours after ingestion without 
being metabolized. As such, urinary mannitol measures absorptive capacity 
whereas urinary lactulose measures diminished barrier function. Thus, high 
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urinary lactulose to mannitol (L:M) ratios are an indication of diminished gut 
barrier function. 
1.3 Exposures associated with EED etiology 
1.3.1 Nutrition 
 
Intestinal luminal nutrients play a critical role in the maintenance of the 
morphology and function of intestinal epithelial cells. Both animal and human 
studies have demonstrated the importance of micronutrients in the proliferation 
and differentiation of intestinal epithelial cells, which is fundamental to the 
maintenance of their structure and function. As an example, dietary 
supplementation of arginine and glutamine was associated with improved 
intestinal mucosa development of weaned piglets21. Similarly, a high protein diet 
has been shown to upregulate expression of genes involved in cell proliferation 
and chemical barrier function in rats22. Also, zinc deficiency was found to 
compromise digestive capacity of weaned piglets23. In humans, zinc deficiency 
was associated with increased intestinal permeability,24 which is one of the 
characteristics of EED, and treatment with zinc was associated with lower L:M 
ratios25. In brief, these findings suggest that a lack of essential nutrients can lead 
to impairment of intestinal epithelial function and morphology. Thus, EED may 
cause nutrient deficiency through inefficient absorption and this may reduce the 
capability for the intestinal lining to be well maintained, thereby exacerbating 
EED.    
 
In contrast, there is evidence suggesting that iron supplementation can put one 
at greater risk of developing EED. A study in Kenya reported that iron 
supplementation to weaning infants increased the abundance of pathogenic 
bacteria and also induced intestinal inflammation26. In this study, fecal samples 
were collected from infants at baseline, 3 weeks and 4 months after iron 
supplementation. Fecal calprotectin, a biomarker of intestinal inflammation, was 
measured and pyrosequencing was used to characterize the gut microbiota. 
Pyrosequencing showed a significantly higher abundance of Clostridium and 
Escherichia/Shigella and a trend towards lower abundance of genus 
Bifidobacterium in infants with iron supplementation compared to infants without 
iron supplementation at 4-months follow-up. Additionally, infants who received 
iron supplementation had significantly higher levels of fecal calprotectin 
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compared to infants without iron supplementation at 4 months of follow up. 
Calprotectin is a dimer of calcium binding proteins that accounts for 60% of 
soluble protein content of the neutrophil cytosol, it is therefore considered a 
marker of neutrophil influx. Neutrophils are first-line responders to acute-phase 
inflammation caused by bacterial infection; high fecal levels of calprotectin 
therefore indicate intestinal inflammation. Taken together, these results suggest 
a bidirectional relationship between nutrients and EED.  
1.3.2 The contaminated environment 
 
There is evidence implicating microorganisms, including parasites, bacteria and 
viruses, in the etiology of EED. Over a decade ago, the parasite Giardia 
duodenalis was associated with elevated L:M ratios in Nepali infants27 and 
Giardia-specific IgM antibody titers were positively associated with L:M ratios in 
Gambian infants28. Similarly, rotavirus infection has been associated with 
increased L:M ratios in Peruvian children29 and infection with the bacterium 
Citrobacter rodentium has been associated with reduced villous height seen in 
jejunal biopsies taken from Zambian adults30.  Enteroaggregative Escherichia coli 
(EAggEC) infection without diarrhea in Brazilian children has been associated 
with increased fecal lactoferrin, IL-8, and IL-1b31. Fecal lactoferrin, also used as 
a marker of intestinal inflammation, and IL-1b, a pro-inflammatory cytokine, have 
been associated with an increase in intestinal epithelium tight junction 
permeability32. Also, in vitro studies have associated Campylobacter jejuni, a 
common cause of human bacterial enteritis, with disruption of tight junctions 
leading to loss of intestinal epithelial barrier function33.  
1.4 The EED pathway and its links to growth faltering 
 
Stunting is very common in Sub-Saharan Africa and elsewhere in low-income 
countries. It is defined as having a height-for-age Z (HAZ) score more than two 
standard deviations below the World Health Organization (WHO) child growth 
standard median34. Worldwide patterns indicate that HAZ scores fall dramatically 
6 months after birth until 2 years of age in a high proportion of children in low-
income countries35. It is estimated that nearly 167 million under-5-year old 
children in low-income countries are stunted36. Being stunted has been 
associated with hindered developmental potential, childhood mortality and 
morbidity37,38. Associations between being stunted in the early years of life and 
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cognitive performance have also been reported. In Zimbabwean pre-school 
children, improvements in HAZ scores were associated with increased grade 
score and early enrollment in school39. Likewise, HAZ scores were positively 
associated with good performance in school40. Stunting therefore represents a 
significant public health concern and as such, its management and prevention 
have become a WHO global health target in recent years41.  
 
Stunting is a cumulative process that can start in utero and continue during the 
first 2 years of life. Various factors contribute to stunting in utero and during the 
early years of life. Maternal undernourishment during pregnancy, maternal short 
stature, inadequate dietary intake, enteric infections and exposure to aflatoxins 
are some of the known factors that contribute to stunting (Table 1.4.1). While it 
has been suggested that poor nutrient intake contributes to stunting, fortification 
of complementary foods with micronutrients has largely failed to enhance linear 
growth or prevent childhood stunting42-45, which has triggered interest to 
investigate other causes of growth faltering.  
 
There is a growing belief that EED may be responsible for some measure of 
growth faltering but the specific mechanism by which this occurs has not been 
clearly identified. Nutrition, microbes and toxins are some of the suggested key 
exposures in EED etiology and subsequent growth faltering, however, their role 
in EED remains unclear. Lunn proposed a causal pathway linking EED to growth 
faltering46. According to Lunn’s proposition, increased consumption of microbial 
pathogens through poor hygiene and sanitation leads to chronic activation of 
mucosal immunity resulting in intestinal damage and increased permeability. This 
in turn leads to the translocation of bacteria or bacterial antigens across the 
intestinal epithelium causing chronic immune activation and the repartitioning of 
nutrients away from growth towards increased synthesis of antibodies, acute-
phase proteins and cytokines. Prendergast and colleagues recently expanded 
this model by suggesting that the ingested microbes change the composition and 
function of the gut microbiota resulting in dysbiosis that triggers intestinal 
inflammation leading to subsequent villus atrophy and impaired enterocyte tight 
junctions that allow microbial translocation (Figure 1.4.1)47. The presence of 
mucosal and systemic inflammation in EED has been supported by recent 
evidence from a Malawian study characterizing the fecal transcriptome of children 
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where the L:M ratio test was used to indicate EED48. In this study, total RNA was 
extracted from human cell-enriched fecal samples and thereafter assayed by 
high-density microarray. The study identified 51 transcripts associated with EED, 
which were mapped to pathways related to inflammation and cell adhesion. The 
study also highlighted several immune responses associated with intestinal 
mucosa damage and upregulation of epithelial tissue repair among others. 
Intestinal mucosa damage, as a result of chronic inflammation, may expose 
intestinal microbes to pattern recognition receptors (PRRs) thereby inducing 
innate immune responses49 that lead to the secretion of acute phase proteins and 
pro-inflammatory cytokines, which have been shown to suppress growth50. A 
study in a mouse model in the late 1990s found a negative correlation between 
insulin growth factor 1 (IGF-1) and the pro-inflammatory cytokine, IL-651. IGF-1 is 
a hormone that mediates growth hormone (GH)-stimulated somatic growth as 
well as GH-independent anabolic responses in many cells and tissues. Similarly, 
a recent study in Zimbabwean infants identified an association between low grade 
chronic inflammation and suppression of IGF-1 levels where levels of acute 
phase proteins (CRP and AGP) were higher and IGF-1 levels were lower in 
stunted infants throughout the first year of life52. These findings therefore suggest 
that elevated levels of proinflammatory cytokines suppress growth. In EED, 
innate immune responses are not the only important immunological responses; 
adaptive immune responses are also impacted. T-cell activation, indicated by 
increased expression of CD3+CD69+, CD3+HLA-DR+ and CD25+ T-cells, is the 
most apparent adaptive immune response documented in EED and has been 
associated with crypt hyperplasia, villous atrophy and mucosal damage3,15.  
 
The above evidence therefore suggests that intestinal inflammation, intestinal 
damage and systemic inflammation are some of the key features in EED. 
However, available evidence on the links between these key features of EED and 
growth faltering is mixed. One multi-site, longitudinal study that assessed the 
relationship between biomarkers of intestinal inflammation, intestinal permeability 
and linear growth in infants living in low-income settings of South Asia, Sub-
Saharan Africa and Latin America showed that high levels of these biomarkers 
predicted a decline in infant’s length-for-age z (LAZ) scores 6 months after the 
tests53. Similarly, a recent case-control study examining the link between 
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potential biomarkers of EED and subsequent growth impairment in rural Brazilian 
children aged between 6-26 months showed an association between higher 
levels of fecal biomarkers of intestinal inflammation, intestinal permeability and 
growth faltering54. This study reported a significant relationship between high 
levels of these biomarkers at baseline and poor HAZ scores in the subsequent 2-
6 months of follow-up. However, other studies conducted in similar settings have 
not shown associations between similar fecal biomarkers of intestinal 
inflammation, intestinal permeability and growth faltering55,56. A case-control 
study conducted in Zimbabwean infants that explored associations between 
plasma biomarkers of intestinal damage (intestinal fatty acid binding protein [I-
FABP]), microbial translocation (soluble CD14 and IgG EndoCAb) and stunting 
showed no differences in the plasma levels of I-FABP, secretory CD14 and IgG 
EndoCAb between stunted and non-stunted infants52. Similarly, Lin et al did not 
find an association between microbial translocation, indicated by plasma IgG 
EndoCAb, and HAZ scores14. In brief, some of the published data supports the 
associations between intestinal inflammation and growth faltering53,54, between 
systemic inflammation and growth faltering57,58and between gut bacterial 
community structure and intestinal permeability59 but, the available data is 
conflicting and therefore not sufficient to make any firm associations between 
EED and growth faltering. One of the reasons for the discrepancies in the 
published data could be the differences in the study designs. Longitudinal studies 
have more often reported significant associations between biomarkers of EED 
and growth faltering than cross-sectional studies53,55-57,60. 
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Table 1.4.1 Factors associated with stunting 
 
Author Objective Study design Findings 
Victora et al. 200837 
 
 
 
 
 
 
 
 
To assess the long-term effects of 
undernutrition on adult human capital, 
including height, school achievement, 
economic productivity, and birthweight 
of the offspring 
 
 
 
 
 
 
 
Meta-analysis review of 5 
prospective cohort studies from 
Brazil, India, The Philippines, 
Guatemala and South Africa   
 
 
 
 Maternal height was positively associated 
with adult offspring height 
 Maternal undernutrition during pregnancy 
was associated with lower birthweight 
 Maternal intrauterine growth restriction was 
associated with reduction in birthweight 
 
 
 
 
 
 
Umeta et al. 200361 
 
 
 
 
 
 
 
To estimate the prevalence of 
malnutrition and identify factors 
associated with stunting 
 
 
 
 
Cross-sectional study of breast-
fed Ethiopian infants aged 5-11 
months 
 
 
 
 
 
 Infants of mothers with low concentrations of 
zinc in their breastmilk were more likely to 
be stunted 
 
  Assis et al. 2004
62 
 
 
 
 
 
To evaluate the relationship between 
stunting, Schistosoma mansoni 
infection and dietary intake in 
schoolchildren 
 
 
Cross-sectional study of 
Brazilian schoolchildren 
 
 
 
  
 Children heavily infected with S. mansoni 
had a higher risk of stunting than uninfected 
children 
 Children with inadequate intake of lipid had 
an increased risk of stunting compared to 
those with adequate diets 
Gong et al. 200463 
 
 
 
 
 
To assess the effects of aflatoxin 
exposure on growth 
 
 
 
 
 
Longitudinal study of 16-37 
months West-African children 
who were residents of villages 
with low or high aflatoxin 
exposure. The children were 
followed up over an 8-month 
period 
 Higher aflatoxin exposure was associated 
with height retardation over the 8-month 
follow-up period 
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Figure 1.4.1 The proposed EED pathway. (Figure adapted from Prendergast et al.34) 
1.5 The gut microbiota 
1.5.1 Development of the gut microbiota 
 
Human gut microbial colonization starts at birth and continues to change in 
species abundance during the breastfeeding period up until the end of 
complimentary feeding when the microbiota is more adult-like64. Gut microbiota 
composition in infants is influenced by several factors including mode of delivery 
(vaginal versus caesarian section), breast milk composition, dietary diversity, the 
environment, and the immune system65-67. Available evidence reveals how 
breastfeeding in infancy influences the composition of an infant’s gut microbiota. 
A study by Bezirtzoglou and colleagues in Greek infants showed breastfed infants 
to have a more uniform gut microbiota dominated by Bifidobacteria and 
Lactobacillus compared to formula fed infants66. Similarly, Lee et al. reported 
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higher relative abundance of Bifidobacterium in breastfed Korean infants 
compared to formula fed infants while the phyla Firmicutes and Proteobacteria 
were found to be in higher in abundance in fecal samples of formula-fed infants 
compared to breastfed infants. Another study that compared fecal microbiota 
composition of exclusively breastfed and formula-fed Dutch infants reported 
higher abundance of C. difficile and B. fragilis group in exclusively formula-fed 
infants. Nonetheless, the infant’s gut microbiota is less stable and less diverse 
compared to that of an adult, which is dominated by Firmicutes, Bacteroidetes 
and Actinobacteria64. A study by Odamaki et al. reported an increase in gut 
microbiota diversity with increasing age that continued sequentially until one’s 
twenties when it stabilized68. 
1.5.2 The gut microbiota and intestinal health 
 
In their reviews, Flint et al. and Hooper et al. state that the gut microbiota plays a 
crucial role in nutrient utilization, immune development, and maintenance of the 
intestinal structure and function69,70. Flint et al. state that fermentation of 
nondigestible dietary carbohydrates by the gut microbiota produces short-chain 
fatty acids (SCFAs), which contribute to the host’s energy intake and expenditure 
thereby maintaining energy balance. SCFAs, which include acetate, butyrate and 
propionate, also have several biological effects on the host as reported by in vitro 
and in vivo studies detailed below. A study conducted in a mouse model to 
understand molecular mechanisms underlying the modulation of host defense 
responses and protection against enteric pathogens by commensal bacteria 
reported an association between an increase in the production of acetate by 
certain Bifidobacterium species and inhibition of an enterohemorrhagic E. coli 
toxin. This effect was mediated by a carbohydrate transporter that was present 
in certain Bifidobacterium strains71. In an in vitro study using an epithelial cell 
line, treatment of the cells with butyrate was shown to accelerate the assembly 
of tight junctions72. These findings indicate a potential role of the gut microbiota 
in preventing colonization by enteric pathogens thereby maintaining gut 
integrity.  
 
In addition to playing a role in carbohydrate metabolism, gut bacteria also 
degrade mucins. Mucins are the main structural component of the intestinal 
protective layer of mucus that also offers attachment sites to intestinal bacteria. 
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Additionally, mucins are an important source of carbon for the intestinal bacteria 
at the distal colon, which is made available through mucin degradation by 
proteolytic enzymes from the host and commensal bacteria. As demonstrated by 
in vivo and in vitro studies, the degradation or absence of mucin results in the 
loss of the barrier function of the intestinal epithelium73. There is emerging 
evidence linking a recently discovered gram-negative mucin-degrading 
bacterium, Akkermensia muciniphila, to gut health. A. muciniphila is thought to 
colonize the intestinal tract early in life with increased abundance within the first 
year of life, accounting for approximately 1 to 3% of the total microbiota74. Since 
mucin degradation can result in the loss of the barrier function of the intestinal 
epithelium, the role of A. muciniphila in mucin degradation and its abundance in 
the human intestine warrant further studies. 
1.5.3 The gut microbiota and growth 
 
Certain gut microbiota profiles have also been associated with growth 
phenotypes. A study in Malawi that compared the gut microbiota of mice 
transplanted with fecal samples from malnourished children to that of mice 
transplanted with fecal samples from healthy children reported differences in gut 
microbiota composition between the two groups75. A week before transplantation, 
the mice were fed a sterilized pseudo rural Malawian diet. After fecal 
transplantation, the mice stayed on the pseudo Malawi diet for 3 weeks and then 
switched to ready-to-use therapeutic food (RUTF), usually given to 
undernourished children, for 2 weeks. The mice were switched back to the 
pseudo Malawian diet after 2 weeks on the RUTF. Mice that harbored fecal 
samples from malnourished children had higher proportions of Bilophila 
wadsworthia and Clostridium innocuum compared to mice that were transplanted 
with fecal samples from their healthy siblings. Prominent increases in the 
abundance of Bifidobacterium (B. longum and B. bifidum) and Ruminococcus (R. 
torques and Faecalibacterium prausinitzii) were also reported in mice that were 
transplanted with fecal samples from malnourished children compared to 
recipients of fecal samples from healthy co-twins. The study also reported a 
reduction in weight within 20 days after fecal transplantation in mice that were 
transplanted with fecal samples from malnourished twins compared to mice that 
were transplanted with fecal samples from their healthy co-twins. Another 
corresponding study reported a causal relationship between gut microbiota 
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maturity and growth phenotypes in a mouse model76. In this study, mice were put 
on a sterile, pseudo rural Malawian diet, 3 days before fecal transplantation and 
remained on that diet throughout the study. Mice that were transplanted with fecal 
samples from healthy Malawian children gained more total body weight and lean 
mass than mice colonized with microbiota from undernourished children. 
Additionally, the study also identified specific bacteria associated with weight gain 
in mice, which included Bifidobacterium longum, Faecalibacterium prausinitzii 
and Dorea formicigenerans. The above results from the murine studies indicate 
an association between a weight loss phenotype and the gut microbiota, which 
was contingent on the pseudo Malawian diet and the use of germ-free mice. 
Another study, conducted in Bangladeshi children, that characterized the gut 
microbiota composition of healthy and malnourished children reported a higher 
abundance of Proteobacteria (which includes pathogenic genera like Klebsiella 
and Escherichia) in malnourished children compared to healthy children while 
Bacteroidetes was found to be less abundant in the malnourished children77. 
These findings indicate the potential role of gut microbiota in growth and warrant 
further studies to investigate the links between carriage of certain bacteria and 
growth in the human population.  
1.5.4 Exposures that affect gut microbiota composition 
 
Living in unsanitary and unhygienic conditions puts children at a risk of ingesting 
fecal-associated bacteria and microbial toxins. These may be ingested as 
children play or via contaminated food78. Recently, enteropathogen burden has 
been positively associated with higher L:M ratios79. It has been hypothesized that 
the ingested bacteria may affect intestinal bacterial composition resulting in a 
pathological shift in the microbiota composition and function in the small 
intestine80. 
1.5.5 Associations between the gut microbiota and EED 
 
There is limited data suggesting associations between changes in the gut 
microbiota composition and EED. A recent study that was done in rural Malawian 
children to identify the gut bacterial community structure associated with intestinal 
permeability, measured by the L:M ratio test, reported differences in fecal 
microbiota composition between children with higher and lower L:M ratios59. At 
phylum level, the study found a significant reduction in Proteobacteria in children 
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with higher L:M ratios. At genus level, Megasphaera, Mitsuokella, 
and Sutterella were found to be more prevalent in children with higher L:M ratios 
while Succinivibrio, Klebsiella, and Clostridium_XI were found to be less 
prevalent in children with higher L:M ratios. These results indicate potential 
associations between the gut microbiota and intestinal permeability.  
1.6 Potential targets for EED interventions  
 
Interventions that may reduce or prevent EED have recently been outlined in a 
review by McKay et al.81. In this review, the authors suggest possible 
interventions that could be used to target the various steps in the EED pathway 
leading to growth faltering, summarized in Figure 1.6.1 below.  
 
Figure 1.6.1 Schematic showing EED pathway steps that can be targeted by 
various interventions. Adapted from McKay et al.81 (A) Better sanitary conditions and 
hygiene, (B) Nutrition aimed at maintaining the integrity of the intestinal epithelium, (C) 
Nutrition aimed at enhancing immune activity, (D) Enhancement of digestion and 
absorption, (E) Provision of anti-inflammatory drugs/agents to supplement the present 
anti-inflammatory processes.  
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As chronic exposure to fecal pathogens is one of the initial steps in EED etiology, 
interruption of the fecal-oral pathogen transmission route may be critical in 
preventing EED. Promotion of breastfeeding in infants, expansion of vaccine 
coverage by developing new vaccines for enteropathogens, improvement of 
sanitation and consumption of hygienic food and clean water are some of the 
suggested ways to interrupt the fecal-oral route82. 
 
In EED, chronic intestinal responses to enteric pathogens damage the intestinal 
epithelium thereby impairing gut function. Therefore, nutritional interventions 
aimed at aiding enterocyte regeneration might help maintain mucosal integrity 
eventually improving intestinal absorptive capacity. Vitamin A and zinc have 
potential to improve gut integrity of children living in resource limited settings83,84 
whilst some amino acids have been linked with increased mucin synthesis in 
infants85. As such, these nutrients would be viable intervention options for 
targeted nutrition to improve gut integrity. Targeted nutritional interventions in 
EED may also help replenish nutrients that are repartitioned towards immune 
responses. As an example, intestinal mucosal immune responses involve 
utilization of amino acids86. Therefore, targeted nutritional interventions using 
proteins would replenish these amino acids as well as help in enterocyte 
regeneration thereby maintaining gut integrity. Moreover, supplementation of 
amino acids has been shown to improve intestinal mucosa development in 
animals21. Villus atrophy and crypt hyperplasia that occur in EED are associated 
with impaired intestinal absorptive capacity as a result of loss of digestive 
enzymes and presence of fewer absorptive cells. Malabsorption may result in 
reduced availability of nutrients essential for growth. Provision of pre-digested 
foods, for instance by fermenting raw materials, and supplementation of foods 
with digestive enzymes are some of the measures proposed to improve the 
digestion and absorption of nutrients in EED as some of these methods seem to 
work in animals81. Supplementation of feed with organic acids has been shown 
to increase villi length in growing pigs thereby improving nutrient absorption87.  
 
The gut microbiota is one other important aspect of EED etiology. It has been 
suggested that altered gut microbiota composition may impair metabolism of 
dietary components76. Inefficiency in metabolism of dietary components and an 
imbalance in mucosal immune responses can affect gut integrity. Since diet has 
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been shown to shape the gut microbiota88, nutritional interventions that could 
promote/support a beneficial gut microbiota profile, such as Bifidobacterium and 
Faecalibacterium that have been associated with good growth in mouse 
models75,76, may help maintain gut integrity. 
 
Intestinal and systemic inflammation are the most prominent features seen in 
EED and have been associated with growth faltering53,58. One possible 
explanation for the link between inflammation and growth faltering is that during 
inflammation more nutrients are directed towards sustaining inflammatory 
responses leaving inadequate nutrients available for growth and other body 
processes. The other explanation is that inflammation directly suppresses growth 
hormones as indicated by studies, described above, that found a negative 
relationship between pro-inflammatory cytokine51, acute phase proteins52 and 
IGF-1. Hence, use of anti-inflammatory agents/drugs has been suggested as a 
feasible intervention in EED. 
1.7 Tested EED interventions 
1.7.1 Water, sanitation and hygiene (WASH) 
 
There is growing interest in how WASH interventions might support strategies to 
reduce EED and stunting in affected settings. Drawing from evidence reported by 
animals studies89,90, Mbuya and Humphrey suggest that improving hygiene and 
sanitation plus ensuring a clean infant feeding and play environment may 
interrupt specific pathways through which feco-oral transmission occurs in the 
first two years of life91.   
 
There are several interventional studies currently going on in sub-saharan Africa 
(Kenya, Tanzania, South Africa and Zimbabwe), parts of Asia (Bangladesh, India, 
Nepal and Pakistan) and South America (Brazil and Peru) aimed at identifying 
the contributions of WASH interventions to EED and infant growth and also 
assessing the sustainability of the implemented practices92-94. Results from these 
studies are expected to give a better understanding of the benefits of WASH 
interventions aimed at reducing both EED and stunting. A study in Kenya that 
assessed the impact of WASH interventions, directed to mothers, on diarrhoea 
and linear growth in their children found no association between WASH and linear 
growth95. Similarly, WASH interventions did not prevent enteric infections in rural 
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Zimbabwean infants96. These results highlight the need for more alternative 
intensive approaches when implementing WASH interventions to successfully 
interrupt the fecal-oral route. 
1.7.2 Targeted nutrition 
 
There have been many studies of nutrition and stunting reported but few of 
nutrition and EED81. However, the few studies done on nutrition and EED have 
reported mixed results. A study done in malnourished Brazilian children aged 2 
to 60 months reported slight improvements in L:M ratios at 10 days follow-up in 
children who received formula supplemented with glutamine or glycine for 10 
days compared to children who received non-supplemented formula97. Another 
study investigating the impact of nutrient supplementation, coupled with an 
anthelminthic, on EED in rural Malawian children reported no impact98. In this 
study, Malawian children aged 12 to 35 months received a placebo or a single 
dose of albendazole at enrollment, a daily dose of zinc for 14 days and multiple 
micronutrient supplement for 24 weeks. L:M ratios were then measured in urine 
collected at 12-and-24 weeks of follow up. The study reported no differences in 
L:M ratios at either follow up visit and called for alternative interventions. 
Currently, clinical trials evaluating the effect of common beans or cowpeas on gut 
barrier function and growth are being implemented in Malawi99. These trials will 
administer pre-processed legumes to enhance their digestion and absorption and 
the results are expected to elucidate the potential of these two commonly grown 
grain legumes on gut health and growth in children at risk of developing EED.  
1.7.3 Anti-inflammatory agents 
Available evidence supporting the association between gut inflammation and 
growth faltering53,54 has triggered research into the use of anti-inflammatory 
agents as a remedy for EED. A trial of stunted Kenyan children with severe acute 
malnutrion (SAM) tested the role of an anti-inflammatory agent on EED and child 
growth. In this trial, children were assigned to treatment with mesalazine or 
placebo for 28 days and HAZ scores were calculated at baseline, 28 days and 56 
days of follow-up. EED was indicated by biomarkers of intestinal inflammation 
(fecal calprotectin), bacterial translocation (endotoxin) and systemic inflammation 
(C-reactive protein [CRP]). There were no differences in linear growth between 
the two groups at 28 days or 56 days of follow-up, however, baseline 
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concentrations of Insulin-like growth factor-1 (IGF-1) had a strong negative 
correlation with CRP. This became less apparent in the mesalazine group at later 
time points suggesting that mesalazine had achieved modest reductions in 
CRP60. Although children were not followed up for an extended period of time in 
this study, the finding still warrants further investigations of gut specific 
immunomodulatory therapies targeted at chronic immune activation in order to 
address EED and stunting. 
1.7.4 Antibiotics 
Early studies comparing animals given prophylactic antibiotics in their feed 
versus untreated animals reported growth-promoting effects of antibiotics100-102. 
Recent evidence gathered by meta-analysis and systematic review of 
randomized clinical trials suggests that prophylactic antibiotics and antibiotics 
given for infection have growth promoting effects in pre-pubertal children living in 
low-income countries, although the effect is more pronounced for weight than it 
is for linear growth103. Additionally, the prescription of antibiotics for infection in 
infants living in low-income settings of South Asia, sub-Saharan Africa and Latin 
America has been reported to increase weight in the early years of human life104. 
Infants treated with antibiotics in the first 6 months of life had higher weight-for-
age z (WAZ) score from 6 to 24 months compared to untreated children in a 24-
month follow-up period. The specific mechanism(s) by which antibiotics promote 
growth is/are not clearly established. One hypothesis is that antibiotics mediate 
growth by clearing enteric pathogens or by modulation of the intestinal 
microbiota105,106. However, studies looking at the impact of antibiotics on 
biomarkers of EED have reported mixed results. A study in a rat model reported 
a reduction in intestinal bacterial load and a change in intestinal microbial profile 
followed by reduction in mucosal inflammation after 10 days of treatment with 
rifaximin107. In humans, short treatment with rifaximin did not improve L:M ratios 
in children with EED108. Grassly et al., recently reported that short term treatment 
with azithromycin aimed at improving immunogenicity of oral polio vaccine 
significantly reduced fecal biomarkers of EED109. In this study, infants were 
randomized to receive a 3-day treatment with azithromycin or placebo and fecal 
levels of myeloperoxidase, calprotectin, neopterin and alpha-1 antitrypsin were 
quantified at baseline and 14 days after treatment in both groups. The prevalence 
of enteric pathogens was also determined at baseline and at 14 days after 
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treatment in the intervention and placebo groups. The study reported significant 
decreases in fecal levels of myeloperoxidase, alpha-1 antitrypsin and calprotectin 
in azithromycin treated infants. Significant reductions in the prevalence of 
Enteroaggregative, enteropathogenic, and shiga-toxin-producing Escherichia coli 
and Campylobacter were found in the azithromycin group compared to the 
placebo group 14 days after treatment, which correlated with the reduction in the 
fecal biomarkers. Whether or not these effects persist for a longer time period is 
not known. 
1.8 The potential role of azithromycin treatment on child health 
 
Azithromycin is a broad spectrum, macrolide antibiotic characterized by a long 
intra- and extra-cellular half-life. Its use is indicated in the treatment of atypical 
pneumonia, skin and soft tissue infections and sexually transmitted infections110. 
Mass azithromycin treatment at the community level is a corner-stone of the 
WHO-recommended strategy for control of ocular infection with the intracellular 
bacterium Chlamydia trachomatis, the etiological agent of trachoma111. Available 
evidence from studies of mass azithromycin distribution (MDA) for trachoma 
control in trachoma endemic areas indicates that mass azithromycin treatment 
could have secondary effects, which include reductions of child morbidity and 
mortality112-114. In The Gambia, azithromycin MDA for trachoma was shown to 
have favorable short-term effects on childhood morbidity, including diarrheal 
disease, in rural areas115 whilst in Tanzania, reduced risks of diarrhea and acute 
lower respiratory infections related to azithromycin MDA for trachoma control 
were reported in young children113,116. A study in Ethiopian children between 1 
and 9 years of age showed an association between MDA of azithromycin for 
trachoma control and reduced mortality114. In this study, childhood mortality was 
reduced in communities that received azithromycin compared to control 
communities. Interest in these results led to a multi-site trial, conducted in Malawi, 
Tanzania and Niger, which most recently reported lower mortality rates in children 
under 5 years of age living in low-income settings who received mass 
azithromycin treatment compared to recipients of a placebo117. The study 
reported a 6% lower mortality rate in Malawian children who received 
azithromycin compared with placebo, 18% lower mortality rate in Niger children 
who received azithromycin compared to placebo recipients, and 3% lower 
mortality rate in Tanzanian children who received azithromycin compared to 
Page | 37 
 
placebo recipients. The specific mechanism through which azithromycin reduced 
mortality in children is not understood, however, available evidence suggests that 
prolonged mass azithromycin distribution can affect carriage of pathogenic 
bacteria. For example, azithromycin MDA reduces the abundance of 
Campylobacter spp. in the gut118 and reduces the community burden of 
nasopharyngeal carriage of Streptococcus pneumoniae119. 
 
Azithromycin has both antibacterial and immunomodulatory properties and as 
such azithromycin treatment may provide insight into the etiology of EDD. 
Inhibition of protein synthesis, disruption of bacterial quorum sensing120,121 and 
interruption of adherence to host cells122,123 are the main antimicrobial 
mechanisms of azithromycin while modulation of the nuclear factor kappa B (NF-
κB) pathway is the main immunomodulatory mechanism124,125. The NF-κB 
pathway regulates pro-inflammatory responses among other functions. A recent 
study that investigated the effect of one round of mass oral azithromycin 
treatment on conjunctival immune responses in 6 to 10 year old Tanzanian 
children reported a downregulation of pro-inflammatory cytokines and 
chemokines 3 months after treatment underscoring the immunomodulatory 
effects of azithromycin126. There is also evidence on the impact of the 
antimicrobial effect of azithromycin on the gut microbiota. In the clinical trial of 
azithromycin by Grassly and colleagues described above109, the gut microbiota 
was characterized at baseline and 14 days post-treatment in fecal samples from 
infants who were randomized to a 3-day course of azithromycin or placebo. The 
study reported a reduction in microbiota richness, a reduction in relative 
abundance of phyla Proteobacteria and Verrucomicrobia and a reduced risk of 
colonization by E. coli and Campylobacter in azithromycin treated infants. 
Another study that investigated the impact of macrolide (azithromycin or 
clarithromycin) use in early childhood reported that the antimicrobial effect on the 
microbiota is long lasting127. The study characterized the fecal microbiota in fecal 
samples collected from Finnish children aged between 2-7 years, which were 
grouped according to antibiotic use as follows: children who had not used 
antibiotics for at least 2 years but had used antibiotics frequently during early life, 
children who had used macrolide antibiotics within 6 months of sample donation, 
children who had used macrolide antibiotics within 6–12 months of sample 
donation, children who had used macrolide antibiotics within 12–24 months of 
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sample donation and children who had not used antibiotics for a period of more 
than 2 years in addition to limited antibiotic use in the early years of life (control 
samples). Here a reduction in microbial richness was detected in fecal samples 
from children who had used macrolide antibiotics within 12–24 months of sample 
donation compared to control samples. The study also reported a significant 
decrease in the relative abundance of Actinobacteria and an increase in 
Bacteroidetes and Proteobacteria in fecal samples from children who had used 
macrolide antibiotics within 6 months of sample donation compared to controls. 
Nonetheless, these phyla-specific changes were not observed in the groups that 
had used macrolide antibiotics within 6–12 months and 12-24 months before 
sample donation. The above results reporting varying persistent effects of 
azithromycin on the gut microbiota together with the results reported by Grassly 
et al.109on the reduction of fecal biomarkers of EED following a short course of 
azithromycin treatment warrant further research to look at short and long-term 
effects of azithromycin on the gut microbiota in the context of EED.  
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2. HYPOTHESES AND RESEARCH QUESTIONS 
  
Page | 40 
 
The hypotheses and research questions below were posed to characterize the 
fecal microbiota in rural Malawian children, test for associations between the fecal 
microbiota and biomarkers of EED and assess the long-term impact of mass 
azithromycin treatment on the fecal microbiota: 
2.1 Fecal biomarkers of gut function are associated with growth in 
Malawian children 
 
2.1.1 What is the magnitude and prevalence of intestinal inflammation and 
permeability in rural Malawian children? 
 
2.1.2 Are fecal biomarkers of intestinal inflammation and permeability 
associated with growth outcomes in rural Malawian children? 
 
2.2 Intestinal bacterial carriage of mucolytic bacteria and other bacteria 
previously associated with growth in a mouse model is associated with 
biomarkers of EED  
 
2.2.1 What is the prevalence of intestinal carriage of mucolytic bacteria and 
bacteria associated with weight gain in a mouse model in children living 
in rural Malawi? 
2.2.2 Is there a relationship between fecal carriage of these bacteria and 
growth outcomes in rural Malawian children? 
2.2.3 Is there a link between intestinal carriage of these bacteria and 
intestinal inflammation and permeability in rural Malawian children? 
 
2.3 Gut microbiota profiles in children with signs of EED are different 
from children without signs of EED 
 
2.3.1 What are the phylogenetic groupings of bacteria found in children with 
intestinal inflammation? 
 
2.3.2 Do certain phylogenetic groupings predict intestinal inflammation? 
 
2.3.3 Does a relationship exist between phylogenetic groupings that predict 
intestinal inflammation and stunting? 
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2.4 Azithromycin treatment, given in a mass drug administration 
program, has a persistent impact on gut microbiota composition 
 
2.4.1 What is the effect of azithromycin treatment on the gut microbiota after 
two and four biannual azithromycin administrations? 
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3. METHODS 
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3.1 Details of the demographic and anthropometry data used and biological 
samples tested 
3.1.1 An overview of MORDOR-Malawi  
 
This PhD project utilized data and biological samples collected by investigators 
during the course of the Mortality Reduction after Oral Azithromycin in Malawi 
study (MORDOR-Malawi). MORDOR-Malawi consisted of a series of studies 
investigating the potential for treatment with the broad-spectrum antibiotic 
azithromycin to reduce childhood mortality and morbidity. The main MORDOR-
Malawi study was the MORDOR-Malawi mortality trial, a double-blind, placebo-
controlled, cluster-randomized trial designed to test the hypothesis that MDA with 
azithromycin reduces mortality in children under five years of age. The trial was 
conducted in Mangochi, Malawi between May 2015 and June 2017 and involved 
4 bi-annual rounds of MDA. Three hundred and thirty-four clusters were 
randomized to receive MDA with either azithromycin or placebo given to children 
aged 1 to 59 months. A cluster was defined as the catchment of one Health 
Surveillance Assistant (HSA). Childhood mortality was assessed through six-
monthly census rounds that recorded all 1 to 59-month-old children in the study 
area and any deaths that occurred between rounds. The primary outcome was 
all-cause mortality.  
 
Running alongside the MORDOR-Malawi mortality trial was MORDOR-Malawi 
morbidity, a parallel trial designed to explore mechanisms by which azithromycin 
MDA may reduce childhood mortality and to monitor the emergence of 
antimicrobial resistance. MORDOR-Malawi morbidity study was also a double-
blind, placebo-controlled, cluster-randomized study that collected biological 
samples in repeat cross-sectional surveys. MORDOR-Malawi morbidity was 
conducted in a separate set of 30 clusters that were also randomized to receive 
4 bi-annual rounds of MDA with either azithromycin or placebo given to children 
aged 1 to 59 months. Within these clusters, the effect of azithromycin on anemia, 
malaria parasitemia, carriage of respiratory and gastrointestinal pathogens, 
trachoma and nutritional status was assessed through biological sampling and 
anthropometry measures. This PhD project utilized demographic data, 
anthropometry data and fecal samples collected in these 30 clusters.  
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3.1.2 MORDOR trial setting 
 
Malawi is a low-income country with a total estimated population of 17.6 million 
as of 2018128. Only 30% of the total population live on more than $1.90 a day129. 
Access to sanitation is poor, particularly in the rural areas; 63% of the total 
population live in households with improved sanitation facilities (a facility that 
hygienically separates human excreta from human contact) but only 39% of 
households in rural areas use improved sanitation facilities130. A recent Malawi 
healthy key indicators survey reported 75% coverage of early childhood 
vaccinations in Malawian children less than 2 years of age. While breastfeeding 
is high in early infancy (81% of Malawian infants at 0-1 months of age are reported 
to be exclusively breastfed), exclusive breast feeding in older infants is low such 
that only 34% of infants at 4-5 months of age are exclusively breastfed. Over 50% 
of Malawian children between 6-49 months of age in rural areas are stunted131.  
 
MORDOR-Malawi took place in Mangochi, a lakeside district located in the South-
Eastern region of Malawi. It is one of the most populated, poorest districts of 
Malawi with high birth rates and low literacy levels128,131. A recent study of 
carriage of enteric viruses and parasites in infants in the district reported over 
60% prevalence of Enterovirus, 28% Rhinovirus, 23% Parechovirus, 24% 
Norovirus, 3% Rotavirus, 10% Giardia lamblia and 6% Cryptosporidium132. 
Prevalence of intestinal helminths in children in the district is low; there is less 
than 8% prevalence of Hookworm spp., Taenia spp., Ascaris lumbricoides, 
Strongyloides and Trichuris trichura133,134.  
3.1.3 Selection of clusters and participants in MORDOR-morbidity  
 
For logistical purposes, MORDOR–Malawi split the district into 5 geographical 
zones namely Monkey Bay, Mangochi, Namwera, Makanjira and Chilipa (Figure 
3.1.3.1).  
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Figure 3.1.3.1 Map of Malawi and the five study zones in Mangochi district. 
Mangochi district is marked in red and the five study zones in Mangochi district 
(Mangochi, Chilipa, Monkey Bay, Makanjira and Namwera) are marked by location icons. 
 
MORDOR-Malawi morbidity was conducted in 30 clusters that were randomly 
selected such that each of the 5 geographical zones were represented by 6 
clusters. Half the clusters were randomly allocated 4 rounds of bi-annual MDA 
with azithromycin, and the other half to 4 rounds of MDA with placebo. Eligible 
communities met the following criteria: (i) the community was in the Mangochi 
district and identifiable as within the catchment of an HSA, (ii) the community 
leadership consented to participation (this did not remove the need for individual 
consent, but without overall leadership consent, the community could not 
participate), (iii) had an estimated population of between 200–2,000 people and 
(iv) did not fall within an urban area. The allocation of community assignments 
was conducted using simple random sampling assigned from the same list of 
eligible communities.  
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Before children were randomly selected and recruited for biological sampling, 
field workers visited the village and collected/updated census information 
including dates of birth, sex, village location. A random sample of 50 children per 
cluster was then generated using a computer-generated simple random sample 
with the aim of recruiting 40 children from each cluster. If the target of 40 children 
could not be reached from the initial randomization list of 50 children, either due 
to absence or non-participation, additional children were randomly selected from 
the census list until 40 children in each cluster were recruited. All recruited 
children had to meet the following criteria to be eligible to participate in the study: 
(a) be a resident in the study community, (b) be aged between 1 and 59 months 
and (c) have a parent or guardian willing to give consent. Children less than 3.8kg 
in weight were excluded.  
 
The following were collected from recruited children at baseline, 12 and 24-
months surveys: fecal samples, dried blood spots, nasopharyngeal swabs, 
conjunctival swabs, and anthropometry measurements. Enrollment, participation 
in fecal sample collection and samples included in the analyses of this thesis are 
shown in Figure 3.1.3.2 below.
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Figure 3.1.3.2 Flow chart of the children enrolled and included in the analyses of this PhD. The figure shows the number of children selected by 
MORDOR-Malawi Morbidity, children enrolled, children who provided fecal samples and children included in the final analyses of this PhD. 
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3.1.4 Azithromycin / Placebo administration 
 
Children aged 1-59 months on the current census were offered weight- or height-
based, directly observed, oral azithromycin suspension (or oral placebo). Children 
under 1 year of age were weighed and received a dose of 20mg/kg body weight. 
Children over 1 year of age were dosed according to their height as performed in 
trachoma control programs135. Individuals allergic to macrolides or azalides were not 
given the study drug but were included in the outcomes. Treatment was given by the 
HSA of the community. 
 
3.1.5 Fecal sample collection and storage 
 
Fecal samples for participating children were collected by their mothers or 
guardians. Mothers or guardians were provided with fecal collection kits and 
given verbal instruction, by a field nurse, on how to collect the sample. Fecal 
samples were collected into pre-labelled, sterile 50ml falcon tubes without 
preservative. Mothers or guardians were asked to return the falcon tube with the 
fecal sample, sealed in a Ziploc bag, to the field team as soon as possible after 
collection. These samples were put in a cool box with ice packs until the end of 
the day (not more than 8 hours). If a sample was not collected by the end of field 
work in that village, field workers returned the following day with a cool box to 
collect any remaining samples. Samples were brought to the laboratory at the 
end of the day and stored at -80°C.  
 
3.1.6 Anthropometry measurements 
 
The SECA 877 scale (Chasmors Ltd., London, UK) was used to weigh infants 
and children to the nearest 0.1 kg. Children were weighed with no shoes, no hair 
ornaments and no jewelry. If called for, children wore light clothes to protect their 
modesty. If a child was less than 2 years of age or otherwise unable to stand on 
the scale unaided, s/he was held by a parent or guardian and the tare function 
was used to subtract the weight of the adult.  
 
The SECA Leicester height measure (Chasmors Ltd.) was used to measure 
height for children who were ≥2 years of age and able to stand whereas the SECA 
417 infantometer (Chasmors Ltd.) was used to measure recumbent length for 
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children who were <2 years of age or unable to stand unaided. Both height and 
length were measured to within 0.1 cm.  
 
To monitor the accuracy of the weighing scales over time, a 5 kg test weight 
(Chasmors Ltd.) was weighed at the beginning and end of each day. All 
measurements were taken in triplicate by field nurses. 
 
3.1.7 Ethical considerations 
 
The MORDOR-Malawi study was approved by the London School of Hygiene 
and Tropical Medicine (UK) and the College of Medicine Research Ethics 
Committee (Malawi). Use of samples and data collected by MORDOR-Malawi for 
this PhD project was also approved by both boards (Appendix).  
During the MORDOR-Malawi study, consent was first obtained at the community 
level through discussions with the village chief and community elders who then 
indicated the willingness, or unwillingness, of the community to participate 
through verbal consent. Information and consent forms for individual recruitment 
were translated into local languages (Yao and Chichewa) prior to their approval 
by the local ethics committee. These were read aloud, by project staff fluent in 
the local languages, to parents or guardians of all children during the sensitization 
process, prior to recruitment. Written, informed consent (by thumbprint or 
signature) was obtained from the parent or guardian of each child before 
recruitment. During the consenting process, all parents and guardians were 
informed of their freedom to withdraw their child from the study at any time without 
giving any reason for doing so. 
3.1.8 Laboratory analyses 
3.1.8.1 Myeloperoxidase enzyme linked immunosorbent assay (ELISA) 
 
The myeloperoxidase (MPO) ELISA kit (Immundiagnostik, Germany) was used 
for the assay. Proteins were extracted from the fecal samples prior to the assay 
as follows: frozen fecal samples were thawed at 2-8°C and then warmed to room 
temperature. Up to 100mg of the thawed fecal sample was weighed on an FX-
300i WP electronic weighing scale (A&D Company Ltd, UK) and the weight was 
recorded. For fecal samples that were less than 100mg, any amount of fecal 
sample available (but not less than 50mg) was weighed and recorded. One ml of 
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1 wash buffer was added to the weighed fecal sample and the mix was 
homogenized at 1400rpm for 2 minutes using a Stuart Vortex Mixer SA8 (Stuart 
Equipment, UK). The homogenized sample was centrifuged at 800g for 10 
minutes and the resulting supernatant was centrifuged again at 15000g for 5 
minutes using a bench-top microcentrifuge (Eppendorf, UK). The supernatant 
obtained from the second centrifugation was then diluted 1/50 with 1 wash 
buffer. 
  
One hundred µl of the final dilution of samples above, assay controls and 
standards were added to corresponding ELISA plate wells. All samples were 
assayed in singles except assay standards and controls, which were assayed in 
duplicate. Each run included 5 standards of known concentration and 2 controls 
(low and high). Plates were then incubated for 1 hour at room temperature to 
allow the MPO to bind the antibodies, which were immobilized to the surface of 
the microtiter plate. After the incubation, the contents of the ELISA plates were 
decanted, and each plate well was washed 5 times with 250µl of 1 wash buffer 
to remove all unbound substances. This was followed by the addition of a 
peroxidase-labeled antibody against MPO to each well, incubation at room 
temperature for 1 hour and then additional washing (as above) to remove 
unbound substances. After the second washing step, tetramethylbenzidine 
(TMB), an enzyme substrate, was added to each well and plates were incubated 
for 15 minutes. Stop solution (1M H2SO4) was then added to stop the reaction 
and the intensity of the colorimetric reaction was determined immediately using 
a HALO LED96 microplate reader (Dynamica Scientific Ltd, UK) set to a 
wavelength of 450nm and a correction wavelength set to 620nm.  
3.1.8.2 Alpha-1 antitrypsin ELISA 
 
The alpha-1 antitrypsin (AAT) ELISA kit (Immundiagnostik) was used for the 
assay. Proteins were extracted from the fecal samples prior to the assay using 
the provided extraction buffer as follows: frozen fecal samples were thawed at 2-
8°C and warmed to room temperature. From the thawed fecal sample, 15mg was 
weighed on an FX-300i WP electronic weighing scale (A&D Company Ltd) and 
the weight for each sample was recorded. For fecal samples that were less than 
15mg, any amount of fecal sample available was weighed and recorded. One 
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and a half ml of 1 AAT extraction buffer was added to the weighed fecal sample 
and the mix was vortexed until suspension was homogenous. More solid samples 
were soaked in the buffer for 10 minutes to improve suspension before vortexing. 
The homogenized sample was then left to stand for 10 minutes at room 
temperature until any sediment settled. The resulting supernatant was diluted 
further with 1 wash buffer to a final dilution of 1/25,000, which was used for the 
assay.  
 
The ELISA plate wells were washed 5 times with 1 wash buffer after which 100µl 
of diluted samples, assay controls (low and high) and 5 standards of known 
concentration were added to respective ELISA plate wells. This was followed by 
1-hour incubation at room temperature after which the contents of the ELISA 
plates were decanted and each well washed 5 times with 250µl of 1 wash buffer. 
Thereafter, a peroxidase-labeled antibody against AAT was added to each well 
and plates were incubated at room temperature for 1 hour followed by another 
wash as previously described. After the third washing step, TMB was added to 
each well and incubated for 15 minutes after which the stop solution was added. 
The intensity of the colorimetric reaction was determined as described in section 
3.1.8.1. 
3.1.8.3 Neopterin ELISA 
 
The ELISA assay was performed using the Neopterin (NEO) ELISA kit (GenWay, 
Biotech, San Diego, CA, USA). Fecal samples were prepared for as follows: 
frozen fecal samples were thawed at 2-8°C and warmed to room temperature 
before analysis. All samples were kept under a cardboard box on the bench as 
NEO is light sensitive. A maximum of 50 mg of the thawed fecal sample was 
weighed on an FX-300i WP electronic weighing scale and the weight for each 
sample was recorded. For fecal samples that were less than 50mg, any amount 
of fecal sample available was weighed and recorded. One ml of 1 phosphate 
buffered saline (PBS) (Fisher Bioreagents, USA) was added to the weighed fecal 
sample and the mix was homogenized on a PowerLyzer 24 Homogenizer 
(Qiagen, Germany) at a speed of 500rpm for 5 minutes. After the 
homogenization, the sample was centrifuged for 5 minutes at 800g in a bench-
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top microcentrifuge. The resulting supernatant was diluted a further 1/5 with 1 
PBS and this dilution was used for the ELISA assay.  
 
Twenty µl of samples, assay controls (low and high) and 6 standards of known 
concentration were added to respective ELISA wells followed by 100µl of enzyme 
conjugate and 50µl of Neopterin antiserum. Plates were then incubated for 1.5 
hours at room temperature on a standard analog rocker (VWR, USA) at a speed 
of 500 rpm in the dark. After the incubation, the contents of the wells were 
decanted, and the wells were washed three times with 1 wash buffer. Thereafter, 
TMB was added to each well followed by incubation for 10 minutes at room 
temperature in the dark. After TMB incubation, 1M H2SO4 was added to stop the 
reaction and the intensity of the colorimetric reaction was determined as 
described in section 3.1.8.1. 
3.1.8.4 Extraction of total genomic DNA from fecal samples 
 
Total, genomic DNA was isolated from fecal samples using the PowerSoil DNA 
Isolation Kit (MO BIO Laboratories Inc, Carlsbad, CA, now a part of Qiagen, 
Germany). Briefly, 250mg of fecal sample was weighed and added to a tube with 
PowerSoil beads. This was gently vortexed to mix and subsequently lysis buffer 
was added. The mix was then homogenized using the PowerLyzer 24 
Homogenizer at a speed of 1500rpm for 2.5 minutes. This was followed by 
centrifugation at 10,000g for 30 seconds at room temperature using a bench-
top microcentrifuge. The resulting supernatant was transferred to a 1.5ml sterile 
tube followed by incubation with precipitation buffer at 4C for 5 minutes and 
centrifugation at 10,000g for 1 minute. The incubation and centrifugation steps 
above were then repeated.  
 
The resulting supernatant was transferred to a 1.5ml sterile tube followed by the 
addition of a high concentration salt solution, enabling DNA, but not non-DNA 
organic and inorganic material, to bind to the silica membrane on a spin column 
filter. This mixture was loaded onto the spin column filter and centrifuged at 
10,000g for 1 minute. An ethanol-based wash solution was then added onto the 
spin column filter, to remove residual salt, humic acid, and other contaminants, 
and the spin column filter was then centrifuged at 10,000g for 1 minute. The spin 
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column filter was then placed in a clean tube followed by addition of 100µl elution 
buffer and a 30 second centrifugation at 10,000g.  
 
As a quality control measure, 10% of samples were randomly selected to quantify 
the DNA yield using the Qubit dsDNA HS assay kit (Invitrogen, CA, USA) as 
follows. Five µl of the DNA sample was added to 195µl of working solution 
prepared by adding 1µl of the reagent to 199µl of buffer provided in the assay kit. 
The mix was then incubated for 2 minutes at room temperature, followed by DNA 
quantitation on the Qubit 2.0 fluorometer (Invitrogen). The fluorometer was 
calibrated with two standards (low and high concentration) before measuring the 
samples.  
3.1.8.5 Microbial detection qPCR  
 
Endpoint qPCR was performed to detect the presence of the following bacteria in 
DNA extracts from fecal samples: Akkermensia muciniphila, Bifidobacterium 
longum Dorea formicigenerans, and Faecalibacterium prausnitzii. To negate any 
unwanted effects of high DNA yield e.g. PCR inhibition and non-specific binding, 
the DNA sample was first diluted 1/10 with PCR grade water (Qiagen) and the 
diluted DNA was then used as a template in the PCR reaction. The qPCR was 
performed using the Rotorgene Q PCR machine (Qiagen, Hilden, Germany) 
where samples were run in a 72-well rotor format. The total volume of a single 
PCR reaction was 12.5µl and each reaction contained 6.25µl of commercially 
available microbial qPCR master mix (Qiagen, Germany), 0.5µl of commercially 
available microbial DNA qPCR assay containing primers and probes (Qiagen) 
and 3µl template DNA in an aqueous solution. A no template control and a 
microbial DNA positive control (Qiagen) were included on each run. Thermal 
cycling conditions for the assay were 95C for 10 minutes followed by 40 cycles 
of 95C for 15 seconds and 60C for 2 minutes.  
3.1.8.6 Bacterial quantification qPCR 
 
The published BactQuant assay136 was used to measure total bacterial load in 
the genomic DNA extracted from fecal samples. Minor adjustments were made 
to the original protocol, which included, running the standard curve and the no-
template control in singles to reduce reagent costs, reducing the number of cycles 
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to 35, increasing template volume from 1µl to 2.5µl and adding 2.5µl of PCR 
grade water to have a final reaction volume of 12.5µl. The DNA sample was 
diluted 1/10 prior to the assay to negate any undesirable effects of high DNA 
yield.  
 
The total volume of a single PCR reaction was 12.5µl. Each PCR reaction 
included 1.8μM of each forward (5′-CCTACGGGDGGCWGCA-3′) and reverse 
primer (5′- GGACTACHVGGGTMTCTAATC-3′), 4.5μM of the TaqMan® probe 
(6FAM) 5′-CAGCAGCCGCGGTA-3′ (MGBNFQ), 5µl of 2Platinum® 
Quantitative PCR SuperMix-UDG with ROX (Invitrogen Corp., UK) and 2.5µl 
template DNA. Each run included serial dilutions of PCR products of known-
concentration (0.016ng/µl–1.6e-7ng/µl in 10-fold serial dilutions) and a no 
template control. The PCR was performed on the Rotorgene Q platform (Qiagen) 
with 72-well rotor format using the following thermal cycling conditions: 3 min at 
50°C for UNG treatment, 10 minutes at 95°C and 35 cycles of 95°C for 15 
seconds and 60°C for 1 minute. 
 
3.1.8.7 16S rRNA gene sequencing 
 
The 16S rRNA gene sequencing procedure included DNA library preparation, 
dilution and denaturation of the DNA library, paired-end DNA sequencing and 
preparation of 16S rRNA gene sequence reads for analysis. The flow of the V4-
16S rRNA sequencing process is illustrated in Figure 3.1.8.7.1 below. 
 
 
 
 
 
Figure 3.1.8.7.1 16S rRNA gene sequencing workflow 
 
3.1.8.7.1 DNA library preparation 
 
Total, genomic DNA, extracted as described in section 3.1.8.4, was used for DNA 
library preparation. This involved a series of PCR i.e. amplicon PCR and indexing 
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PCR. DNA libraries were prepared by amplifying an approximately 390-bp V4 
region of the 16S rRNA gene during amplicon PCR using 10µM each of forward 
(515F_Indexed; 5'-adapter- GTGCCAGCMGCCGCGGTAA-3') and reverse 
(806R_Indexed; 5'-adapter-GGACTACHVGGGTWTCTAAT-3') primers, which 
amplify sequences for both Bacteria and Archea. Each 23.5μl reaction contained 
10μl 2.5 Quantabio 5prime HotMasterMix (Quantabio, Beverly, MA, USA), 10μM 
primers (SIGMA, UK), 4μl template DNA and 8µl PCR grade water (Qiagen). PCR 
reactions were added in a 96 well-plate and amplified on a Veriti™ 96 well thermal 
cycler (Applied Biosystems, UK) using the following thermal cycling conditions: 
94°C for 3 minutes, 35 cycles of 30 seconds at 94°C, 30 seconds at 50°C and 45 
seconds at 72°C, then 10 minutes at 72°C. Each PCR run included a mock 
bacterial community, which acted as a positive control, and a no template control. 
The mock bacterial community was composed of Hemophilus influenza, 
Moraxella catarrhalis and Staphylococcus epidermis. After the amplicon PCR, 4µl 
of amplicon was run on a 2% agarose gel stained with Ethidium Bromide (EtBr) 
to verify amplicon size and PCR efficiency. The agarose gel was prepared by 
adding 3g of agarose to 150ml of 1×Tris-Borate-EDTA (TBE) buffer. The mix was 
heated in a microwave until mixture was clear. This was followed by adding 7.5µl 
of EtBr (10mg/ml) to the mixture, which was cooled down before being poured in 
the gel tray. Amplicons that were checked on the agarose gel included the mock 
control, the no template control and a random selection of 6% of samples. Using 
the V4 515F-806R primers, the expected amplicon size was approximately 
390bp. 
  
Having verified amplicon sizes and PCR efficiency, all amplicons in the 96 well 
plate were purified using 0.6 v/v AMPure XP beads (Beckman Coulter, CA, USA) 
and 70% ethanol as follows. The AMPure XP beads were equilibrated to room 
temperature before use and then vortexed gently for 30 seconds before adding 
20µl to each reaction well. The 96-well plate with the bead-amplicon mix was 
incubated at room temperature for 5 minutes and then placed on a super magnet 
plate for 2 minutes to separate the beads from solution. The cleared solution from 
each well was aspirated without disturbing the beads and the plates were then 
washed twice with 200µl of 75% ethanol, with each wash followed by incubation 
for 30 seconds at room temperature. The reaction plate was left to air-dry for 2 
minutes and then 27.5µl of nuclease free water was added to each well of the 
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reaction plate and mixed by pipetting several times to fully re-suspend the beads. 
Following 2-minutes incubation, the plate was returned to the super magnet plate 
for 1 minute to separate the beads. Twenty-two µl eluate containing the amplicons 
was transferred to a new reaction plate, sealed and stored at -20°C to use for 
index PCR.  
 
The second PCR (index PCR) was done to add unique barcodes to each DNA 
amplicon obtained in the amplicon PCR to enable downstream multiplexing. The 
sequences for the unique barcode primers were recorded on a mapping file 
matching each sample identifier. The total volume for a single reaction of index 
PCR was 49μl. Each 49μl PCR reaction contained 20μl 2.5 Quantabio 5prime 
HotMasterMix (Quantabio, Beverly, MA, USA), 2μM MID Illumina primers 
(Illumina, CA, USA), 22μl of amplicon and 5.5µl of PCR grade water (Qiagen). 
The index PCR was setup in a 96-well plate using the following thermal cycling 
conditions: 94°C for 3 minutes followed by 5 cycles of 10 seconds at 94°C, 30 
seconds at 58°C and 45 seconds at 72°C then 10 minutes at 72°C. Each run 
included one mock control and a no template control. 
 
After the PCR, 10µl of the amplicon was run on a 2% agarose gel to verify 
amplicon size and PCR efficiency. The resulting amplicons were again cleaned 
as described in this section above, however, twice the volume of the AMPure XP 
beads was used. Additionally, re-suspension of beads in index PCR was done 
with 15µl of elution buffer (Qiagen, Germany) instead of nuclease free water. The 
eluate containing the amplicons was then transferred to a new 96-well plate and 
each amplicon was quantified on the Qubit 2.0 Fluorometer (Invitrogen) as 
described in section 3.1.8.4. 
3.1.8.7.2 Pooling amplicons 
 
Before pooling individual DNA amplicons, the concentrations of individual 
amplicons were converted from ng/µl to nM using formula A below. Each 
amplicon was diluted to a final concentration of 12.5nM using 10mM Tris pH 8.5 
and 5µl aliquots of diluted DNA from each amplicon were then mixed in one sterile 
Eppendorf tube. Up to 117 individual amplicons were pooled for a single 
sequencing run. The final pooled DNA library was quantified on a Qubit 2.0 
fluorometer (as described in section 3.1.8.4) and run on the Agilent Bioanalyzer 
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2100 with Agilent 1000 DNA chips (Agilent Technologies Inc., USA), using a 
standard protocol137, to determine its concentration and size.  
A                 (Individual library concentration in ng/µl) × 106 =     XnM              
 660g/mol x 427 (average library size in bp) 
       
3.1.8.7.3 Denaturing and diluting the pooled DNA libraries for sequencing 
 
The MiSeq v3 reagent kit (Illumina Inc., San Diego, CA, USA) was used to 
prepare the DNA library for cluster generation and sequencing. The MiSeq 
reagent cartridge was thawed in cold water for 1 hour and thereafter placed in a 
refrigerator (2-8C) as the DNA library and PhiX control were being denatured 
and diluted. All other reagents were thawed on ice.  
 
The DNA library was denatured with a sodium hydroxide solution (0.2N NaOH) 
and then diluted with hybridization buffer (HT1) to a final loading concentration of 
15pM. The diluted library was spiked with 10% PhiX control, which served as an 
internal control for low-diversity libraries. The Phix-spiked DNA library was heat-
denatured at 96C for 2 minutes and then 600µl was loaded into the sample well 
of the MiSeq reagent cartridge. The MiSeq flow-cell was rinsed with Milli-Q® water 
and 75% ethanol then gently dried with KimwipesTM (Kimberly-
Clark™Professional, USA) before being placed into the MiSeq sequencer 
(Illumina, San Diego, CA, USA). The reagent cartridge was then assayed by 
2×300bp paired-end sequencing for a total of 600 cycles using a standard 
protocol138. 
3.1.8.7.4 Preparation of the 16S rRNA sequence reads for analysis 
 
Raw sequence reads generated by the Illumina MiSeq sequencer were 
automatically uploaded to BaseSpace (Illumina) where FastQ files were 
generated. The FastQ files were processed in QIIME 2139 to link sequences to 
their individual samples, filter out poor quality sequencing reads, trim sequencing 
adapters and barcodes, combine each set of paired-end reads into a single 
sequence and cluster near-identical sequences using an identity cut-off to form 
operational taxonomic units (OTU). These steps are explained in detail below: 
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3.1.8.7.4.1 Demultiplexing  
 
This step assigned each sequence read to the individual sample it originated 
from. The sequences were linked back to their original samples via the DNA 
barcode incorporated into each sequence during the indexing PCR. The barcode 
sequences, unique and corresponding to each sample, were recorded on a 
mapping file and using the demux function in QIIME 2, the sequences were 
assigned back to their original samples. 
3.1.8.7.4.2 Quality filtering  
 
During this step, sequencing reads were trimmed to a consistent length and low-
quality reads were removed based on Phred Q scores, which is a probability of 
error in base calling during sequencing. High-quality score implied that a base 
call was more reliable and less likely to be incorrect. Thus, given an assertion, A, 
the quality score, Q(A), expresses the probability that A is not true, P(~A), 
according to the relationship: 
                                 Q(A) =-10 log10(P(~A)) 
 
where P(~A) is the estimated probability of an assertion A being wrong140. The 
relationship between the quality score and error probability is shown in Table 
3.1.8.7.4.2.1 below. Using QIIME 2, per base quality scores across all reads were 
manually inspected to identify where the median quality score dropped below 
Phred score Q=20 for forward and reverse reads respectively. Reads were 
trimmed at the identified threshold and filtered using the DADA2 plugin with 
default parameters. Trimming and filtering was performed on paired reads jointly, 
i.e. both reads had to pass the filter for the pair to pass. Additionally, the filtering 
steps incorporated checking for and removing chimeras. 
 
Table 3.1.8.7.4.2.1 Relationship between the quality score and 
error probability 
Quality Score, Q (A) Error probability, P (~A) 
10 0.1 
20 0.01 
30 0.001 
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3.1.8.7.4.3 OTU clustering and taxonomy assignment 
 
Paired filtered reads were then merged and clustered de novo according to their 
intrinsic similarities141. The clustered sequences were deemed to have come from 
the same bacterial taxon if they were ≥ 97% identical. These clusters formed 
OTUs that were assigned taxonomy using a naïve Bayes classifier pre-trained on 
the SILVA 16S database142. An OTU count table with taxonomy ranking down to 
the genus level was created after taxonomy assignment and exported from QIIME 
2 for analyses.  
3.1.8.7.4.4 OTU data quality filtering and normalization 
 
Further quality filtering was conducted on the OTU count data (generated as 
described in section 3.1.8.7.4.3 above) to remove spurious OTUs from the OTU 
table. Briefly, samples with >1000 total reads were retained and from these, only 
bacterial OTUs identified to the genus level, with sequences more than 0.005% 
of the total number of sequences143 and a frequency of more than 0.01% in any 
sample were kept. To account for unequal DNA library sizes, OTU data was 
rarefied to 1000 reads with 1000 permutations before calculating diversity indices 
and determining bacterial community differences between samples or by 
cumulative sum scaling (CSS) before performing univariate analysis of individual 
taxa144,145.  
3.1.9 Statistical analyses 
3.1.9.1 Primary analysis 
 
All statistical analyses were completed in STATA 15 (StataCorp, College Station, 
USA) and R studio version 1.1.447146. Participants enrolled in the MORDOR-
morbidity study who were included in the analyses of this thesis are shown in 
Figure 3.1.3.2. The primary outcomes for this thesis were child stunting, fecal 
microbiota diversity and composition, intestinal bacterial carriage, fecal 
biomarkers of EED (AAT, MPO, NEO) and the composite EED score, which were 
defined/calculated as detailed below.  
3.1.9.1.1 Stunting 
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The WHO 2006 Child Growth Standards were used for age-and-sex 
standardization of length/height i.e. calculation of HAZ scores34. Participants with 
out-of-range HAZ (>6 or <-6) were not included in analyses of HAZ. HAZ scores 
were used in analyses as continuous variables or categorized into stunted or not-
stunted centered around a HAZ score of -2. Thus, individuals with a HAZ score 
of <-2 were categorized as stunted while individuals with a HAZ score of ≥-2 were 
categorized as not stunted. 
3.1.9.1.2 Fecal biomarkers of EED 
 
A four-parameter logistic regression model (4plm) was used to calculate 
concentrations from optical density (OD) values generated by the ELISA assays 
described above (sections 3.1.8.1-3.1.8.3). The 4plm model estimates 4 
parameters needed to fit a sigmoid curve namely: a=minimum value that can be 
obtained, d=maximum value that can be obtained, c=point on the sigmoid curve 
halfway between a and d, and b=steepness of curve at point c (see formula B 
below). A sigmoid curve was fit on all OD values to determine concentrations 
using formula B below. In the formula below, a, b, c and d are the 4 parameters 
estimated by the 4plm whereas y is the absorbance value and x the unknown 
concentration. 
         B   
 
Samples with concentrations above the highest standard were diluted further and 
re-tested. Samples with concentrations below the lowest standard were diluted 
less and re-tested. If they were still low after being re-tested, they were assigned 
a concentration value of 0.001. The magnitude of intestinal inflammation was 
determined from the MPO or NEO whilst the AAT concentrations were used to 
determine the magnitude of intestinal permeability. Additionally, associations 
between intestinal inflammation or permeability and stunting or HAZ scores were 
explored using regression models. 
 
The three biomarkers (MPO, AAT and NEO) were combined to form an EED 
score as described by Kosek et al.53 with slight modifications. Briefly, raw 
concentrations for each biomarker were categorized into quartiles according to 
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their distribution as follows: 0 (concentration less than or equal to the 25th 
quartile), 1 (concentration between the 25th and 75th quartile) and 2 (concentration 
more than or equal to 75th quartile). Principal components with natural log of raw 
continuous data were generated for each biomarker. Instead of using rounded 
weightings from the principal component analysis (PCA) to multiply with the 
quartile-categorized values as stated in the published method53, absolute 
weightings were used to generate continuous EED scores. The products of the 
three biomarkers were then summed to get the EED score. The steps taken for 
the formation of the composite EED score are summarized in Figure 3.1.9.1.2.1 
below. Associations between the composite EED score and stunting were also 
explored using regression models. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.9.1.2.1 Steps for forming the composite EED score 
 
3.1.9.1.3 Intestinal carriage 
 
Published biostatistical rules on classification of continuous real-time qPCR data 
into positive or negative147 were adopted and used to classify the microbial qPCR 
results as positive or negative with minor modifications. Briefly, a 4plm was fitted 
Raw concentration 
of NEO, AAT & 
MPO 
Natural log 
transformation of 
raw 
concentrations of 
NEO, AAT & MPO  
PCA conducted on 
log transformed 
concentrations of 
NEO, AAT & MPO 
NEO PCA weighting × (NEO category) + AAT PCA weighting × (AAT category) 
+ MPO PCA weighting × (MPO category) = composite EED score 
Concentration categorised as 0,1 & 
2 using distribution quartiles to give 
NEO (0,1,2), AAT (0,1,2) & MPO 
(0,1,2) categories  
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on raw amplification data and its parameters were used to estimate fluorescence 
values through each qPCR cycle for each sample. The estimated fluorescence 
values were then compared to the actual fluorescence values to determine the 
variation between the two values. Additionally, the final actual fluorescence 
values for each sample were modelled onto mixtures of two normal distributions. 
A sample was considered positive if the percentage variation between its 
estimated and actual fluorescence values was less than 15 and if the sample 
clustered within the right-most population of a mixtures-model of two normal 
distributions (final fluorescence >0.15). The steps for the determination of a 
positive or negative qPCR result are summarized in Figure 3.1.9.1.3.1 below. 
Prevalence of bacterial carriage was then calculated from the qPCR results. 
Additionally, associations between intestinal bacterial carriage and fecal 
biomarkers of EED (individually or as a composite EED score) were explored 
using logistic regression analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.9.1.3.1 Steps for determining a positive or negative qPCR result 
 
Does amplification 
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3.1.9.1.4 Gut microbiota diversity and composition 
 
Shannon (H) and Simpson (D) diversity indices were calculated from the OTUs 
to indicate alpha diversity in the fecal samples using the phyloseq R package148. 
Shannon index considers both richness and evenness whereas Simpson index 
considers evenness of OTUs in each sample. A larger Shannon or Simpson value 
indicates a higher level of diversity. To determine bacterial phylogenetic 
distances between samples, weighted and unweighted UniFrac distance 
matrices were calculated using the phyloseq R package. The UniFrac distance 
metric compared relatedness of community members based on phylogenetic 
distances between organisms; the weighted UniFrac metric indicated presence 
or absence of OTUs while accounting for relative abundance whereas 
unweighted UniFrac only indicated presence or absence of OTUs. The 
phylogenies used to calculate the UniFrac distances were computed using 
RAxML v8.2.11149 from a variable sites alignment using a generalized time-
reversible (GTR) + gamma model.  
 
Differences in the distribution of continuous variables between groups were 
calculated using Student t-test or ANOVA for parametric data while the Wilcoxon 
rank sum test or the Kruskal-Wallis test was used for non-parametric data. Linear 
regression models were used to assess the relationship between predictors and 
continuous outcomes while logistic regression models were used to assess 
associations between the predictors and dichotomous outcomes. Both models 
were adjusted for a set of covariates. To compare bacteria community 
compositional differences between groups, PERMANOVA with 1000 permutation 
tests using the default Bonferroni P-value correction in Adonis function, under the 
vegan R package150, was run on UniFrac distance matrices. Non-normalized 
OTU data was used to determine differential abundance of OTUs between 
samples using the DESeq2 package in R151. Statistical significance of log2 fold 
changes was assessed using the default Wald test with Benjamini-Hochberg p-
value correction in DESeq2. Cut-off for all significant tests was set at P<0.01. The 
relationship between the identified differentially abundant OTUs and outcomes of 
interest was tested using a zero-inflated negative binomial regression model, 
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implemented within the glmmTMB R package152, to adjust for probability of zero 
count in relation to library size controlling for a set of covariates. 
 
3.1.9.2 Secondary analysis 
 
The secondary analyses for this thesis included testing for associations between 
demographics (age, sex, geographic zone) and biomarkers of EED, gut 
microbiota diversity and composition and intestinal carriage. Relative abundance 
of the selected bacteria (Akkermensia muciniphila, Bifidobacterium longum 
Dorea formicigenerans, and Faecalibacterium prausnitzii) in the fecal samples 
was also calculated using the delta CT method153. For this, amplification data for 
each of the 4 bacteria was normalized relative to the amplification of the bacterial 
16S rRNA gene (described in section 3.1.8.6) in the same sample. The bacterial 
16S rRNA gene was chosen as most suitable for normalization as it is expressed 
in all bacteria. Associations between predictors (intestinal bacterial carriage, 
relative bacterial abundance, fecal biomarkers of EED) and weight metrics were 
also explored. The weight metrics included weight-for-age (WAZ) and weight-for-
height (WHZ) Z scores, which were calculated using the WHO 2006 Child Growth 
Standards34. Participants with out-of-range WAZ (>5 or <-6) and WHZ scores (>5 
or <-5) were not included in analyses of WAZ and WHZ respectively. WAZ and 
WHZ were used as continuous response variables or categorized into 
underweight or not-underweight and wasted or not-wasted as shown in Table 
3.1.9.2.1 below. 
Table 3.1.9.2.1 Categorization of WAZ and WHZ scores into growth 
status 
Z score Cut-off Category 
WAZ <-2 Underweight 
WAZ ≥-2 Not underweight 
WHZ <-2 Wasted 
WHZ ≥-2 Not wasted 
 
3.1.10 Data management 
 
Demographic (date of birth, sex and location), treatment and anthropometry data 
(weight and height) from the MORDOR trial were captured electronically in the 
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field on tablets using the Salesforce platform (Salesforce.com, Inc., San 
Francisco, CA, USA), which uploaded the data to a password secured central 
server at the end of each day. The server was only accessible to MORDOR trial 
investigators.  Laboratory data was captured on various platforms depending on 
the experiment. OD values for all ELISA assays were captured in the Halo LED 
96 capture software and exported as comma-separated values (CSV) files. All 
quantitative PCR amplification data was captured in the Rotorgene Q software 
version 2.3.4 and later exported as CSV files. Raw 16SrRNA gene sequencing 
data was automatically uploaded to BaseSpace (Illumina) and FastQ files were 
generated at the end of each run. All biological samples were assigned de-
personalized identifiers that could not be linked to participant data in the 
laboratory. Each participant was given a unique identifier in the field, which was 
used to link anthropometry, demographic, treatment and laboratory data after all 
experiments were complete. 
 
To ensure quality of data collected, demographic data, including dates of birth, 
was verified by MORDOR trial staff who revisited selected households in the 
weeks following the census. For demographic data that had implausible dates of 
birth, MORDOR trial staff revisited participants’ homes and verified dates of birth 
against the health passports. Anthropometry data was captured using an 
electronic collection tool that had pre-set acceptable ranges for anthropometry 
measures so that flags would appear when unlikely measures were entered. For 
data collected through laboratory experiments, positive and negative controls 
were included in every experiment. Results of the controls were compared to their 
expected results and runs for which the controls did not give the acceptable 
results were repeated. 
 
Data was cleaned in STATA 15 and RStudio version 1.1.447 to make it suitable 
for analysis. All data were checked for consistency, duplicates, completeness and 
implausible values. Additionally, all sample and participant identification numbers 
were checked for clerical errors. Implausible and inconsistent anthropometry and 
treatment data were verified by the MORDOR trial coordinator. All data with 
inconsistencies that could not be resolved were excluded from analysis. 
Anonymized qPCR, 16S rRNA gene sequencing and ELISA data will be made 
publicly available to other researchers via accession in the LSHTM research data 
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repository. Additionally, the 16S rRNA gene sequences will be deposited in the 
Sequence Read Archive (SRA). However, data-linking laboratory data to named 
participants is restricted and as such, this data will not be made available to 
outside researchers. 
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4. Fecal biomarkers of intestinal inflammation and 
permeability and associations with growth outcomes 
in rural Malawian children 
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4.1.1 Introduction 
 
EED is a subclinical condition of the gut characterized by structural changes in 
the intestinal epithelium and underlying chronic inflammatory responses2,3. More 
than two-thirds of children living in low-income settings are thought to have signs 
of EED11,12. The cause of EED is not well defined, however, its epidemiology 
suggests microbial infections and exposure to poor sanitation and hygiene play 
a role. A hypothetical model suggests that ingestion of contaminated food or 
water as well as exposure to unsanitary conditions changes the composition and 
function of the gut microbiota, resulting in structural changes of the intestinal 
epithelium. This then allows translocation of microbes or microbial antigens from 
the lumen into the systemic circulation causing chronic immune activation, which, 
in turn, causes growth faltering either by repressing growth hormones or by 
repartitioning nutrients away from growth towards increased immune 
metabolism47.  
 
Confirming a diagnosis of EED requires visualization of the intestinal epithelium 
using endoscopy or biopsy. Studies that have utilized these techniques to 
investigate mechanisms underlying EED development and the impact of some 
interventions on EED have reported important findings. A recent study, involving 
adults in Zambia, conducted to better understand mechanisms underlying EED 
reported an association between translocation of gut microbes and defects in the 
intestinal epithelial lining154. The study collected intestinal biopsies from adults 
who were HIV seropositive or seronegative and not infected by helminths at the 
time of enrollment. Morphometry of the collected biopsies showed villous blunting 
and crypt lengthening with all the biopsies having a Villous Height:Crypt Depth 
less than the normal Western ratio of 3:1155 regardless of participant HIV status. 
In addition, endomicroscopy of the duodenum showed epithelial lesions and 
evidence of gut leakage in 80% of the participants. Immunohistochemical 
analysis of the epithelial tight junction integrity and distribution revealed loss of 
tight junctions as indicated by presence of claudin 4, a tight junction protein, at 
sites of cell shedding. Also, transcriptomic analyses of the biopsies showed an 
association between biopsies with severe and mild EED and downregulation of 
genes responsible for epithelial repair processes. Another study in Zambian 
adults showed that multiple macronutrient supplementation improved small bowel 
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villous height and absorptive area156. The study reported an increase in villous 
height and Villous Height:Crypt Depth ratio in HIV seronegative participants who 
received multiple macronutrient supplement over a period of 6 weeks compared 
to their counterparts who received a placebo over the same follow-up period.   
 
Although intestinal histopathological tests provide important details that can 
inform interventions that may reduce EED, their use in asymptomatic young 
children is considered unethical as endoscopy or biopsy are invasive tests. 
Alternative non-invasive tests are therefore used to measure different aspects of 
EED in children. The urinary L:M ratio test is one of the commonly used non-
invasive tests for EED and measures intestinal absorptive capacity and 
diminished intestinal barrier function. The test involves challenging a subject, 
after a period of fasting, with a solution that has a known concentration of 
lactulose and mannitol 19,20. Lactulose is a large sugar that is not normally 
absorbed by the small intestine while mannitol is a smaller sugar that is absorbed 
by the small intestine in proportion to absorptive surface area. Both sugars are 
excreted in the urine a few hours after ingestion without being metabolized. As 
such, urinary mannitol measures absorptive capacity whereas urinary lactulose 
measures diminished barrier function. Despite its significant association with 
intestinal histopathological changes3, the L:M ratio test is inconsistent among 
studies; procedural details like fasting prior to ingestion, sugar dosage, time of 
urine collection and method of detection vary among studies thereby making 
comparison of results between studies difficult. Additionally, there are technical 
difficulties associated with sample collection for the test, especially from infants, 
as the test requires fasting before collection of urine sample and a long duration 
of sample collection. Leakage of sample and contamination by stool are other 
additional challenges in infants. 
 
 
The lack of a convenient yet robust diagnostic test for EED makes it difficult to 
understand the pathobiology of EED and to determine interventions likely to lead 
to significant reductions in EED. Potential biomarkers using stool and blood are 
being tested as proxies of EED14,56,60,157-159. These biomarkers measure the 
various processes involved in EED, which include intestinal epithelial damage, 
intestinal inflammation, intestinal permeability, microbial translocation and 
systemic inflammation47, and can easily be quantified in blood and/or fecal 
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samples using ELISA techniques. Blood and fecal samples are relatively easy to 
collect from children and ELISA techniques are easy to perform, therefore the 
use of these biomarkers to aid EED diagnosis in children is feasible. 
  
MPO, AAT and NEO are some of the potential biomarkers that are being 
evaluated for use in EED diagnosis. MPO is an enzyme found in the granules of 
neutrophils, which are first-line responders to acute-phase inflammation caused 
by bacterial infection. Inside the granules of the neutrophils, MPO catalyzes the 
oxidation of substances through the hydrogen peroxide (H2O2) system, which has 
a toxic effect on many microorganisms160. Thus, MPO is a marker of neutrophil 
activity and high levels of fecal MPO indicate intestinal inflammation. In serum, 
AAT makes up the majority of serine protease inhibitors and protects tissues from 
protease damage during inflammation. AAT is synthesized primarily in the liver 
but also to a small extent in intestinal macrophages, monocytes, and intestinal 
epithelial cells. Since AAT is relatively resilient against enzymatic digestion, its 
increased levels in fecal samples indicate intestinal protein loss and increased 
mucosal permeability. NEO, on the other hand, is a low molecular weight 
molecule belonging to the chemical group known as pteridines. It is synthesized 
by cellular immune reaction of macrophages and dendritic cells upon stimulation 
with the cytokine interferon gamma (IFN-γ) and subsequently released. Thus, 
elevated fecal levels of NEO indicate intestinal inflammation.  
 
Studies looking at the association between individual concentrations of AAT, 
MPO, NEO and growth in children at risk of developing EED have yielded mixed 
results. One multi-site, longitudinal study that assessed the relationship between 
these 3 biomarkers and linear growth in infants living in low-income settings of 
South Asia, Sub-Saharan Africa and Latin America showed that high levels of 
AAT, MPO, NEO predicted a decline in infant’s length-for-age z (LAZ) scores in 
the subsequent 6 months within a 15-month follow-up period53. Similarly, a recent 
case-control study examining the link between potential biomarkers of EED and 
subsequent growth impairment in rural Brazilian children aged between 6-26 
months showed an association between higher fecal levels of MPO or AAT and 
growth faltering54. In this study, levels of fecal biomarkers of EED in malnourished 
and age-sex matched non-malnourished controls were measured at baseline. 
Follow-up anthropometry measurements were taken at 2 to 6 months after initial 
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sampling. The study reported a significant relationship between high levels of 
MPO or AAT at baseline and poor HAZ scores in the subsequent months of 
follow-up. Arndt et al. utilized data from the Bangladeshi site within the multi-site, 
longitudinal study described above to describe longitudinal patterns of AAT, MPO 
and NEO and their contribution to linear growth failure in Bangladeshi children. 
Child anthropometry measurements were collected every month for 2 years and 
AAT, MPO and NEO were quantified in fecal samples that were collected 
quarterly throughout the follow-up period. This study did not find any association 
between levels of AAT, MPO or NEO  in the full follow-up period (3-21 months) 
and subsequent 3-month linear growth55. Another study in rural Bangladeshi 
children that investigated the relationship between biomarkers of EED and 
stunting in under five children also reported no significant associations between 
baseline levels of AAT, MPO or NEO and stunting56. In this study, levels of AAT, 
MPO, NEO and calprotectin were measured in fecal samples collected at 
baseline in children aged 6-30 months. Anthropometry measurements were also 
collected at the 9-month follow-up visit.  No significant associations were 
observed between baseline levels of AAT, MPO or NEO and stunting at the 9-
month follow-up visit.  
 
Available data suggests that no single biomarker is sufficient to indicate 
EED161,162. In the multi-site, longitudinal study described above53, Kosek et al. 
combined raw concentrations of AAT, MPO and NEO using PCA to form a 
composite EED score. They then used the composite EED score to explore the 
relationship between EED and linear growth in infants from low-income settings 
of South Asia, Latin America and Sub-Saharan Africa. The study reported an 
association between higher composite EED scores and a projected decline in 
LAZ scores in the subsequent 6 months53. In a different study, George and 
colleagues adopted Kosek et al.’s composite EED score and explored its 
relationship with growth in Bangladeshi children. This study reported that children 
with higher composite EED scores were more likely to be underweight compared 
to children with lower composite EED scores56.  
 
The present study investigated the prevalence and magnitude of intestinal 
inflammation and permeability in rural Malawian children using these biomarkers. 
Associations between fecal biomarkers of intestinal inflammation or permeability, 
Page | 72 
 
measured individually and as composite scores, and measures of growth 
impairment were also assessed.  
 
4.1.2 Study design and analyses 
 
This study utilized data and biological samples collected by the MORDOR-
morbidity study, the details of which are described in chapter 3. Briefly, the 
baseline MORDOR-morbidity aimed to recruit 1200 randomly selected children 
aged between 1-59 months and resident in 5 geographical zones of Mangochi 
district, Malawi. One-thousand- ninety children from a randomization list of 1704 
names were enrolled into the MORDOR-morbidity study at baseline. 
Anthropometry measurements (height and weight), demographics (age and sex) 
and fecal samples were collected as described in chapter 3. Height and weight 
measurements and demographics were subsequently used to calculate HAZ, 
WAZ and WHZ scores using WHO growth standards34. 
  
Protein extracts from the fecal samples were used to quantify fecal MPO, AAT 
and NEO levels using ELISA assays described in sections 3.1.8.1 to 3.1.8.3 of 
chapter 3. Briefly, fecal samples, collected and archived at -80ºC until processing, 
were diluted 1/100 (for NEO), 1/500 (for MPO) and 1/25,000 (for AAT) and then 
processed using commercially available kits. Determination of fecal MPO, AAT 
and NEO concentration from ELISA absorbance values was done using the 4plm 
in RStudio146. Fecal samples with out-of-range concentration values were re-
tested at a different dilution. Both MPO and NEO indicated intestinal inflammation 
whereas AAT indicated intestinal permeability and protein loss.  
 
To describe the prevalence of intestinal inflammation and permeability, 
proportions of fecal samples with elevated concentrations of AAT, MPO and NEO 
relative to Western values as reported in the literature53,161-163 were calculated. 
Additionally, the distribution of biomarker concentration was calculated by age, 
sex and geographic location and the differences between groups were 
statistically tested using the Kruskal-Wallis or Wilcoxon rank sum tests. HAZ, 
WAZ and WHZ score distributions between normal and elevated biomarker 
concentration or low and high composite EED score were calculated and the 
differences were tested by Student’s t-test. Furthermore, associations between 
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biomarkers, as individual markers and as a composite EED score (using a 
method by Kosek et al.53 described in chapter 3) and stunting, wasting or 
underweight were also investigated.  
4.2 Results 
4.2.1 Demographic characteristics and descriptive statistics 
 
The MORDOR-Malawi morbidity study enrolled 1090 children at baseline 
however only 709 of these chose to participate in the fecal sampling; enrollment 
and participation in fecal sample collection is shown in Figure 3.1.3.2 of chapter 
3. Of the 709 samples collected, 523 fecal samples were available for inclusion 
in this study. Characteristics of all enrolled children and those included in the final 
analyses are shown in Table 4.2.1.1. The proportion of participants residing in 
Makanjira zone were comparable between all enrolled participants and those 
included in the final analyses, however, the distribution of participants from the 
remaining zones was different. Average height, weight, age and sex of 
participants included in the analyses were different from all enrolled participants 
(Table 4.2.1.1).   
Table 4.2.1.1: Characteristics of participants who were included in 
analyses compared to all enrolled participants.  
Participant 
characteristic 
All enrolled 
participants 
Participants with fecal 
sample included in 
analyses 
 
P-value 
Number of participants 1090 523  
Male sex N (%) 487 (44.68%) 264 (50.5%) 0.03 
Mean (SD) height, cm 83.38 (12.45) 85.02 (11.56) 0.005 
Mean (SD) weight, kg 11.34 (3.12) 11.76 (2.94) 0.01 
Mean (SD) age, months 29.59 (16.42) 31.97 (16.02) 0.008 
Geographical location 
  
 
   Chilipa N (%) 235 (21.6%) 147 (28.11%) 0.005 
   Makanjira N (%) 225 (20.6%) 100 (19.12%) 0.518 
   Mangochi N (%) 237 (21.7%) 87 (16.63%) 0.02 
   Monkey Bay N (%) 192 (17.6%) 126 (24.09%) 0.003 
  Namwera N (%) 201 (18.4%) 63 (12.05%) 0.001 
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4.2.2 Distribution of biomarker concentration in the fecal samples 
 
Out of the 523 fecal samples that were included in the final analyses, 488 had 
ELISA assay results for MPO, 425 for NEO, 495 for AAT and 425 had results for 
all the 3 markers. Fecal biomarker concentration distribution was calculated in all 
samples and compared by age, sex and geographic location. Concentration of 
the three biomarkers was positively skewed (Figures 4.2.2.1 - 4.2.2.3). A larger 
proportion of children (62%) had elevated NEO levels relative to reference values 
(Figure 4.2.2.1). Approximately, one third of the children had elevated MPO 
levels (Figure 4.2.2.2). AAT was the least elevated fecal biomarker in all children; 
16% of the children had elevated levels of fecal AAT (Figure 4.2.2.3). The 
relationship between the biomarkers was tested using Pearson’s correlation and 
no relationship was found (Table 4.2.2.1)  
 
Figure 4.2.2.1: Fecal NEO concentration distribution. Normal values were based on 
Western values reported in the literature53,161,162(NEO <=70 nmol/L). 324(61.9%) fecal 
samples had NEO concentration of more than 70nmol. 
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Figure 4.2.2.2: Fecal MPO concentration distribution. Normal values were based on 
Western values reported in the literature53,161,162 (MPO <=2000 ng/ml). 106 (20.3%) fecal 
samples had MPO concentration more than 2000ng/ml. 
 
 
Figure 4.2.2.3: Fecal AAT concentration distribution. Normal values were based on 
Western values reported in the literature53,161,162(AAT <=0.27 mg/g). 81 (15.6%) fecal 
samples had AAT concentration more than 0.27mg/g. 
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Table 4.2.2.1: Relationship between the individual biomarkers of 
EED.  
Variable aCoefficient (95%CI) aP-value 
AAT vs MPO 0.05 (-0.04,0.14) 0.24 
AAT vs NEO 0.002 (-0.09,0.092) 0.97 
MPO vs NEO  -0.012 (-0.11,0.08) 0.81 
 
CI = confidence interval 
aThe correlation coefficient (95% CI) and P-values were obtained with Pearson’s product-moment 
correlation. 
Child age in months was then categorized into 5 groups as follows: 0-12, 13-24, 
25-36, 37-48 and 49-60. The Kruskal-Wallis test was used to test for the 
differences in biomarker concentration distribution among the age groups. There 
were significant differences in biomarker distribution among the 5 age groups. 
Median fecal concentration for all the 3 biomarkers decreased with age (Table 
4.2.2.2). Biomarker concentrations were also compared between the male and 
female sex. The Wilcoxon rank sum test did not show any differences in MPO 
and AAT concentrations by sex, but NEO concentration was higher in female 
children compared to male children (Table 4.2.2.3). Comparison of biomarker 
distribution by geographical location showed differences in the distribution of 
MPO and AAT. Median MPO and AAT concentrations were higher in fecal 
samples from children in Namwera compared to the other geographical zones 
while fecal samples from children in Chilipa had lower concentration of MPO 
(Table 4.2.2.4). 
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Table 4.2.2.2: Biomarker concentration by age  
Variable 
Age (months)  
0 -12 13 - 24 25 - 36 37 - 48 49 - 60 aP-value 
Number of fecal 
samples 
68 (MPO) 104 (MPO) 86 (MPO)  114 (MPO) 86 (MPO) 
 55 (NEO) 99 (NEO) 85 (NEO)  108 (NEO) 81 (NEO) 
66 (AAT) 105 (AAT) 90 (AAT) 117 (AAT) 85 (AAT) 
       
MPO (ng/ml) 4255 (1391,14556) 971 (353,2131) 580 (249,1326) 402 (218,975) 290 (173,530) 2.2e-16 
NEO (nmol/L) 2101 (1050,4153) 402 (112,1491) 133 (37,332) 134 (58,406) 63 (12,165) 1.069e-14 
AAT (mg/g) 0.25 (0.08,0.72) 0.1 (0.04,0.24) 0.06 (0.02,0.13) 0.06 (0.02,0.12) 0.03 (0.02,0.07) 2.2e-16 
 
The concentrations are presented as median (25th,75th quartile).  
aP-value obtained from a Kruskal-Wallis test. 
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Table 4.2.2.3: Biomarker concentration distribution by sex.  
Variable 
                  Sex 
bP-value 
Male Female 
Number of stool 
samples 
228 (MPO) 230 (MPO) 
 231 (AAT) 232 (AAT) 
213 (NEO) 215 (NEO) 
    
MPO (ng/ml) 610 (229,1612) 518 (254,1883) 0.91 
    
AAT (mg/g) 0.06 (0.02,0.16) 0.08 (0.03,0.18) 0.21 
    
NEO (nmol/L) 140 (40,545) 201 (72,1116) 0.02 
 
The concentrations are given as median (25th,75th quartile).  
bP-value obtained from a Wilcoxon rank sum test.
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Table 4.2.2.4: Age and biomarker concentration distribution by geographical location.  
Variable 
Geographical location  
Chilipa Makanjira Mangochi Monkey Bay Namwera P-value 
Number of children 147 97 77 136 58  
Mean (SD) age 31 (16.7) 32 (14.6) 32.6 (16.3) 33.7 (16.4) 30 (15.1) 0.59* 
       
Number of fecal 
samples 
139 (MPO) 97 (MPO) 82 (MPO)  113 (MPO) 57 (MPO)  
116 (NEO) 81 (NEO) 75 (NEO)  98 (NEO) 51 (NEO)  
140 (AAT) 98 (AAT) 86 (AAT) 111 (AAT) 60 (AAT)  
       
MPO (ng/ml) 393 (156,1170) 556 (254,1574) 707 (339,1275) 577 (256,1973) 
850 
(269,2117) 
0.009α 
NEO (nmol/L) 229 (55,1092) 117 (53,402) 161 (86,446) 124 (40,329) 
356 
(80,1582) 
0.06 α 
AAT (mg/g) 0.08 (0.04,0.22) 0.08 (0.02,0.16) 0.07 (0.03,0.2) 0.04 (0.01,0.09) 
0.1 
(0.05,0.25) 
 2.66e-7α 
   
Biomarker concentrations are given as median (25th ,75th quartile).  
  *Denotes P-value obtained from ANOVA whereas αdenotes P-value obtained from a Kruskal-Wallis test.
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4.2.3 Fecal biomarkers of EED were not associated with growth outcomes 
 
Individual biomarkers of EED (MPO, NEO and AAT) and anthropometric scores 
(HAZ, WAZ and WHZ) were used to investigate the association between 
intestinal inflammation or permeability and growth outcomes. Of all the 
participants (n=523) whose fecal samples were assayed for MPO, AAT or NEO, 
488 had weight or height measurements and demographic (age and sex) data 
available. After exclusion of Z scores that were out of range (5 out-of-range HAZ, 
2 out-of-range WAZ and 3 out-of-range WHZ scores), 483 participants were 
included in the analyses of HAZ, 486 in the analyses of WAZ and 485 in the 
analyses of WHZ. HAZ, WAZ and WHZ scores were used as continuous 
variables or categorized into stunted or not-stunted, underweight or not and 
wasted or not wasted respectively as described in chapter 3.1.9. HAZ, WAZ and 
WHZ scores were normally distributed (Figures 4.2.3.1). The proportion of 
children who were stunted was 38.9% (188/483), wasted 4.9% (24/485) and 
underweight 16.3% (79/486). 
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Figure 4.2.3.1 (A) HAZ, (B) WAZ and (C) WHZ score distribution for all the 
participants included in the final analyses. Mean (SD) HAZ score was -1.54 (1.54), 
WAZ score was -0.91 (1.21) and WHZ score was -0.05 (1.17). 
 
Raw concentrations of NEO, AAT and MPO were categorized as normal or 
elevated relative to the reference values; biomarker concentrations less than or 
equal to the reference value were categorized as normal while concentrations 
higher than the reference value were categorized as elevated. HAZ, WAZ and 
WHZ score distribution between normal and elevated biomarker concentration 
was not different in any individual biomarker (Table 4.2.3.1). There was no 
association between each of the biomarkers and stunting or wasting, however, 
normal NEO concentration tended to have an association with reduced chances 
of being underweight (Table 4.2.3.2). 
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Table 4.2.3.1 HAZ, WAZ and WHZ distribution in children with normal and elevated biomarkers.  
Variable 
NEO   MPO   AAT   
Normal Elevated P-value  Normal  Elevated 
P-
value Normal Elevated 
P-
value 
Mean (SD) HAZ -1.69 (1.4) -1.47 (1.6) 0.22 -1.63 (1.49) -1.31 (1.68) 0.08 -1.62 (1.49) -1.4 (1.88) 0.32 
Mean (SD) WAZ -1.03 (0.97) -0.91 (1.27) 0.28 -0.92 (1.15) -0.83 (1.3)  0.37 -0.96 (1.2) -0.82 (1.3) 0.37 
Mean (SD) WHZ 
 -0.06 
(0.94) 
-0.05 
(1.26)  0.91  
0.002 
(1.08)  
 -0.11 
(1.24) 0.38  
-0.05 
(1.08)  
-0.04 
(1.45)  0.92  
 
P-values obtained with Student’s t-test.
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Table 4.2.3.2 Proportion of stunting, wasting and underweight in normal and elevated biomarkers.  
Variable 
NEO 
OR  
(95% CI)1 
 MPO   AAT   
Normal Elevated 
 
P-
value1 
Normal Elevated OR  
(95% CI)1 
 
P-
value1 
Normal Elevated OR 
(95% CI)1 
 
P-
value1 
Stunting             
Not stunted 73 (58.4%) a 189 (63.2%)  
1.01 
(0.64,1.58) 
 210 
(60.2%) 
70 
(66.7%) 1.06 
(0.65,1.77) 
 
0.806 
230 
(60.5%) 
47 
(60.3%) 0.73 
(0.42,1.26) 
 
Stunted 52 (41.6%) 110 (36.8%) 0.974 
139 
(39.8%) 
35 
(33.3%) 
150 
(39.5%) 
31 
(39.7%) 
0.255 
Wasting             
Wasted 3 (2.4%) 18 (6%) 
0.57 
(0.13,1.85) 
 10 
(2.7%) 
10 
(9.5%) 
0.41 
(0.15,1.14) 
 
17 (4.4%) 6 (7.8%) 
0.97 
(0.35,3) 
 
Not wasted 122 (97.6%) 283 (94%) 0.4 
341 
(92.3%) 
95 
(90.5%) 
 
0.09 
366 
(95.6%) 
71 
(92.2%) 0.95 
Underweight             
Underweight 15 (12%) 54 (17.9%) 
0.53 
(0.27,0.99) 
 51 
(14.5%) 
20 
(18.9%) 
0.6 
(0.32,1.14) 
 
65 
(16.9%) 
12 
(15.5%) 
0.99 
(0.49,2.11) 
 
Not 
underweight 110 (88%) 248 (82.1%) 0.055 
300 
(85.5%) 
86 
(81.1%) 0.111 
319 
(83.1%) 
65 
(84.5%) 0.977 
 
aNumber of children (proportion) 
OR=odds ratio 
1OR (95% CI) and P-values obtained with logistic regression after adjusting for age and sex 
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The 3 biomarkers were combined to form a composite EED score that was used 
to investigate the association between EED and anthropometry measures. The 
composite EED score was formed as described in chapter 3.1.9. Four hundred 
and twenty-five fecal samples that had ELISA results for all 3 biomarkers were 
used to form the composite EED score. Absolute weightings from the first 
principal component [component with most variance (Table 4.2.3.3)] were used 
for formation of the composite EED score. The plausibility of combining MPO, 
NEO and AAT to make the composite EED score is visualized in Figure 4.2.3.2 
below. Highest and lowest values for all the three biomarkers clustered separately 
along the first principal component (Figure 4.2.3.2 A-C). Also, the composite 
EED score increased with increasing individual biomarker concentration for each 
of the 3 biomarkers (Figure 4.2.3.2 D). The scores ranged from 0 (lowest score) 
to 3.46 (highest score) with a mean (SD) of 1.73 (0.91). The composite EED score 
was categorized into low and high scores centered around the mean (1.73). Of 
the 425 participants with composite EED score data, 396 had corresponding HAZ 
score data, 398 WAZ score data and 397 WHZ score data. The Student t-test 
was then used to compare the distribution of HAZ, WAZ or WHZ scores between 
low and high composite EED scores. There were no differences in mean (SD) 
HAZ, WAZ and WHZ scores in children with low composite EED score compared 
to children with high composite EED score (Table 4.2.3.4). Logistic regression 
analysis was then used to test for associations between composite EED score 
and stunting, wasting or being underweight. There was no association between 
the composite EED score and stunting, wasting or being underweight (Table 
4.2.3.5).  
 
         Table 4.2.3.3 Importance of the principal components (PC)  
Variable PC 1 PC 2 PC 3 
Standard deviation 1.26 0.87 0.8 
Proportion of variance 0.53 0.25 0.22 
Cumulative proportion 0.53 0.78 1 
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Figure 4.2.3.2 PCA plots of quartile categorized values for AAT (A), MPO (B) and 
NEO (C) for PC1 and PC2. (D) Boxplot of quartile categorized fecal biomarker and 
composite EED score. 
 
Table 4.2.3.4 HAZ, WAZ and WHZ score distribution between low 
and high composite EED score.  
  Variable 
Composite EED score   
Low High P-value  
Mean (SD) HAZ -1.61 (1.49) -1.51 (1.64) 0.22 
Mean (SD) WAZ -0.88 (1.24) -0.96 (1.03) 0.49 
Mean (SD) WHZ -0.04 (1.24) -0.03 (1.0) 0.97 
      
   P-values obtained with Student’s t-test. 
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Table 4.2.3.5: Association between composite EED score and 
growth outcomes. 
Variable 
Composite EED score 
 
 
OR (95% 
CI)1 
 
 
P-value1 
 
Low High    
Stunting    
0.89  
(0.56,1.4) 
  
Not stunted 105 (60%) 140 (63.3%)  
     0.61 
 
Stunted  70 (40%) 81 (36.7%)  
Wasting    
0.48 
(0.12,1.51) 
  
Not wasted 171 (97.7%) 207 (93.2%)  
0.22 
 
Wasted 4 (2.3%) 15 (6.8%)  
Underweight      
Not underweight 152 (86.9%) 182 (81.6%) 0.67 
(0.38,1.15) 
 
0.038 
 
Underweight 23 (13.1 %) 41 (18.4%)  
 
OR=Odds ratio. 
1OR (95% CI) and P-values obtained with logistic regression after adjusting for age and sex. 
 
4.3 Discussion 
 
The present study estimated the magnitude and prevalence of intestinal 
inflammation and permeability in rural Malawian children using fecal biomarkers 
assayed by ELISA. The study also assessed associations between the fecal 
biomarkers of intestinal inflammation or permeability and growth in this 
population. The study found NEO to be elevated in almost two-thirds of the 
children, while MPO was raised in one-third of the children and AAT was elevated 
in less than one third of the children making it the least elevated biomarker in this 
population. No correlation was found between the biomarkers suggesting that 
these biomarkers measure different processes. There were differences in 
biomarker concentration by age; biomarker levels decreased with age. The 
present study also found significant differences in fecal levels of AAT and MPO 
but not NEO by geographic location. Fecal samples of children who resided in 
Namwera had higher levels of AAT and MPO compared to fecal samples of 
children from the other 4 geographic locations. There were no significant 
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differences in fecal biomarker concentration by sex. Furthermore, there was no 
significant association between biomarkers of EED (individually or as a 
composite score) and stunting or wasting, but normal NEO concentration was 
weakly associated with reduced chances of being underweight. These results 
indicate effects of age and the environment on intestinal inflammation or 
permeability and suggest that in this population, intestinal inflammation and 
permeability may not be the primary drivers of child growth inhibition. 
4.3.1 The magnitude and prevalence of intestinal inflammation or permeability 
in rural Malawian children 
 
Previous studies of EED have described the magnitude of intestinal inflammation 
and permeability indicated by fecal levels of AAT, MPO and NEO in low-income 
settings. More than 80% of Bangladeshi infant fecal samples were reported to 
have elevated concentrations of MPO, AAT and NEO relative to Western 
values162,163.  In a multisite study that examined the trends in the concentration of 
fecal AAT, MPO and NEO in infants from low-income settings, average 
concentration of AAT, MPO and NEO in the infants was reported to be higher 
than Western reference values and the concentration of each biomarker 
decreased with increasing age161. The current study found a larger proportion of 
fecal samples from children to have elevated levels of NEO indicating higher 
levels of intestinal inflammation. MPO and AAT were elevated in one-third and 
one-sixth of the fecal samples respectively, and the median MPO and AAT 
concentration values were higher in children aged between 1 and 12 months 
compared to reference values. Additionally, the study found higher levels of fecal 
AAT, MPO and NEO in younger children. These findings are similar to data that 
suggests higher levels of intestinal inflammation and permeability in infants from 
resource limited settings162. Also, the inverse relationship between age and fecal 
levels of AAT, MPO, NEO found in this study confirms trends shown by previous 
studies161. 
  
Higher levels of fecal AAT, MPO and NEO in infants have been previously 
associated with breastfeeding161. Although the present study did not investigate 
associations between breastfeeding and fecal levels of AAT, MPO and NEO, the 
elevated biomarker levels in children aged 1 to 12 months compared to the older 
children may suggest a potential effect of breastfeeding on biomarker 
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concentration in this population as most Malawian children of this age consume 
breast-milk131. The current study did not find any relationship between the 
individual biomarkers, indicating that there can be high levels of one biomarker in 
the absence of other biomarkers. Higher levels of intestinal inflammation and 
permeability in children who were resident in Namwera compared to the other 
geographic locations suggest environmental exposures are associated with EED 
in this geographic location.  
4.3.2 Fecal biomarkers of intestinal inflammation and permeability were not 
associated with growth outcomes 
 
Intestinal inflammation and permeability are some of the key features of EED and 
previous studies have shown or predicted associations between high levels of 
MPO, AAT or NEO and growth faltering53,54,57. Conflicting data also exists for the 
relationship between these biomarkers and growth outcomes. George et al. did 
not find significant associations between higher baseline fecal levels of AAT, 
MPO or NEO and stunting or wasting nor did they find a relationship between 
baseline composite EED score and stunting56. Additionally, Campbell and 
colleagues did not find associations between composite EED score and HAZ 
score at 18 months of follow-up163. The findings by the present study are in 
conflict with some studies but consistent with others. Most of the studies that have 
reported associations between the biomarkers of intestinal inflammation or 
permeability and growth were longitudinal studies conducted in children less than 
2 years of age and generally had larger sample sizes53,57,161 compared to the 
present study and other studies that have reported conflicting data56,163. 
Nonetheless, one study that had a sample size similar to the present study 
reported significant associations between high fecal MPO or AAT concentration 
and linear growth impairment54. The absence of a significant association between 
fecal levels of AAT, MPO or NEO and growth outcomes in the present study 
suggests that intestinal inflammation and permeability are not predominant 
drivers of growth failure in this population. Additionally, the present study showed 
higher levels of AAT, MPO and NEO in younger children compared to older 
children suggesting that if associations between intestinal inflammation or 
permeability and child growth exist, they may be more pronounced in the early 
years of life as the relationship between intestinal inflammation or permeability 
and child growth has primarily been reported in studies conducted in infants. Also, 
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the inconsistencies surrounding the relationship between biomarkers of EED and 
child growth underscore the complexity of EED. Thus, the relationship of EED 
and its pathway to growth failure is likely more complex than suggested to date. 
Furthermore, considering that child growth is also determined by many other 
factors, the relationship between intestinal inflammation or permeability and child 
growth might be masked by other factors such as, food insecurity, prevalence of 
enteric infections or diarrheal diseases, social-economic status, maternal 
education and other determinants of growth that were not investigated in the 
present study. 
  
One of the limitations for this study was the availability of fewer fecal samples 
that were included in the analyses compared to the total number of children 
enrolled by the MORDOR-morbidity baseline study, which limited generalization 
of results. However, this study found age-related differences in fecal biomarker 
concentration, which are consistent with trends reported by previous studies 
conducted in similar settings161. 
4.3.3 Conclusion and future work 
 
The present study showed a higher prevalence of inflammation, indicated by fecal 
levels of NEO, in rural Malawian children compared to Western standards. Also, 
intestinal inflammation and permeability was found to be significantly higher in 
younger children compared to older children. These results are consistent with 
existing data suggesting an effect of age on intestinal inflammation and 
permeability. Higher levels of AAT, MPO and NEO were found in the age group 
corresponding to when children are breastfed and breastfeeding has previously 
been shown to be associated with high fecal levels of AAT and MPO161. Since 
fecal AAT in breastfeeding infants is suggested to be derived from human milk 
and not infant protein loss164, future studies should assess maternal breast-milk 
composition in this population, investigate the impact of breast-milk constituents 
on fecal levels of AAT, MPO or NEO and evaluate whether the use of these 
biomarkers in breastfed children is ideal.  
 
This study also found higher levels of intestinal inflammation and permeability in 
children resident in Namwera compared to other geographic locations. There is 
need to investigate if there are any environmental exposures associated with 
Page | 90 
 
intestinal inflammation and permeability in Namwera. To do this, studies should 
investigate the burden of enteric infections, WASH practices, breastfeeding 
patterns and exposure to contaminated foods in this population. The present 
study did not find an association between intestinal inflammation or permeability 
and growth impairment. This adds to the conflicting reports of associations 
between intestinal inflammation and growth. Further studies should be done in 
this population to assess if associations between fecal biomarkers of EED and 
child growth are not masked by other determinants of growth such as food 
insecurity and burden of enteric diseases. Furthermore, the plausibility of using 
the composite EED score as a disease activity score in EED needs to be 
validated with gold standard tests such as biopsy or endoscopy. The validation 
studies should also explore the mechanisms underlying the combined variability 
of the biomarkers that form the composite EED score.  
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5. Prevalence of intestinal carriage in rural Malawian 
children of mucolytic bacteria and bacteria 
associated with growth in a mouse model  
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5.1.1 Introduction 
 
The human gut is colonized by bacteria that play various roles in regulating host 
physiological processes, one of which is nutrient utilization. Anaerobic bacteria 
localized in the colon ferment undigested carbohydrates thereby producing short-
chain fatty acids (SCFAs) that help maintain host’s energy balance69. Intestinal 
bacteria also play a role in resisting pathogen colonization. A review by Pickard 
et al. suggests that intestinal bacteria resist pathogen colonization by producing 
bacteriocins (bactericidal toxins) and by competing for nutrients165. A study 
investigating the effect of a probiotic bacteria-derived bacteriocin on protection 
against Listeria infection in mice showed protective effects of the bacteriocin 
against Listeria monocytogenes infection166. Also, Escherichia coli Nissle 1917, 
administered as a probiotic bacterium in mouse models of acute colitis, was 
shown to outcompete Salmonella Typhimurium for iron subsequently reducing its 
intestinal colonization167. 
 
Emerging evidence from murine studies indicates that the intestinal bacteria 
might also play a role in mediating growth.  A study that assessed whether a 
growth phenotype could be transmitted via gut bacteria reported significant 
associations75. In this study, fecal samples were collected from Malawian twin-
pairs discordant for kwashiorkor, who were less than 3 years old, had no signs of 
diarrhea and were not consuming antibiotics at the time of sample collection. 
Each sample was then transplanted into separate adult germ-free mice that had 
been fed a sterilized diet, typical of a rural Malawian diet a week before 
transplantation. After fecal transplantation, the mice were kept on the pseudo-
Malawian diet for 3 weeks and then switched to ready-to-use therapeutic food 
(RUTF), usually given to malnourished children, for 2 weeks. The mice were 
switched back to the pseudo-Malawian diet after two weeks on RUTF. Mice that 
were transplanted with fecal samples from kwashiorkor co-twins lost more weight 
during the first 3 weeks of consuming a pseudo-Malawian diet compared to mice 
that were transplanted with fecal samples from their healthy co-twins, however, 
all the mice rapidly gained weight during the 2 weeks on RUTF. Re-exposure of 
the mice to the pseudo-Malawian diet after 2 weeks on RUTF did not show 
significant weight variations compared to what was shown by mice colonized with 
the kwashiorkor microbiota during their first exposure to the pseudo-Malawian 
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diet. Comparison of the fecal microbiota composition between the two groups of 
mice during the first 3 weeks on the pseudo-Malawian diet showed no significant 
differences in the abundance of genera Bifidobacterium and Ruminococcus. 
There was prominent increase however in the abundance of genera 
Bifidobacterium (B. longum and B. bifidum), Ruminococcus (R. torques) and 
Faecalibacterium (F. prausnitzii), during the 2 weeks on RUTF, in mice given 
fecal microbiota from malnourished children compared to recipients of fecal 
samples from healthy co-twins. These results indicate an association between a 
discordant weight loss phenotype and a combination of a Malawian diet and a 
kwashiorkor microbiota. Another corresponding study, conducted to test the 
association between gut microbiota development and undernutrition, reported a 
relationship between gut microbiota and growth phenotypes in a mouse model76. 
In this study, fecal samples from rural Malawian children aged 6 or 18 months, 
representing either a healthy or undernourished growth phenotype, were 
transplanted into germ-free mice and followed up for 5 weeks. The mice were put 
on a sterile, typical rural Malawian diet, 3 days before fecal transplantation and 
remained on that diet throughout the study. Mice that harbored microbiota from 
healthy Malawian children gained more total body weight and lean mass 
compared to mice colonized with microbiota from undernourished children for 
both the 6-month and 18-month age bins. There were no significant associations 
between bacteria diversity and growth phenotypes reported. However, the study 
identified specific bacteria associated with weight gain in mice, which included 
Bifidobacterium longum, Faecalibacterium prausnitzii and Dorea 
formicigenerans.  
 
A few studies, conducted in the human population, have also reported 
associations between the gut microbiota and growth phenotypes. A study that 
characterized the fecal microbiota of malnourished and healthy Bangladeshi 
children reported a persistent reduction of intestinal bacterial diversity in 
malnourished children compared to healthy children168. Additionally, the study 
reported a lower relative abundance of Bifidobacterium in malnourished children 
compared to healthy children. These results suggest a potential role of intestinal 
bacteria on a host’s nutritional status, which can subsequently affect growth and 
warrant further research to explore associations between gut bacteria and growth 
in the human population.  
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There is also emerging evidence linking a recently discovered gram-negative 
mucin-degrading bacterium, Akkermensia muciniphila, to gut health and body 
weight. One in vitro study that used human colonic cell-lines to investigate the 
interaction of A. muciniphila with the host mucosa showed that A. muciniphila 
adhered to the intestinal epithelium and reinforced enterocyte integrity, indicating 
the capability of this bacterium to strengthen intestinal barrier169. Another study 
also reported an association between low abundance of A. muciniphila and 
Crohn’s disease (CD) or ulcerative colitis (UC) in in vitro studies of inflammatory 
bowel disease170.  There is also evidence from murine and human studies 
indicating an association between intestinal carriage of A. muciniphila and body 
weight171-173. A study that was conducted in mice to understand the physiological 
roles of A. muciniphila in obesity reported an inverse relationship between 
intestinal carriage of A. muciniphila and body weight174. Similarly, another study 
in Swedish pre-school children reported significantly lower abundance of A. 
muciniphila in overweight or obese children175. Nevertheless, the role of A. 
muciniphila in gut health and growth of children living in low-income settings, who 
are at risk of developing EED, remains to be studied.  
 
Drawing from the above literature, this study utilized fecal samples from rural 
Malawian children to describe the prevalence of the following bacteria that have 
been associated with gut health and weight gain and had commercial PCR kits 
available: Akkermensia muciniphila, Bifidobacterium longum, Dorea 
formicigenerans, and Faecalibacterium prausnitzii. The study also explored 
associations between intestinal carriage of these bacteria, EED and growth 
outcomes.  
5.1.2 Study design and analyses 
 
The current study utilized data and biological samples collected by the baseline 
survey of the MORDOR-Malawi morbidity study, the details of which are 
described in chapter 3. Briefly, the baseline survey sought to recruit 1200 
randomly selected children aged between 1-59 months and residing in 5 
geographical zones of Mangochi district, Malawi. One-thousand-ninety children 
from a randomization list of 1704 names were enrolled into the MORDOR-Malawi 
morbidity study at baseline. Anthropometry measurements (height and weight), 
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demographics (age and sex) and fecal samples were collected as described in 
chapter 3. Height and weight measurements and demographics were 
subsequently used to calculate HAZ, WHZ and WAZ scores using WHO growth 
standards34.  
 
Out of the 1090 enrolled children, 709 provided fecal samples for the study of 
antimicrobial resistance in MORDOR-Malawi morbidity, of which 612 were 
available for inclusion in the current study. Total, genomic DNA was extracted 
from the fecal samples as described in chapter 3.1.8.4. The extracted genomic 
DNA was amplified by qPCR (detailed in chapter 3.1.8.5) to describe fecal 
carriage of the following bacteria: Akkermensia muciniphila, Bifidobacterium 
longum, Dorea formicigenerans, and Faecalibacterium prausnitzii. The qPCR 
results were classified as positive or negative using a recently published 
method147, with modifications as described in chapter 3.1.9. Additionally, 16S 
rRNA PCR described in chapter 3.1.8.6 was performed. To determine relative 
bacterial abundance, amplification data for each of the 4 bacteria was normalized 
relative to the bacterial 16S rRNA gene in the same sample using the delta CT 
method153. Thus, the resultant delta CT values for each bacterium were 
considered as the relative abundance of that bacterium in the fecal sample.  
 
To describe the prevalence of carriage of defined bacteria, proportions of fecal 
samples with a positive qPCR result for each of the defined bacteria were 
calculated. The fecal samples were then stratified by age, sex, geographic 
location, growth outcome (stunting, wasting and underweight) and proportions of 
bacterial carriage were calculated in each group. Stunting, wasting and 
underweight were defined as described in section 3.1.9 of chapter 3. Fisher’s 
Exact or Pearson’s chi-square tests were used to explore associations between 
bacterial carriage and sex, age, geographic location, growth outcomes and EED. 
The associations between bacterial carriage and biomarkers of EED or growth 
outcomes were also explored using regression analyses adjusting for age and 
sex. The delta CT values for each bacterium were used as a predictor in 
regression analyses to explore associations between relative bacterial 
abundance and growth outcomes or biomarkers of EED.  
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5.2  Results 
5.2.1 Baseline characteristics of participants 
 
The MORDOR-Malawi morbidity study enrolled 1090 children at baseline 
however only 709 of these participated in the fecal sampling. Of the 709 samples 
collected, 612 fecal samples were available for inclusion in this study (Figure 
3.1.3.2 of chapter 3). Characteristics of all children enrolled in MORDOR-
morbidity and those included in the final analyses of this study are shown in Table 
5.2.1.1 below. Participant sex, age, height, weight, HAZ, WHZ and WAZ scores, 
and proportion of children residing in the Makanjira, Mangochi and Monkey Bay 
zones were comparable between all enrolled participants and those included in 
this study, however, a larger proportion of children included in this analysis 
resided in Chilipa zone and a smaller proportion in Namwera zone compared to 
all enrolled participants.   
Table 5.2.1.1 Characteristics of participants who were included in 
analyses compared to all enrolled participants.  
Variable 
All enrolled 
participants 
Participants with 
fecal sample 
included in the 
present analyses 
P-value 
Number of participants 1090 612  
Male sex N (%) 526 (48.26%) 299 (48.78%) 0.85¥ 
Height, cm 83.36 (12.43) 84.49 (12.06) 0.07* 
Weight, kg 11.34 (3.13) 11.6 (3.06) 0.09* 
Age, months 29.59 (16.42) 31.1 (16.36) 0.07* 
HAZ score -1.48 (1.81) -1.49 (1.81) 0.9* 
WHZ score 0.11 (3.51) 0.18 (4.36) 0.74* 
WAZ score -0.86 (1.28) -0.87 (1.25) 0.88* 
Geographical location 
   Chilipa N (%) 235 (21.56%) 168 (27.41%)  0.005¥ 
Makanjira N (%) 225 (20.64%) 131 (21.37%) 0.45¥ 
   Mangochi N (%) 237 (21.74%) 106 (17.29%) 0.09¥ 
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   Monkey Bay N (%) 192 (17.61%) 133 (21.7%) 0.12 
   Namwera N (%) 201 (18.44%) 75 (12.23%) 0.0001 
   
Data are presented as mean (SD) unless otherwise stated.  
*Denotes p-values obtained from Student’s t-test while ¥denotes p-values obtained from sample 
proportion test. 
 
5.2.2 Prevalence of bacterial carriage in the fecal samples 
 
Proportions of fecal samples with a positive qPCR result for each of the 4 bacteria 
were calculated (Table 5.2.2.1). D. formicigenerans and F. prausnitzii were the 
most prevalent bacteria; D. formicigenerans was present in 79% of the samples 
while F. prausnitzii was present in 98% of the samples. B. longum was present in 
just over one third of the fecal samples making it the least prevalent bacterium 
tested. Fecal samples were stratified by age, sex and geographic location and 
bacterial carriage was determined in each category. There was no difference in 
the prevalence of F. prausnitzii, B. longum and A. muciniphila between male and 
female children, however, a higher proportion of fecal samples from male children 
were positive for D. formicigenerans compared to the female children (Table 
5.2.2.2). Prevalence of D. formicigenerans, F. prausnitzii and B. longum but not 
A. muciniphila were comparable by geographic location (Table 5.2.2.3). A larger 
proportion (56%) of fecal samples from children residing in Chilipa zone were 
positive for A. muciniphila compared to fecal samples from other zones while a 
lower proportion (26%) of fecal samples from children in Mangochi zone were 
positive for this bacterium. Child age, in months, was categorized into 5 groups 
(1-12, 13-24, 25-36, 37-48 and 49-60) to compare bacterial carriage. Fecal 
bacterial carriage for all the 4 bacteria was different by age (Table 5.2.2.4). B. 
longum was more prevalent in fecal samples from the younger children while D. 
formicigenerans, F. prausnitzii and A. muciniphila were more prevalent in the 
older children.  
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Table 5.2.2.1 Prevalence of bacterial carriage in the fecal samples  
Variable                          Proportion of positive samples (n) 
B. longum 29.2 % (179) 
A. muciniphila 43.1 % (264) 
D. formicigenerans 78.8 % (483) 
F. prausnitzii 98.4 % (603) 
  Total number of fecal samples=612. 
 
Table 5.2.2.2 Bacterial carriage by sex 
Variable 
Sex P-
value1 Female (n=314) Male (n=299) 
B. longum positive N (%) 96 (30.57) 83 (27.76) 0.5 
A. muciniphila positive N (%) 132 (42.04) 132 (44.15) 0.65 
D. formicigenerans positive N (%) 235 (74.84) 248 (82.94) 0.019 
F. prausnitzii positive N (%) 307 (97.77) 296 (99) 0.34* 
  
1All P-values were obtained from Pearson’s chi-square test except *denoted P value that 
was obtained from Fisher’s Exact test. 
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Table 5.2.2.3 Bacterial carriage by geographic location 
Variable 
Geographical location  
Chilipa 
(n=168) 
Makanjira 
(n=131) 
Mangochi 
(n=106) 
Monkey 
Bay 
(n=133) 
Namwera 
(n=75) 
P-value1 
B. longum positive N (%) 
52  
(30.95) 
35  
(26.72) 
28  
(26.42) 
40 (30.08) 
24  
(32) 
0.85 
A. muciniphila positive N (%) 
93  
(55.36) 
53  
(40.86) 
28  
(26.42) 
 
56 (42.11) 
 
34 (45.33) 
 
0.0001  
D. formicigenerans positive N (%) 
131 (77.98) 110 (83.97) 
80  
(75.47) 
110 
(82.71) 52 (69.33) 0.08 
F. prausnitzii positive N (%) 
164 (97.62) 128 (97.71) 
106  
(100) 131 (98.5) 74 (98.67) 0.59* 
 
1All P-values were obtained from Pearson’s chi-square test except *denoted P value that was obtained from Fisher’s Exact test. 
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Table 5.2.2.4 Bacterial carriage by age  
Variable 
Age in months 
 
 
P-value1 
1-12 
(n=104) 
13-24 
(n=134) 
25-36 
(n=120) 
37-48 
(n=144) 
49-60 
(n=111) 
  
B. longum positive N (%) 85 (81.73) 61 (45.52) 17 (16.5) 12 (8.33) 4 (3.6) 2.2e-16 
A. muciniphila positive N (%) 27 (25.96) 64 (47.76) 63 (52.5) 60 (41.67) 50 (45.05)  0.001 
D. formicigenerans positive N (%) 44 (42.31) 109 (81.34) 105 (87.5) 122 (84.72) 103 (92.79) 2.2e-16 
F. prausnitzii positive N (%) 99 (95.19) 132 (98.51) 120 (100) 143 (99.31) 109 (98.2) 0.06* 
 
1All P-values were obtained from Pearson’s chi-square test except *denoted P value that was obtained from Fisher’s Exact test. 
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5.2.3 Intestinal carriage of B. longum and D. formicigenerans was associated 
with biomarkers of EED 
 
Analyses were conducted to test for associations between bacterial carriage and 
biomarkers of EED. Individual biomarkers (AAT, NEO and MPO) and the 
composite EED score described in chapter 4 were used in this analysis. Briefly, 
out of the 612 participants who were included in the analysis of prevalence of 
bacterial carriage, 478 had corresponding ELISA results for at least one of the 3 
fecal biomarkers and so were included in the analysis of the associations 
between bacterial carriage and individual biomarkers of EED. As presented in the 
analyses of chapter 4, 71% (295/417) of fecal samples had elevated NEO 
concentration while 23% (104/449) and 16% (74/454) had elevated 
concentrations for MPO and AAT respectively. Logistic regression analysis was 
conducted to explore associations between bacterial carriage and biomarker 
concentration (categorized as normal or elevated as described in chapter 4) 
adjusting for age, location and sex. In the logistic regression models, bacterial 
carriage was used as a predictor variable while biomarker concentration was 
used as a binary response variable. The analysis found no associations between 
fecal carriage of A. muciniphila or F. prausnitzii and any of the 3 biomarkers of 
EED. However, there was evidence of an association between fecal carriage of 
B. longum and all the 3 biomarkers. Being positive for B. longum carriage 
increased the odds of having elevated biomarker concentrations (vs normal 
concentrations) by factors of 2.6, 2.6 and 4.7 for MPO, AAT and NEO 
respectively. Also, fecal carriage of D. formicigenerans was associated with 
normal MPO concentration; fecal samples that were positive for D. 
formicigenerans had 0.3 odds of having elevated MPO concentration compared 
to those that were negative for D. formicigenerans (Table 5.2.3.1).  
In chapter 4, fecal biomarker concentration was shown to be associated with age. 
In this chapter, age was again associated with bacterial carriage. To mitigate for 
confounding, age in months was stratified into 4 groups (0-12, 12-24, 24-36 and 
36-60) and associations between bacterial carriage and the biomarkers were 
explored in each age group. B. longum carriage in the younger age groups (0-12 
and 12-24) was associated fecal concentrations of MPO and NEO but not in the 
older age groups (> 24 months) [Table 5.2.3.2]. In the 0-12 age group, B. longum 
carriage increased the odds of having elevated MPO concentration (vs normal 
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concentration) by a factor of 7.4 while being positive for B. longum in the 12-24 
age group increased the odds of having elevated NEO concentration (vs normal 
concentration) by a factor of 17.5. D. formicigenerans carriage was associated 
with MPO concentration in the youngest age group after adjusting for sex and 
geographic location (0-12 months, OR=0.18, 95% CI [0.04,0.59], P=0.007); fecal 
samples that were positive for D. formicigenerans in the 0-12 age group had 0.18 
odds of having elevated MPO concentration compared to those that were 
negative for D. formicigenerans. There were no significant associations between 
D. formicigenerans carriage and MPO concentration in the other 3 age groups 
(12-24 months, OR=0.8, 95% CI [0.2,3.3], P=0.7, 24-36 months, OR=1.1, 95% 
CI [0.1,23.2], P=0.96 and 36-60 months, OR=0.3, 95% CI [0.1,1.03], P=0.044). 
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  Table 5.2.3.1 Association between B. longum carriage and biomarkers of EED 
CI= confidence interval, OR=odds ratio. 
n (%) = Number of fecal samples (proportion) positive. 
aOdds ratio (95% CI) and P-values were obtained with logistic regression after adjusting for age, location and sex. Using the Bonferroni correction for multiple testing, 
associations with a P-value less than 0.0125 were considered statistically significant. 
 
Variable 
MPO AAT NEO MPO AAT NEO 
Normal 
(n=345) 
Elevated 
(n=104) 
Normal 
(n=380) 
Elevated 
(n=74) 
Normal 
(n=122) 
Elevated 
(n=295) 
ORa 
(95% CI) 
P-
valuea 
ORa 
(95% CI) 
P-
valuea 
ORa 
(95% CI) 
P-
valuea 
B. longum  
n (%) 
60 
(17.4) 
59 
(56.7) 
72 
(18.9) 
47 
(63.5) 
7 
(5.7) 
98 
(33.2) 
2.6 
(1.4,4.6) 
 
0.002 
2.6 
(1.4,5.1) 
 
0.004 
4.7 
(2.1,12.3) 
 
0.0004 
 
A. muciniphila 
n (%) 
 
159 
(46.1) 
 
41 
(39.4) 
 
176 
(46.3) 
 
27 
(36.5) 
 
61 
(50) 
 
133 
(45.1) 
 
0.9 
(0.5,1.5) 
 
 
0.619 
 
0.8 
(0.4,1.3) 
 
 
0.354 
 
0.8 
(0.5,1.3) 
 
 
0.407 
D. 
formicigenerans 
n (%) 
 
307 
(89) 
 
66 
(63.5) 
 
328 
(86.3) 
 
48 
(64.9) 
 
112 
(91.8) 
 
244 
(82.7) 
 
0.3 
(0.2,0.6) 
 
 
0.001 
 
0.7 
(0.4,1.4) 
 
 
0.298 
 
0.7 
(0.3,1.5) 
 
 
0.427 
F. prausinitzii 
n (%) 
  
340 
(98.6) 
  
102 
(98.1) 
  
374 
(98.4) 
  
73 
(98.7) 
  
121 
(99.2) 
  
291 
(98.6) 
  
0.9 
(0.1,7.6) 
  
 
0.89 
  
2.5 
(0.3,53.6) 
  
 
0.454 
  
0.5 
(0.03,4) 
  
 
0.585 
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Table 5.2.3.2 Association between bacterial carriage and biomarkers of EED stratified by age  
  MPO AAT NEO MPO AAT NEO 
Age 
(months) Normal Elevated Normal Elevated Normal Elevated 
OR  
(95% CI) 
P-
Value 
OR  
(95% CI) 
P-
Value 
OR  
(95% CI) 
P-
Value 
0 – 12 
*n (%) 
¥n=23 n=44 n=34 n=31 n=4 n=50 
7.4  
(1.9,34.5) 0.006 
    
13 (56) 40 (91) 23 (68) 27 (87) 3 (75) 40 (80) 
3.02 
(0.81,13.1) 0.112 
1.4 
(0.02,14) 0.804 
             
12 – 24  
n (%) 
n=72 n=30 n=79 n=24 n=17 n=80 
1.7 
(0.7,4.3) 0.268 
    
29 (40) 16 (53) 30 (38) 16 (67) 1 (6) 41 (51) 
3.1 
(1.2,8.6) 0.023 
17.5 
(3.26,324.8) 0.007 
             
24 – 36  
n (%) 
n=73 n=10 n=79 n=8 n=28 n=53 
2.1 
(0.3,11.8) 0.427 
    
7 (10) 2 (20) 6 (8) 3 (38) 0 7 (13) 
11.9 
(1.6,121) 0.019 
2.8 
(0.03,14.2) 0.991 
             
36 – 60  
n (%) 
n=177 n=20 n=188 n=11 n=73 n=112 
 0.68 
(0.04,11.8) 0.727  
    
 11 (6)  1 (5)  13 (7)  1 (9)  3 (4) 10 (9)  
 1.28 
(0.06,8.5) 0.822  
 2.4 
(0.7,11.3) 0.204  
         *n (%) = Number (proportion) positive for B. longum  
         ¥Number with normal or elevated biomarker concentration 
           CI= confidence interval, OR=odds ratio.  aOdds ratio (95% CI) and P-values were obtained with logistic regression after adjusting for location and sex. Using the   
Bonferroni correction for multiple testing, associations with a P-value less than 0.0125 (highlighted in bold) were considered statistically significant. 
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Of the 478 participants who had ELISA results, only 389 had ELISA results for all 
the 3 biomarkers from which the composite EED score could be calculated. Thus, 
data from these 389 participants was used to explore the associations between 
bacterial carriage and the composite EED score. Composite EED scores were 
categorized into low and high scores centered around the mean score (1.73). 
Logistic regression analysis, adjusted for age and sex, was conducted to explore 
associations between bacterial carriage and composite EED score; bacterial 
carriage was used as a predictor variable while the composite EED score was 
used as a binary response variable in the logistic regression model. The analysis 
showed no associations between fecal carriage of A. muciniphila, F. prausnitzii 
or D. formicigenerans and the composite EED score, however, fecal samples that 
were positive for B. longum had 7.0 increased odds of having high composite 
EED scores relative to those that were negative for B. longum (Table 5.2.3.3). 
Table 5.2.3.3 Association between bacterial carriage and 
composite EED score 
Variable Composite EED score 
 
Low 
(n=175) 
High 
(n=214) 
  
OR (95% CI)1 
 
P-value1 
B. longum 9 (5.1) 90 (42.1)  7.0 (3.3,16.3) 1.08e-06 
A. muciniphila 83 (47.4) 96 (44.9)  1.0 (0.6,1.6) 0.979 
D. formicigenerans 162 (92.6) 169 (79)  0.7 (0.3,1.5) 0.06 
F. prausnitzii 172 (98.3) 212 (99.1)  1.4 (0.2,12.6) 0.73 
 
CI= confidence interval. 
OR=Odds ratio. 
1Odds ratio (95% CI) and P-values obtained with logistic regression after adjusting for age, 
location and sex. 
 
 
5.2.4 Intestinal carriage of F. prausnitzii and B. longum was associated with 
growth outcomes 
 
Associations between bacterial carriage and growth outcomes were explored 
using regression analyses. HAZ, WHZ and WAZ scores were used as continuous 
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response variables in linear regression analyses to explore associations between 
bacterial carriage and Z scores. Linear regression analysis, adjusted for age and 
sex, showed no associations between any of the 4 bacteria and HAZ or WHZ 
scores, however, B. longum and F. prausnitzii were associated with lower WAZ 
(Table 5.2.4.1). The Z scores were then categorized into stunted or not-stunted, 
wasted or not-wasted and underweight or not-underweight as described in 
chapter 3.1.9. Comparison of bacterial carriage by growth outcome showed 
similar proportions of D. formicigenerans, F. prausnitzii and A. muciniphila 
between fecal samples from stunted and non-stunted, wasted and not wasted 
and underweight or not-underweight children (Table 5.2.4.2). Logistic regression 
analysis, adjusting for age and sex, showed no association between intestinal 
carriage of D. formicigenerans, F. prausnitzii,  A. muciniphila  and stunting, 
wasting or being underweight, however, B. longum carriage was associated with 
2.7 increased odds of being underweight compared to not being underweight 
(Table 5.2.4.2).  
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 Table 5.2.4.1 Association between bacterial carriage and Z-scores 
Variable  HAZ  WHZ                   WAZ 
    
Coefficient 
 (95% CI) a P-valuea 
Coefficient 
 (95% CI) a 
 
0.49 
(-0.45,1.44) 
 
-0.35 
(-1.05,0.35) 
 
-1.07 
(-1.97, -0.17) 
 
-3.04 
(-5.78, -0.31) 
 
P-valuea 
Coefficient   
(95% CI) a    
 
-0.49 
(-0.75, -0.23) 
 
-0.14 
(-0.34, 0.05) 
 
-0.06 
(-0.31,0.2) 
 
-1.53 
(-2.23, -0.77) 
 
P-valuea 
B. longum   
-0.26  
(-0.0.64,0.12) 0.175 
 
 
0.31 
 
 
0.0003 
A. muciniphila   
- 0.24  
(-0.53,0.03) 0.083 
 
 
0.33 
 
 
0.15 
       
D. formicigenerans   
- 0.08  
(-0.44,0.28) 
 
0.656 
 
0.02 
 
0.66 
 
F. prausnitzii 
  
 -0 .01  
(-1.1, 1.08) 0.985 
 
 
0.029 
 
 
9e-05 
  CI= confidence interval. 
   aCoefficients (95% CI) and P-values obtained from a linear regression analysis after adjusting for age and sex. Using the Bonferroni correction for multiple 
testing, associations with a P-value less than 0.0125 (highlighted in bold) were considered statistically significant. 
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Table 5.2.4.2 Association between bacterial carriage and growth outcomes 
 
*Number of positive samples (proportion of positive samples). 
aP-value obtained with logistic regression analysis adjusted for age and sex. 
Using the Bonferroni correction for multiple testing, associations with a P-value less than 0.0125 were considered statistically significant.
Variable 
Stunting Wasting Underweight Stunting Wasting Underweight 
Stunted 
(n=229) 
Not 
stunted 
(n=384) 
Wasted 
(n=28) 
Not 
wasted 
(n=585) 
Yes 
(n=93) 
No 
(n=520) 
ORa 
(95% CI) 
P-
valuea 
ORa 
(95% CI) 
P-
valuea 
ORa 
(95% CI) 
P-
Valuea 
B. longum  
n (%) 
 
55 
(24%)* 
 
124 
(32.3%) 
 
16 
(57.1%) 
 
163 
(28.9%) 
 
35 
(37.6%) 
 
144 
(27.7%) 
 
0.99 
(0.62,1.57) 
 
 
0.97 
 
1.66 
(0.63,4.53) 
 
 
0.31 
 
2.7 
(1.5,5.1) 
 
 
0.001 
 
A. muciniphila 
n (%) 
107 
(46.8%) 
157 
(40.9%) 
10 
(35.7%) 
254 
(43.4%) 
47 
(50.5%) 
217 
(41.7%) 
1.21 
(0.86,1.69) 
 
0.27 
0.87 
(0.37,1.93) 
 
0.73 
0.87 
(0.37,1.93) 
 
0.15 
D. formicigenerans 
n (%) 
 
190 
(83%) 
 
293 
(76.3%) 
 
18 
(64.3%) 
 
465 
(79.5%) 
 
74 
(79.6%) 
 
409 
(78.6%) 
 
1.18 
(0.76,1.85) 
 
 
0.47 
 
0.83 
(0.34,2.09) 
 
 
0.67 
 
0.83 
(0.34,2.09) 
 
 
0.87 
F. prausinitzii 
n (%) 
 
226 
(99%) 
 
377 
(98.2%) 
 
28 
(100%) 
 
575 
(98.3%) 
 
93 
(100%) 
 
510 
(98.1%) 
 
1.13 
(0.3,5.38) 
 
 
0.86 
 
3.4 
(0.006,6.77) 
 
 
0.99 
 
3.1 
(0.006,6.8) 
 
 
0.98 
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5.2.5 Relative bacterial abundance was associated with biomarkers of EED but 
not growth outcomes 
 
Relative bacterial abundance was determined by normalizing amplification data 
for the specific bacteria relative to amplification of total bacterial DNA in each 
sample. Only samples that had a target from the species-specific PCR (detailed 
in chapter 3.1.8.5) amplified before 40 cycles were used to calculate relative 
bacterial abundance. Six hundred and twelve samples had D. formicigenerans or 
F. prausnitzii amplified before 40 cycles, 603 B. longum and 352 A. muciniphila 
and therefore were included in this analysis. Logistic regression analysis was 
conducted to explore associations between relative bacterial abundance and 
biomarkers of EED, stunting, wasting and underweight while linear regression 
analysis was conducted to explore the relationship between relative bacterial 
abundance and Z scores. Both regression models were adjusted for age, sex or 
geographic location. Exploratory analyses on the relationship between relative 
bacterial abundance and biomarkers of EED showed no relationship between 
relative abundance of D. formicigenerans or A. muciniphila and all the 3 
biomarkers of EED. However, there was a significant association between 
relative abundance of B. longum and MPO or NEO (Table 5.2.5.1). An increase 
in relative abundance of B. longum was associated with increased odds of having 
elevated concentration of MPO (odds ratio of 1.1, P=0.0015) and NEO (odds ratio 
of 1.1, P=0.017). Additionally, relative abundance of F. prausnitzii and fecal 
concentrations of MPO and AAT were associated. An increase in relative 
abundance of F. prausnitzii was associated with reduced odds of having elevated 
MPO (odds ratio of 0.9, P= 0.007) and AAT (odds ratio of 0.89, P=0.01). There 
was no association between relative abundance of A. muciniphila, F. prausnitzii, 
D. formicigenerans and the composite EED score, but, relative abundance of B. 
longum and composite EED score were associated (Table 5.2.5.2). An increase 
in relative abundance of B. longum was associated with increased odds of high 
composite EED score (odds ratio=1.13, P=0.0004). There was no relationship 
between relative bacteria abundance and HAZ or WAZ scores nor was there an 
association between relative bacteria abundance and stunting, wasting or being 
underweight after adjusting for age and sex.  B. longum and F. prausinitzii, 
however, were associated with WHZ score (Table 5.2.5.3). A unit increase in the 
relative abundance of B. longum was associated with a 0.12 increase in WHZ 
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score whereas increase in the relative abundance of F. prausnitzii was associated 
with a 0.11 decrease in WHZ score.  
Table 5.2.5.1 Association between relative bacterial abundance 
and biomarkers of EED 
Variable 
MPO AAT NEO 
OR  
(95% CI) 
P-
value1 
OR  
(95% CI) 
P-
value
1 
OR  
(95% CI) 
P-
value
1 
B. longum 
 
1.1  
(1.0, 
1.2) 0.0015 
1.1  
(1,1.1) 0.073 
1.1 
(1.02,1.2) 0.017 
A. muciniphila 
 
1.0  
(0.9, 
1.1) 0.868 
1.1 
(1.0,1.2) 0.114 
1.0 
(0.9,1.1) 0.298 
D. 
formicigenerans 
 
1.0 (0.94, 
1.14) 0.496 
1.1 
(0.96,1.15) 0.274 
0.99 
(0.9,1.1) 0.779 
F. prausnitzii 
  
0.9 (0.82, 
0.97) 0.007  
 0.9 
(0.82,0.97)  0.01 
 0.94 
(0.87,1.02) 0.137 
CI= confidence interval, OR=odds ratio. 
1OR (95%CI) and P-values obtained from logistic regression after adjusting for age, location and 
sex.  
Table 5.2.5.2 Association between relative bacterial 
abundance and composite EED score 
Variable 
Composite EED score 
OR (95% CI)1 
P-
value1 
B. longum 1.13 (1.06,1.22) 0.0004 
A. muciniphila 1.07 (0.99,1.17) 0.09 
D. formicigenerans 0.99 (0.9, 1.04) 0.754 
F. prausnitzii  0.9 (0.8,0.98)  0.013 
CI= confidence interval, OR=Odds ratio. 
1Odds ratio (95% CI) and P-values obtained with logistic regression after adjusting for age, 
location and sex. 
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               Table 5.2.5.3 Association between relative bacterial abundance and Z-scores 
Variable 
HAZ WHZ WAZ 
Coefficient  
(95% CI)1 P-value1 
Coefficient  
(95% CI)1 P-value1 
Coefficient  
(95% CI)1 
P-
value1 
B. longum 0.001 (-0.03,0.04) 0.961 0.12 (0.02,0.23) 0.024 -0.01 (-0.04,0.01) 0.391 
A. muciniphila -0.02 (-0.06,0.03) 0.476 0.01 (-0.03,0.05) 0.709 -0.004 (-0.037,0.029) 0.808 
D. 
formicigenerans 0.01 (-0.03,0.06) 0.579 0.02 (-0.01,0.05) 0.204 0.02 (-0.01,0.048) 0.21 
F. prausinitzii  0.004 (-0.04,0.037)  0.845 -0.11 (-0.22,-0.01) 0.031  0.02 (-0.01,0.04)  0.301  
 
CI= confidence interval. 
1Denotes regression coefficient and P-value obtained with linear regression after adjusting for age and sex.
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5.2.6 The effect of D. formicigenerans carriage in EED was dependent on B. 
longum carriage 
 
In the above results, B. longum carriage and relative abundance of B. longum 
were both significantly associated with biomarkers of EED (individually or as a 
composite score). B. longum carriage was also associated with WAZ while 
relative abundance of B. longum was associated with WHZ.  Additionally, 
intestinal carriage of B. longum or D. formicigenerans was associated with MPO 
concentration. B. longum carriage or relative abundance and composite EED 
score were then included as exposures in a multi-variable linear regression 
analysis, together with age and sex, to test the link between B. longum carriage 
or relative abundance, EED and WAZ or WHZ. There was no relationship 
between B. longum carriage, EED and WAZ neither was there a relationship 
between relative abundance of B. longum, EED and WHZ.  In another multi-
variable logistic regression model, B. longum and D. formicigenerans were also 
included as exposures, with age and sex, to test the independence of the 
associations between intestinal carriage of B. longum or D. formicigenerans and 
EED. Intestinal carriage of B. longum, but not D. formicigenerans, was associated 
with 6.33 increased odds of having high composite EED scores compared to low 
composite EED scores (Table 5.2.6.1).   
Table 5.2.6.1 Multi-variable logistic regression models for 
composite EED score in the presence of B. longum, D. 
formicigenerans, age and male sex 
Variable 
Composite EED score 
OR (95% CI) P-value 
B. longum 6.33 (3.02, 14.59) 3.4e-06 
D. formicigenerans 0.58 (0.27,1.24) 0.169 
Age  0.96 (0.94,0.98) 1.1e-5 
Sex (Male)  0.92 (0.58,1.46)  0.725 
 
OR = odds ratio  
CI= confidence interval 
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5.3  Discussion 
 
The present study described the prevalence of intestinal carriage Akkermensia 
muciniphila, Bifidobacterium longum, Dorea formicigenerans, and 
Faecalibacterium prausnitzii in rural Malawian children. The associations 
between intestinal carriage of these bacteria and biomarkers of EED or child 
growth were also explored. F. prausnitzii and D. formicigenerans were found to 
be the most prevalent of the bacteria studied, with F. prausnitzii being present in 
98% of all fecal samples. D. formicigenerans was present in over two-thirds of 
the fecal samples tested while A. muciniphila was present in almost half of the 
children and B. longum was the least prevalent of bacteria tested; just over one-
third of the children carried this bacterium. Comparison of bacterial carriage by 
age showed significant differences. B. longum was more prevalent in younger 
children compared to older children while D. formicigenerans was more prevalent 
in older children. Additionally, prevalence of D. formicigenerans was higher in 
fecal samples from male children compared to female children. Fecal samples of 
children residing in Mangochi had a significantly lower proportion of A. 
muciniphila compared to children from the other 4 geographic locations. Intestinal 
carriage and relative abundance of B. longum were associated with elevated 
individual biomarker concentration and high composite EED scores while 
carriage of D. formicigenerans was associated with normal MPO concentration 
and tended to be associated with reduced chances of having high composite EED 
scores. The study also found an inverse relationship between relative abundance 
of F. prausnitzii and AAT or MPO concentrations. Analyses of the relationship 
between intestinal carriage of B. longum, F. prausnitzii and weight metrics 
showed associations. Intestinal carriage of B. longum and F. prausnitzii was 
associated with lower WAZ. Additionally, increased relative abundance of B. 
longum correlated with an increase in WHZ while increased relative abundance 
of F. prausnitzii was associated with lower WHZ. Multi-variable regression 
analysis showed no relationship between intestinal carriage or relative 
abundance of B. longum, EED and WAZ or WHZ, however, B. longum carriage 
was shown to negate the association between D. formicigenerans carriage and 
biomarkers of EED. These findings suggest a potential role of individual bacteria 
species in EED development and as mediators of weight-related growth in rural 
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Malawian children. Additionally, the results suggest that the effects of D. 
formicigenerans in EED are not independent.  
 
5.3.1 Prevalence of bacterial carriage in children 
 
F. prausnitzii is one of the most common and abundant intestinal bacteria in the 
human gut176. This bacterium has been shown to be present in very small 
proportions in infants during the first 6 months of life, with a gradual increase in 
abundance at 7 months of life that doubled during the second year of life177. 
Studies that used a machine-learning-based approach to define a healthy gut 
microbiota of Bangladeshi or Malawian children identified F. prausnitzii as one of 
the most important age discriminatory bacteria and confirmed its low abundance 
in early life and subsequent increase76,168. Similarly, D. formicigenerans was 
shown to be higher in abundance after 10 months of age in Bangladeshi 
children168. The present study investigated the prevalence of bacterial carriage in 
children less than 5 years using qPCR. The study found a larger proportion of 
fecal samples that were positive for F. prausnitzii and D. formicigenerans. 
Prevalence of D. formicigenerans increased with age while F. prausnitzii 
prevalence showed a trend that increased with age. These results reflect the age 
prevalence and abundance reported by other studies that have used real-time 
PCR and 16S rRNA gene sequencing 76,168,177. This study also found that D. 
formicigenerans tended to be more prevalent in male children compared to 
female children. To date, there is no study that has reported a relationship 
between D. formicigenerans carriage and sex. Since there is limited data 
available on the associations between intestinal bacteria and sex in children, 
further large-scale studies are needed to validate the effect of sex on D. 
formicigenerans carriage in children and indeed its significance.  
 
This study also detected A. muciniphila in almost half of the fecal samples tested. 
A. muciniphila is a recently discovered gram-negative bacterium that produces 
several enzymes that degrade mucin (mucous lining of the gut) subsequently 
providing carbon and nitrogen to other intestinal bacteria178. Collado et al. 
reported that A. muciniphila colonized the intestinal tract early in life and 
developed close to the level observed in healthy adults within 1 year179. The 
finding from the present study that A. muciniphila was present in one-third of 
Page | 115 
 
children aged between 1 and 12 months supports the data indicating early gut 
colonization by A. muciniphila. Additionally, the observation that the proportion of 
fecal samples positive for A. muciniphila doubled in age groups older than 12 
months is in agreement with the finding that indicated increased abundance of A. 
muciniphila, close to the healthy adult level, within 1 year of life74. The current 
study also found significant differences in A. muciniphila carriage by geographic 
location. The proportion of A. muciniphila carriage was significantly lower in 
children from Mangochi compared to the other 4 locations (Chilipa, Makanjira, 
Monkey and Namwera) where bacterial carriage was comparable. Mangochi can 
be considered a peri-urban setting in comparison to the other 4 rural geographical 
zones so this finding suggests an environmental effect on A. muciniphila carriage.  
 
B. longum is considered a beneficial bacteria that is widely used in developing 
probiotics180. Khonsari et al. reported higher abundance of B. longum in infants 
compared to adults181 suggesting that B. longum colonizes the infant gut more 
than that of older children. The current study found a lower prevalence of 
intestinal carriage of B. longum than other studies. One explanation for this could 
lie in the number of infant participants as the current study had a larger proportion 
of older children. The observation that B. longum carriage was more often found 
in children younger than 12 months compared to the older age groups supports 
data from previous studies that indicated higher numbers of B. longum in infants 
compared to older children64,68,181. The higher abundance of B. longum in children 
aged 1-12 months may be attributed to breastfeeding, which is common in this 
age group. B.  longum has been shown to be present in breast-milk182,183.  
5.3.2 B. longum and D. formicigenerans were associated with biomarkers of 
EED 
 
There is limited data on the associations between intestinal bacteria and 
biomarkers of EED. A study that was conducted to identify the gut bacterial 
community structure associated with moderate to severe EED (defined by an L:M 
ratio test) in Malawian children did not document any relationship between B. 
longum or D. formicigenerans and L:M ratios59. Although there is no data 
available indicating the role of B. longum or D. formicigenerans in EED, studies 
of IBD have reported mixed results on the role of the genus Bifidobacterium. 
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Fyderek et al. reported a lower abundance of Bifidobacterium in adolescents with 
IBD compared to their controls184, while other studies have shown no reduction 
in the abundance of Bifidobacterium in patients with active CD185,186. Interestingly, 
an increase in the relative abundance of Bifidobacterium was reported in IBD 
adult patients compared to their healthy controls187,188.  
 
The present study found an association between fecal carriage and relative 
abundance of B. longum with biomarkers of EED. Fecal carriage of D. 
formicigenerans and biomarkers of EED were also significantly associated. B. 
longum carriage and relative abundance were associated with elevated fecal 
levels of AAT, MPO, NEO and high composite EED scores while carriage of D. 
formicigenerans was associated with normal MPO concentration and marginally 
associated with reduced chances of having high composite EED scores. The 
positive association between B. longum carriage and elevated biomarkers of EED 
is unusual considering that this bacterium has been largely shown to have 
beneficial effects in the human host. Nonetheless, this finding is consistent with 
data from IBD studies that showed an increase in the number of Bifidobacterium 
in IBD patients188. The positive association between B. longum and biomarkers 
of EED in the present study could be due to confounding by other factors such 
as breastfeeding and enteric infections, which were not assessed in the present 
study. Breastfeeding and enteric infections have been associated with elevated 
levels of MPO and AAT in Bangladeshi infants161. Nevertheless, age was 
adjusted for in the analyses and given the association between age and 
breastfeeding, adjusting for age in the analyses should have mitigated for 
confounding by breastfeeding. D. formicigenerans was associated with normal 
fecal MPO levels and reduced chances of having high composite EED scores in 
this study suggesting that this bacterium might be an indicator of normal gut 
health. However, multi-variable analysis showed that presence of B. longum 
negated the association between D. formicigenerans and composite EED score. 
This suggests D. formicigenerans association with composite EED score may be 
driven by reduced prevalence of B. longum in D. formicigenerans positive 
individuals, rather than a direct effect of D. formicigenerans.  
 
5.3.3 F. prausnitzii and B. longum were associated with growth outcomes 
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The association between relative abundance of F. prausnitzii, D. 
formicigenerans, B. longum and ponderal (weight-related) growth has been 
shown before in murine studies. A study that compared fecal microbiota 
composition of mice transplanted with fecal samples from malnourished or 
healthy Malawian children reported a positive association between relative 
abundance of B. longum, F. prausnitzii, D. formicigenerans and weight gain in 
mice that harbored fecal samples from healthy children76. The present study 
found a negative association between intestinal carriage of B. longum, F. 
prausnitzii and anthropometric scores of ponderal growth (WAZ and WHZ). 
Intestinal carriage of B. longum and F. prausnitzii was associated with lower 
WAZ. Additionally, an increase in the relative abundance of B. longum was 
associated with increase in WHZ while an increase in the abundance of F. 
prausnitzii was associated with lower WHZ. To date there is no data on the 
association between presence or absence of B. longum, F. prausnitzii and 
ponderal growth in children but data exists on the association between relative 
abundance of genus Bifidobacterium and WHZ in children. Subramanian et al. 
found a lower abundance of the genus Bifidobacterium in Bangladeshi children 
with poor WHZ compared to children with better WHZ168. This finding is supported 
by data from this study that showed a positive relationship between relative 
abundance of B. longum and WHZ although the study by Subramanian et al. did 
not assess the associations at species level.  
 
The negative associations between intestinal carriage of B. longum, F. prausnitzii 
and WAZ have not been reported before in human studies. This data suggests a 
potential role of these bacteria in ponderal growth. Murine studies have reported 
a positive association between the relative abundance of B. longum, D. 
formicigenerans, F. prausnitzii and weight gain, which is different from the data 
shown here. The inconsistency between these results suggests that these 
bacteria might have different effects on ponderal growth in mice and humans.  
 
This study was limited by a number of factors. The use of commercial qPCR kits 
to describe prevalence of bacterial carriage limited the number of bacterial targets 
studied as primers and probes for other targets were not commercially available. 
The lack of standards in the commercial PCR kits precluded absolute 
quantification of each bacterium. The availability of data for a few demographic 
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variables limited the number of possible covariates that could have been 
considered in the analyses. Data analysis in the present study involved multiple 
comparisons, which could have had an effect on the interpretation of the 
results. Benjamini-Hochberg false discovery rate, Bonferroni correction and 
permutation are some of the methods used to correct for multiple comparisons. 
Further more refined analysis exploring multivariate models to examine 
collinearity in explanatory variables and examination of co-variance within the 
data are also methods by which the effect of individual predictors may be 
identified. 
 
The use of a published bacterial qPCR assay that allowed relative quantification 
of each bacteria was one of the strengths of this study. Relative quantification of 
B. longum had a different relationship with WHZ compared with presence or 
absence of the bacterium suggesting that the association between B. longum and 
WHZ is dependent on the abundance and not just the presence of the bacterium.  
5.3.4 Conclusion and future work 
 
This study showed high prevalence of F. prausnitzii and D. formicigenerans in 
fecal samples from rural Malawian children. Carriage of these bacteria was more 
prevalent in older children compared to younger children. B. longum was found 
to be the least prevalent bacteria in the fecal samples and its carriage was 
associated with younger age. These results are consistent with existing data. A. 
muciniphila, which was present in almost half of the samples, was also shown to 
be associated with geographic location. Further investigations are needed to 
understand how the environment affects carriage of A. muciniphila and establish 
any subsequent effects in the context of EED and child growth. The study also 
found a relationship between B. longum or D. formicigenerans and biomarkers of 
EED. The positive relationship between B. longum and biomarkers of EED 
reported by this study is unusual as B. longum is widely thought of as beneficial 
to gut health. Therefore, there is need for further research to confirm the 
existence of such an association in this population. Additionally, future studies 
might sequence B. longum strains carried by children in this population to 
establish if there are any genetic differences with the strains that have been 
identified as beneficial in other populations as such data is lacking. Further 
studies should investigate if breastfeeding, hygiene, sanitation and other factors 
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confound or interact with the relationship between B. longum and biomarkers of 
EED.  
 
This study also reported negative associations between intestinal carriage of B. 
longum, D. formicigenerans, F. prausnitzii (identified by qPCR) and ponderal 
growth in children from low-income settings for the first time. These findings are 
different from results of experimental studies in mice that indicated a positive 
association between relative abundance of these 3 bacteria and weight gain. As 
such, there is need for further studies to validate such associations in children. 
Future studies could also investigate the effects of absolute bacterial count on 
ponderal growth compared to presence or absence of a bacterium. Interestingly, 
this study found a positive association between relative abundance of B. longum 
and WHZ. This finding supports data reported previously in children from similar 
low-income settings.  
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6. Characterization of the gut microbiota in EED 
 
  
Page | 121 
 
6.1.1 Introduction 
 
The human gastrointestinal tract is inhabited by more than 100 trillion 
microorganisms, which include bacteria, archaea and eukarya. This collection of 
microorganisms is referred to as the gut microbiota. More than 50 bacterial phyla 
are known to make up the gut microbiota with Bacteroidetes and Firmicutes the 
most dominant phyla189. Microbial colonization of the gut starts at birth. A healthy 
human fetus is said to develop in a microbe-free environment, however, 
depending on the mode of delivery, the neonate encounters various maternal 
microbes that make up the initial gut microbiota at birth. Vaginally delivered 
infants have been reported to acquire bacterial communities like their mother’s 
vaginal microbiota dominated by Lactobacilli and Prevotella while infants born via 
Cesarean section were shown to acquire bacterial communities like those found 
on their mother’s skin surface dominated by Staphylococcus and 
Corynebacterium65. Gestation age also has an influence on gut microbiota 
composition and development. Preterm infants have been reported to have 
intestinal microbiota dominated by Proteobacteria and Enterobacteriaceae 
compared to full-term infants190.  
 
The gut microbiota continues to develop during the breastfeeding period and 
changes in species abundance during the complimentary feeding period towards 
a more ‘adult-like’ gut microbiota, with nutrition and the environment being the 
primary drivers. Breastfed infants have a Bifidobacterium dominated gut 
microbiota191 which shifts to Bacteroidetes, Clostridium and Eubacteria spp. 
during weaning192. De Fillipo et al. compared the gut microbiota of rural African 
children, consuming a diet rich in fiber and non-animal protein, to the gut 
microbiota of European children who consumed a diet high in animal protein, 
sugar, starch and fat and low in fiber. The gut microbiota of rural African children 
was dominated by Actinobacteria and Bacteroidetes while Firmicutes and 
Proteobacteria were more abundant in European children88. This finding 
emphasizes the effect of diet on gut microbiota.  
 
Another study that was undertaken to investigate age-related changes in gut 
microbiota composition showed that the infant gut microbiota is less stable and 
less diverse compared to that of an adult, which is dominated by Firmicutes, 
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Bacteroidetes and Actinobacteria64. More evidence on the impact of age on the 
gut microbiota has been shown recently by Odamaki et al. who reported that gut 
microbiota diversity increased sequentially with age until one’s twenties when it 
stabilized68.  Nevertheless, the stability of the adult gut microbiota does change 
with age. A less diverse gut microbiota with reduced abundance of Firmicutes 
and an increase in Bacteroidetes has been reported in the elderly (between 65 
and 96 years)193.  
 
Flint and Hooper suggest the gut microbiota plays a crucial role in regulating 
physiologic and metabolic processes, which include nutrient utilization, immune 
development, pathogen inhibition and maintenance of the intestinal epithelium 
integrity69,70. Intestinal bacteria ferment undigested carbohydrates to short-chain 
fatty acids (SCFAs) under anaerobic conditions; SCFAs are major sources of 
energy for the host therefore the gut microbiota helps in the maintenance of host’s 
energy balance70. Emerging evidence from in vitro studies indicates that the gut 
microbiota may also be key in the degradation of nondigestible dietary 
polysaccharides. It has been suggested that Firmicutes may be key degraders of 
nondigestible dietary polysaccharides thereby making energy available for 
utilization by the host194,195. The gut microbiota also plays a role in immune 
development. Evidence from animal studies indicate that the gut microbiota is key 
in the development of lymphoid structure particularly in the gastrointestinal tract 
of germ-free mice196-198. Furthermore, the gut microbiota prevents invasion and/or 
suppresses growth of enteric pathogens.  
 
One of the ways through which intestinal bacteria prevent growth of pathogens is 
by releasing bacteriocins which are bactericidal molecules. A study investigating 
the effect of a probiotic bacteria derived bacteriocin on protection against Listeria 
infection in mice showed protective effects of the bacteriocin against Listeria 
monocytogenes infection166. Intestinal bacteria also prevent colonization by 
enteric pathogens by producing pathogen-inhibitory metabolites. SCFAs, which 
are metabolites of carbohydrate fermentation by intestinal bacteria, have been 
shown to inhibit intestinal colonization by pathogenic bacteria. Acetate produced 
by Bifidobacteria was shown to protect mice against death induced by E. 
coli O157:H771 while depletion of butyrate-producing Clostridia was associated 
with expansion of pathogenic S. typhimurium in mice199.  
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The gut microbiota may also help in promoting mucosal barrier function of the 
intestinal epithelium via mucus production. It has been reported that the thin 
mucus layer of germ-free mice was restored to the thickness of that of 
conventionally raised mice upon exposure to luminal bacterial products 
potentially suggesting that the gut microbiota contributes to mucus production200. 
 
The gut microbiota is therefore essential in maintaining normal gut physiological 
and metabolic processes. Perturbations of the gut microbiota composition and 
function have been associated with disease201. Inflammatory bowel disease (IBD) 
refers to two conditions, ulcerative colitis (UC) and Crohn’s disease (CD), which 
are characterized by chronic gut inflammation. The specific cause of IBD is not 
well established however its etiology has been linked with a mixture of genetics, 
gut microbiome, immune responses and environment that trigger unexpected 
immune responses to gut flora in people with genetic susceptibility202-205. With 
regard to the associations between gut microbiota and IBD, Actinobacteria and 
Proteobacteria have been reported to be more abundant in individuals with both 
IBD phenotype and genotype compared to controls while Firmicutes have been 
shown to be more abundant in the controls206. A study that explored gut bacterial 
community differences between individuals with IBD, specifically CD, reported a 
lower abundance of Faecalibacterium prausnitzii and an increased abundance of 
Escherichia coli in individuals with CD compared to their healthy twins207.  
 
Changes in the gut microbiota structure have also been linked with EED etiology. 
EED is a subclinical condition of the gut characterized by partial villous atrophy, 
impaired enterocyte tight junctions and underlying chronic inflammatory 
responses. Like IBD, the specific cause of EED is not clearly established however 
its etiology has been associated with ingestion of enteric pathogens and toxins 
via contaminated food and water. This exposure changes gut microbiota 
composition and function resulting in intestinal inflammation and changes in the 
intestinal epithelium structure47. There is limited data suggesting associations 
between the gut microbiota and EED. Recently, Ordiz and colleagues used 16S 
rRNA gene sequencing of fecal samples from rural Malawian children to identify 
the gut bacterial community structure associated with moderate to severe EED 
defined by an L:M ratio test result ranging from 0.15 to 0.45. The study reported 
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a significant reduction in Proteobacteria in children with EED compared to 
children without EED while gut microbiota diversity was not different59.  
 
The primary objective of this section of study was to characterize the fecal 
microbiota defined by 16S rRNA gene sequencing and explore associations with 
biomarkers of EED in rural Malawian children. 
 
6.1.2 Study design and analyses 
 
This study utilized baseline demographic data and fecal samples collected by the 
MORDOR-morbidity cross-sectional survey, described in detail chapter 3. Briefly, 
demographic data (age, sex and geographic location) and fecal samples were 
collected by the MORDOR-Malawi morbidity cross-sectional baseline survey 
from 709 children who were randomly selected in 30 rural clusters of Mangochi 
district. The MORDOR-Malawi morbidity study also had subsequent surveys at 
12 months and 24 months after the baseline survey where fecal samples were 
also collected. To characterize the gut microbiota in EED, 103 baseline fecal 
samples were selected from the 709 baseline fecal samples that were collected 
by the MORDOR-Malawi morbidity baseline survey. Selection of the 103 fecal 
samples was based on the availability of corresponding samples at the 
subsequent 12-month or 24-month surveys as changes in the gut microbiota 
overtime was among the objectives of the PhD project. Thus, the 103 baseline 
fecal samples were from children who were randomly selected by the MORDOR-
Malawi morbidity cross-sectional surveys at more than one-time point (baseline 
and 12 months, baseline and 24 months and all 3 time-points).  
 
Proteins were extracted from the fecal samples and used for the quantification of 
biomarkers of intestinal inflammation (NEO and MPO) and intestinal permeability 
and protein loss (AAT) by ELISA as described in chapter 3. Total, genomic DNA 
was extracted from the fecal samples, as described in chapter 3.1.8.4, and 515F-
806R indexed primers were used to amplify the V4 region of the bacterial 16S 
rRNA gene. This was followed by 2x300bp paired-end sequencing of purified 
amplicons on the Illumina MiSeq platform as described in chapter 3.1.8.7. 
Reagent and non-template controls were extracted and sequenced according to 
the same procedure. Reads were processed using QIIME 2 software (version 
2018.6)139 as described in chapter 3.1.8.7.4. Briefly, 16S rRNA sequences were 
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de novo-clustered into OTUs at ≥ 97% identity. Taxonomy was assigned to the 
OTUs using a naïve Bayes classifier pre-trained on the SILVA 16S database142 
subsequently generating an OTU table. To exclude spurious OTUs, only bacterial 
OTUs identified to the genus level, with sequences more than 0.005% of the total 
number of sequences and a frequency of more than 0.01% in any sample were 
retained in the analyses. 
 
Characteristics of children whose fecal samples were selected for analysis were 
compared to those of all enrolled children to determine if they differed. Median 
(25th ,75th quartile) concentration of individual fecal biomarkers of EED were 
calculated to determine distribution of the concentrations. Western cut-off values 
for each of the 3 biomarkers53,161 were used to determine proportions of fecal 
samples with elevated biomarkers. Raw concentrations of the 3 biomarkers were 
combined to form a composite EED score as described in chapter 3. Shannon 
(H) and Simpson (D) diversity indices were calculated from the OTUs to indicate 
alpha diversity using the phyloseq R package148. The relationship between alpha 
diversity and individual biomarker concentration was initially examined using 
scatterplots and Pearson correlation was conducted to explore the relationship 
between alpha diversity and biomarker concentration where the scatterplots 
indicated a linear relationship. Significant relationships between alpha diversity 
indices and outcomes of interest were investigated using regression analyses 
adjusted for a set of covariates. To determine bacterial phylogenetic distance 
between samples, weighted and unweighted UniFrac distance matrices were 
calculated using the phyloseq R package. To compare bacteria community 
compositional differences between groups, PERMANOVA with 1000 permutation 
tests was run on weighted and unweighted UniFrac distances and principal 
coordinate analysis (PCoA) plots were used to visualize differences in UniFrac 
clustering by groups. Differential abundance analysis at the genus level was 
performed to identify OTUs differentially abundant in EED. Zero-inflated negative 
binomial regression analysis was conducted, adjusting for age and sex, to 
establish the relationship between the differentially abundant OTUs and 
biomarkers of EED.  
6.2 Results 
6.2.1 Baseline characteristics of participants 
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A total of 1704 children were randomly selected out of which 1090 were enrolled 
into the MORDOR-Malawi morbidity baseline survey. Out of the 1090 children 
enrolled, 709 participated in fecal sampling at the baseline survey for the study 
of antimicrobial resistance. Of the 709 fecal samples, 103 had corresponding 
samples collected at 12-months and 24-months surveys and therefore were 
selected for 16S rRNA sequencing and ELISA assays at baseline. Enrollment 
and selection of samples for analyses are shown in Figure 3.1.3.2 of chapter 
3.1.3. Age, sex and residential location of children whose fecal samples were 
included in analyses compared to all enrolled children are shown in Table 6.2.1.1 
below. Proportions of male children and children who resided in Chilipa, 
Makanjira and Mangochi were comparable between all enrolled participants and 
those whose fecal samples were included in this study. However, children whose 
fecal samples were included for analyses were younger (mean age of 22.95 
months vs mean age of 29.59 months) compared to all enrolled participants. 
Additionally, a larger proportion of children included in this analysis resided in 
Monkey Bay and a smaller proportion in Namwera compared to all enrolled 
participants. Out of the 103 fecal samples that were selected, 68 were tested for 
AAT, 62 for NEO and 75 for MPO. A total of 60 fecal samples had ELISA results 
for all 3 biomarkers.  
 
 
 
 
 
 
Page | 127 
 
Table 6.2.1.1: Characteristics of all participants who provided fecal 
samples compared to those enrolled.  
Participant 
characteristic 
Children 
included 
for 
analyses 
All 
enrolled 
children  
 
P-value 
Number of participants 103 1090  
Male sex N (%) 52 (50.98%) 487 (44.7%) 0.3 
Mean (SD) age in months  22.95 (13.54) 29.59 (16.42) 1.292e-05 
 
Geographic location N (%) 
 
Chilipa 22 (21.34%) 235 (21.6%) 0.99 
Makanjira 27 (26.21%) 225 (20.6%) 0.23 
Mangochi 17 (16.5%) 237 (21.7%) 0.26 
Monkey Bay 31 (30.1%) 192 (17.6%) 0.003 
Namwera 6 (5.83%) 201 (18.4%) 0.002 
 
6.2.2 Sequence reads characteristics and taxon abundance in the fecal 
samples 
 
A total of 103 fecal samples were processed for bacterial 16S rRNA gene 
sequencing. One sample consistently failed to amplify and could not be 
sequenced. All sequences for the 102 samples were subjected to post-
sequencing quality filtering processes and all samples (n=102) were retained for 
analysis after the quality filtering processes. The final dataset generated a total 
of 1,685,792 reads with an average read depth per sample of 16,527±11,071. A 
total of 9 phyla, 16 classes, 25 orders, 43 families and 117 classified and 6 
unclassified genera were identified from the sequence reads. Seven genera 
(Faecalibacterium, Streptococcus, Bacteroides, Haemophilus, Subdoligranulum, 
Bifidobacterium and Escherichia-Shigella) were present in about 62% of the 
samples and together they accounted for 46.4% of the whole bacterial 
community; Faecalibacterium was prevalent in 81% of the samples making it the 
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most prevalent genus. Bifidobacterium was prevalent in 51% of the samples and 
it had the highest number of reads, which accounted for 14.9% of the total reads. 
After rarefaction to 1000 reads with 1000 permutations, 69 genera belonging to 
7 phyla, Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria, Proteobacteria, 
Tenericutes, Verrucomicrobia, were retained. Out of the 7 identified phyla, 
Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria were the most 
dominant and accounted for 64.23%, 13.8%, 8.9% and 6.5% of the total bacterial 
community respectively (Figure 6.2.2.1).  
 
As part of quality control, qPCR data for the 4 bacteria described in chapter 5 (B. 
longum, A. muciniphila, D. formicigenerans, F. prausnitzii) and Ruminococcus 
gnavus (tested as detailed in chapter 3.1.8.5) was used to verify genera presence 
in the OTUs. Table 6.2.2.1 shows the number of samples classified as positive 
for each of the specific bacterial species tested by qPCR and that were positive 
for the corresponding bacterial genera (OTU).  Of the 47 samples that tested 
positive for B. longum in the specific qPCR, 44 had the genus Bifidobacterium 
present in the OTUs, 99 samples positive for F. prausnitzii in the qPCR, 88 had 
the genus Faecalibacterium present in the OTUs while only 14 of the 49 samples 
that tested positive for A. muciniphila in qPCR had their genus present in the 
OTUs (Table 6.2.2.1). A mock bacterial community that composed of Hemophilus 
influenza, Moraxella catarrhalis and Staphylococcus epidermis was also included 
as a positive control in all sequencing runs. Only reads corresponding to the 3 
genera (Hemophilus, Staphylococcus and Moraxella) were obtained from the 
mock control sample. Reagent and non-template controls were processed 
together with the samples and these generated 21,550 reads. The major taxon 
present in these controls was Streptococcus. 
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Table 6.2.2.1 Verification of genera presence in OTUs by specific 
qPCR 
Variable (n=102) Genus in OTU 
qPCR target Absent Present 
Bifidobacterium longum positive 3 44 
Akkermansia muciniphila positive 35 14 
Dorea formicigenerans positive 44 29 
Faecalibacterium prausnitzii positive 18 81 
Ruminococcus gnavus positive 20 3 
 
 
Figure 6.2.2.1 Relative abundance of major phyla found in fecal samples. The 
proportion of total number of reads for each phylum in a sample represents phylum 
abundance after rarefaction to 1000 reads. 
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Figure 6.2.2.2 Relative abundance of major genera in fecal samples. The proportion 
of total number of reads for each genus in a sample represents genus abundance after 
rarefaction to 1000 reads. The stacked bar plot only shows the 10 most abundant genera. 
The remaining genera have been grouped as “Other”.  
 
6.2.3 Effect of age on the fecal microbiota 
 
The effect of age on fecal microbiota composition and diversity in the samples 
was tested using the rarefied OTU dataset (comprised of 102 samples 
contributing 7 phyla and 69 genera). Simpson and Shannon diversity indices were 
calculated from the rarefied OTU data to indicate alpha diversity in the samples. 
Visualization of the distribution of Shannon and Simpson indices in all fecal 
samples showed a normal distribution for Shannon and a left-skewed distribution 
for Simpson index (Figure 6.2.3.1). The mean (SD) Shannon index was 1.72 
(0.45) and median (25th, 75th quartile) Simpson index was 0.75 (0.66,0.82). Child 
age in months was categorized as 0-12, 13-24, 25-36 and 37-60. The differences 
in Shannon and Simpson distribution by age group were statistically tested using 
ANOVA and the non-parametric Kruskal-Wallis test respectively. There were 
significant differences in the distribution of both Shannon (P<0.001, Figure 
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6.2.3.2 A) and Simpson (P=0.004, Figure 6.2.3.2 B) by age. Both Shannon and 
Simpson indices were lower in fecal samples from younger children compared to 
older children, indicating increasing diversity with age.  
 
 
Weighted UniFrac and unweighted UniFrac distances were calculated to 
determine bacterial phylogenetic distances between samples. PERMANOVA 
with 1000 permutation tests was used to statistically compare weighted UniFrac 
and unweighted UniFrac distances between age groups and PCoA plots were 
used to visualize differences in clustering. Age again had a significant effect on 
fecal microbiota as indicated by PERMANOVA outputs using unweighted and 
weighted UniFrac (R2 =0.17, F=6.4, P=0.001 and R2=0.29, F=12.8, P=0.001 
respectively) and PCoA plots for both unweighted UniFrac and weighted UniFrac 
(Figures 6.2.3.3 and 6.2.3.4). Stacked bar plots were then plotted to visualize 
taxa that were different at phylum and genus levels between age groups (Figure 
6.2.3.5 and 6.2.3.6). Fecal samples from younger children (0-12 months) were 
shown to have a higher abundance of Actinobacteria and lower abundance of 
Bacteroidetes (Kruskal-Wallis test P=0.01). At genus level, higher abundance of 
Bifidobacterium and a lower abundance of genus Faecalibacterium were 
observed in younger children (0-12 months) compared to the older age groups 
(Kruskal-Wallis test P=0.01). 
 
Figure 6.2.3.1 Shannon and Simpson diversity indices distribution for all the fecal 
samples included in final analysis. 
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Figure 6.2.3.2 Comparison of (A) Shannon and (B) Simpson indices distribution 
between age groups. P-value for Shannon index (P<0.001) was obtained from ANOVA 
while P-value for Simpson index (P=0.004) was obtained from the Kruskal-Wallis test.  
 
Figure 6.2.3.3 PCoA plot of unweighted UniFrac by age. PCo1 explained 25% of total 
variation while PCo2 explained 11.7% of total variation. Children aged 0-12 months were 
clustered in the negative space of PCo1. Children aged >24 months were clustered in 
the positive space of PCo1. Children aged 13-24 months clustered between 0-12 and 
37-60 age groups. 
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Figure 6.2.3.4 PCoA plot of weighted UniFrac by age. PCo1 explained 42.5% of total 
variation while PCo2 explained 21.1% of total variation. Children aged 0-12 months were 
clustered in the negative space of PCo1. Children aged >24 months were clustered in 
the positive space of PCo1. Children aged 13-24 months spread across PCo1. 
 
Figure 6.2.3.5 Relative abundance of phyla age. 
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Figure 6.2.3.6 Relative abundance of genera by age. The stacked bar plot only shows 
the 10 most abundant genera. The remaining genera were grouped as “Other”. 
 
6.2.4 Effect of sex on fecal microbiota  
 
The effect of sex on fecal microbiota diversity and composition in the samples 
was also tested. The Student’s t-test showed no difference in Shannon 
distribution by sex (P=0.12) while the Wilcoxon-rank test showed no difference in 
Simpson distribution by sex (P=0.27).  
 
Weighted UniFrac distances were then calculated to determine bacterial 
phylogenetic distances between samples by sex. Significant effect of sex on fecal 
microbiota composition was detected by PERMANOVA using both weighted 
UniFrac distances (R2=0.04, F=4.3, P=0.002) and unweighted UniFrac 
(R2=0.037, F=3.9, P=0.001). After adjusting for age however visualization by 
PCoA did not indicate prominent differences in clustering in male and female 
children for both unweighted and weighted UniFrac (Figures 6.2.4.1 and 6.2.4.2). 
Differences in taxa abundance by sex were then visualized at phylum and genus 
levels using stacked bar plots (Figure 6.2.4.3 and 6.2.4.4) and linear regression 
analysis, adjusting for age, was used to test for associations between sex and 
phyla or genera. Sex was not associated with relative abundances of phyla or 
genera (linear regression P>0.9). 
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Figure 6.2.4.1 PCoA plot of unweighted UniFrac by sex. PCo1 explains 25% of total 
variation while PCo2 explained 11.7% of total variation. Male children clustered more in 
the positive space of PCo1 compared to female children. 
      
 
Figure 6.2.4.2 PCoA plot of weighted UniFrac by sex. PCo1 explained 41.7% of total 
variation while PCo2 explained 20.9% of total variation. Male and female children did not 
cluster differently on either PCo1 or PCo2. 
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Figure 6.2.4.3 Relative abundance of phyla by sex 
 
Figure 6.2.4.4 Relative abundance of genera by sex. The stacked bar plot only shows 
the 10 most abundant genera. The remaining genera were grouped as “Other”. 
 
6.2.5 Effect of residential location on fecal microbiota  
 
The effect of participant’s residential location on fecal microbiota diversity and 
composition in the samples was also explored. There were no differences in 
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Shannon distribution by participant’s residential location as indicated by ANOVA 
(P=0.25). Likewise, the Kruskal-Wallis test showed no differences in Simpson 
distribution by residential location (P=0.13).  
 
Weighted and unweighted UniFrac distances were then calculated to determine 
bacterial phylogenetic distances between samples. There were no significant 
effects of residential location on fecal microbiota composition detected by 
PERMANOVA using both unweighted (R2=0.05, F=1.26, P=0.147) and weighted 
UniFrac (R2=0.06, F=1.4, P=0.128). 
 
6.2.6 Associations between measures of fecal microbiota diversity and 
biomarkers of EED 
 
In this analysis, AAT, NEO, MPO and composite EED score described in chapter 
4 were used as biomarkers of EED. Out of the 102 fecal samples that 
characterized the fecal microbiota by 16S rRNA sequencing, 68 had 
corresponding ELISA results for AAT, 75 for MPO, 62 for NEO and 60 had ELISA 
results for all the 3 biomarkers and therefore were included in the presented 
analyses. The relationship between Shannon or Simpson diversity indices and 
raw biomarker concentration was examined using scatter plots and tested using 
Pearson’s correlation. Shannon index showed a linear relationship with all the 3 
biomarkers (Figure 6.2.6.1 A-C) while Simpson showed a significant negative 
correlation with AAT and NEO but not MPO (Figure 6.2.6.1 D-F). Linear 
regression analyses were then conducted to model the relationship between 
Shannon or Simpson diversity and the individual biomarkers, adjusting for age 
and sex. Each of the 3 biomarkers was used in a linear regression model as a 
continuous outcome variable. There was no evidence of a relationship between 
Shannon diversity and AAT (P=0.14) or MPO (P=0.46) nor was there a 
relationship between Simpson diversity and AAT (P=0.09) or MPO (0.92). 
However, there were weak negative associations between Shannon diversity or 
Simpson diversity and NEO. An increase in Shannon diversity or Simpson 
diversity was associated with a reduction in NEO concentration [coefficient= -759, 
P=0.044, 95 % CI (-1496, -21) and coefficient= -2710, P= 0.047, 95% CI (-5386, 
-34) respectively].  
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Figure 6.2.6.1 Scatterplots for the relationship between alpha diversity measures 
and individual biomarkers of EED. (A) Shannon index and AAT, (B) Shannon index 
and MPO, (C) Shannon index and NEO, (D) Simpson index and AAT, (E) Simpson index 
and MPO, (F) Simpson index and NEO. The correlation coefficient values and P-values 
were obtained from Pearson’s product-moment correlation.  
 
Of the 102 participants, 60 had ELISA results for all the 3 biomarkers from which 
the composite EED score could be calculated. Thus, data from these 60 
participants was used to explore the associations between gut microbiota 
diversity and the composite EED score. The composite EED scores were 
categorized into low and high scores centered around the mean score (2.01). 
Logistic regression analysis, adjusted for age and sex, showed no association 
between Shannon or Simpson diversities and composite EED scores (P=0.14 
and P=0.33 respectively).  
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6.2.7 Associations between fecal bacterial community structure and 
biomarkers of EED 
 
Fecal biomarker concentration was then categorized as normal or elevated using 
the Western thresholds for AAT (≤0.27mg/g), NEO (≤70 nmol/L) and MPO (≤2000 
ng/ml)53,161,162. Of the fecal samples included in this analysis, 11.8% (8/68) had 
elevated AAT concentration while 41.3% (31/75) and 82.3% (51/62) had elevated 
concentrations for MPO and NEO respectively. Bacterial community 
compositional differences between fecal samples with normal and elevated 
biomarker concentration were tested using PERMANOVA with 1000 tests. No 
differences in bacterial community composition between normal and elevated 
biomarkers were detected by PERMANOVA for each of the 3 biomarkers. 
 
Differences in fecal microbiota composition between low and high composite 
EED score were also tested using PERMANOVA that was run on unweighted 
and weighted UniFrac distances adjusting for age and sex. PCoA plots were used 
to visualize UniFrac clustering between the two groups. There were significant 
differences in bacterial community composition between fecal samples with low 
and high composite EED scores indicated by PERMANOVA for unweighted 
(F=2.53, R2 =0.04, P=0.011) and weighted UniFrac (F=3.35, R2 =0.05, p=0.017) 
and shown in PCoA plots (Figures 6.2.7.1 and 6.2.7.2).  
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Figure 6.2.7.1 PCoA plot of unweighted UniFrac by composite EED score. PCo1 
explained 18.6% of total variation while PCo2 explained 13.4% of total variation. 
Individuals with low composite EED scores clustered more on the negative space of 
PCo1 while individuals with high composite EED score clustered more on the positive 
space of PCo1. 
 
Figure 6.3.7.2 PCoA plot of weighted UniFrac by composite EED score. PCo1 
explained 42% of total variation while PCo2 explained 22.9% of total variation. 
Individuals with low composite EED scores clustered more on the negative spaces of 
PCo1 and PCo2. 
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Differential abundance analysis at genus level was then conducted to determine 
OTUs that were differentially abundant between low and high composite EED 
score. Three genera (Succinivibrio, Butyrivibrio and Enterococcus) were 
differentially abundant in fecal samples with high composite EED score compared 
to fecal samples with low composite EED score (Table 6.2.7.1). A zero-inflated 
negative binomial regression analysis was conducted to explore the relationship 
between the differentially abundant OTUs and the composite EED scores, 
adjusting for age and sex. Out of the 3 differentially abundant genera, only 1 
genus (Succinivibrio) was associated with composite EED score after adjusting 
for age and sex. An increase in the abundance of Succinivibrio was associated 
with 0.14 reduced odds of a having a high composite EED score compared to low 
composite EED score (Table 6.2.7.1).  
Table 6.2.7.1 Genera differentially abundant in fecal samples with 
high composite EED compared to low composite EED scores.  
Genus 
log2Fold 
Change lfcSE P-valuea padjb 
 
ORc 
(95%CI) 
 
P-
valuec 
Succinivibrio -26.3 2.6 5.24e-24 
2.25e-
22 
0.14 
(0.08,0.23) 
1.51e-
41 
0.791 
Butyrivibrio -25.6 2.9 5.02e-19 
1.08e-
17 
3.52 
(0.68,18.16) 
Enterococcus 23.5 2.9  7.72e-16 
1.11e-
14 
1.82 
(0.25,1.2) 
0.619 
aDenotes unadjusted P-value while bdenotes p-value obtained after adjusting for multiplicity with 
Benjamin-Hochberg P-value correction. 
OR=odds ratio. 
CI=confidence interval. 
cDenotes OR (95%CI) and P-values obtained with zero-inflated negative binomial regression. 
(conditional model) after adjusting for age and sex. 
lfcSE = log fold change Standard Error. 
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6.3 Discussion 
 
The present study explored associations between the fecal microbiota and 
biomarkers of EED in rural Malawian children. Sequencing of the bacterial 
16SrRNA gene and quantification of the biomarkers of EED in fecal samples 
allowed the assessment of associations between fecal microbiota diversity or 
composition and biomarkers of EED (individually or combined). Verification of the 
presence of genera in OTUs by species-specific qPCR showed concordance 
between qPCR and V4-16S rRNA sequencing for Bifidobacterium and 
Faecalibacterium, whereas Ruminococcus, Dorea and Akkermansia differed 
between the two assays. The variations between the two assays suggest a 
difference in sensitivity; qPCR is more sensitive than V4-16S rRNA sequencing. 
Additionally, the quality control results indicate that the accuracy of V4-16S rRNA 
sequencing might be dependent on the abundance of a genus. Bifidobacterium 
and Faecalibacterium, which were well detected by the two assays, were found 
to be high in abundance in the fecal samples included in this study compared to 
the other 3 genera.  
 
The study found no association between fecal microbiota diversity and individual 
fecal concentration of AAT and MPO. Similarly, there was no association between 
fecal microbiota diversity and the composite EED score. However, the study 
found a negative association between fecal microbiota diversity and fecal 
concentration of NEO. A comparison of bacterial community composition by 
individual biomarker concentration showed no significant differences, but 
significant differences in fecal microbiota composition were found when the 
individual biomarkers were combined to form a composite EED score suggesting 
perturbations of overall gut microbiota structure in EED. Secondary analyses on 
the effects of age, sex and residential location showed that age, but not sex or 
residential location, was associated with fecal microbiota. The findings on the 
relationship between age and gut microbiota are consistent with previous 
studies64,68. 
 
 
 
 
6.3.1 Effect of age on microbiota diversity and microbiota composition 
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Age-related changes on fecal microbiota diversity and composition have been 
reported previously. Increased age has been associated with increased fecal 
microbiota diversity and changes in fecal microbiota composition208. The present 
study divided age into 4 categories from 1 to 59 months of age to compare fecal 
microbiota diversity and composition across age groups. Microbiota diversity was 
higher in older age groups compared to younger children. There was a marked 
difference in microbiota diversity seen among children from 1 to 36 months of 
age. The study also found differences in microbiota composition across age 
groups. Fecal samples from younger children were shown to have a higher 
abundance of phylum Actinobacteria and lower abundance of phylum 
Bacteroidetes. At genus level, higher abundance of Bifidobacterium and a lower 
abundance of genus Faecalibacterium were seen in younger children compared 
to the older age groups. These findings are consistent with trends reported by 
recent longitudinal studies64,68. The increase in diversity and changes in intestinal 
microbiota seen with the different age groups are also consistent with changes 
that have been reported during the transition from breast feeding to 
weaning191,192.   
 
6.3.2 Effect of sex on fecal microbiota diversity and composition 
 
Associations between sex and gut microbiota have been reported in adults. One 
study that assessed associations between sex and gut microbiota in European 
adults reported a higher abundance of Bacteroides in males compared to 
females209. However, there is limited data on the associations between sex and 
the gut microbiota in infants and young children. One recent study that explored 
the associations between sex and gut bacteria found higher abundance of 
Lactobacillus, a dominant genus in the vaginal microbiota, in females than males 
in early life210. The present study compared the fecal microbiota of male and 
female children aged not more than 5 years. Fecal microbiota diversity and 
composition were not different in fecal samples from male compared to female 
children suggesting that sex does not impact on gut microbiota in this group of 
children.  
6.3.3 Associations between the fecal microbiota and EED 
 
Page | 144 
 
In the present study, alpha diversity was shown to have no relationship with fecal 
levels of AAT or MPO, however a negative association between alpha diversity 
and NEO, a biomarker of intestinal inflammation, was found. The study found no 
significant differences in fecal microbiota composition between normal and 
elevated fecal biomarker concentration. 
 
To date, there is no data available supporting a relationship between fecal 
microbiota diversity and intestinal inflammation in children at risk of developing 
EED. However, available evidence from inflammatory and autoimmune diseases 
suggest that increased intestinal microbiota diversity is an indication of a healthy 
status while a decrease in intestinal microbiota diversity is associated with 
disease211,212. Additionally, there is data from IBD studies in North American 
pediatric patients suggesting an association between intestinal inflammation 
seen in severe UC and reduced intestinal microbiota diversity213. These results 
are consistent with the present finding that alpha diversity is negatively 
associated with NEO, however, UC and EED are very different conditions that 
manifest differently thus the findings from the present study need to be further 
tested in larger EED studies. The current study did not find any association 
between fecal microbiota diversity and MPO, another biomarker of intestinal 
inflammation, nor were there any bacterial community differences between 
individuals with normal and elevated biomarkers of intestinal inflammation. 
Interestingly, the study showed significant differences in the fecal microbiota 
composition between low and high composite EED score. This finding supports 
the suggestion that no single biomarker is sufficient to indicate EED161,162.  
 
A study by Ordiz et al. that aimed to characterize the bacterial community 
structure in children with EED, as measured by L:M ratio test, reported significant 
differences in the composition of fecal microbiota of children with and without 
EED. At the phylum level, the study reported a significantly higher relative 
abundance of Proteobacteria in children without EED compared to children with 
EED while genera Succinivibrio, Klebsiella and Clostridium_XI were found to be 
reduced in EED59. These results are in part consistent with findings reported by 
the present study. Similar to findings by Ordiz et al., the present study found an 
association between increased abundance of the genus Succinivibrio, of phylum 
Proteobacteria, and reduced EED scores. In the bovine rumen, Succinivibrio, a 
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gram-negative anaerobic bacterium, has been associated with fiber-
degradation214. Also, high abundance of this bacterium has been shown in fecal 
microbiota of rural African children, consuming a diet rich in fiber and non-animal 
protein88 emphasizing the role of this bacterium in fiber degradation. Fiber 
degradation by anaerobic bacteria produces SCFAs that are major sources of 
energy for the host. SCFAs have also been shown to inhibit intestinal colonization 
by pathogenic bacteria71,199. Therefore, the significance of Succinivibrio in EED 
should be investigated further.  
  
One of the limitations of this study included the use of Western values to define 
cut-off limits for normal or elevated biomarker concentration. This limitation is not 
unique to this study; the lack of reference values for the biomarkers of  EED in 
children living in low-income settings has also been cited by other similar 
studies161,162. Current thresholds used by this and other published studies are 
reference values in European adults with IBD. However, the lack of reference 
values for the biomarkers of EED in children living in low-income settings makes 
the Western values the only available choice; there is a need for large-scale 
studies to define reference values of the biomarkers of EED in children living in 
resource-limited settings. The adoption of the Western reference values in this 
study might have undermined the magnitude of inflammation and also affected 
the plausible associations with the fecal microbiota, however, no associations 
between fecal microbiota and the uncategorized concentration values were 
found.  
6.3.4 Conclusion and future work 
 
This study suggested an association between intestinal microbiota diversity and 
intestinal inflammation, measured by fecal NEO, in children at risk of EED; 
increased fecal microbiota diversity was associated with a reduction in intestinal 
inflammation. However, the study did not find any significant associations 
between gut diversity and another marker of intestinal inflammation nor were 
there any differences in fecal microbiota composition between normal and 
elevated biomarkers. There is a need for large-scale studies to further test the 
relationship between microbiota diversity and intestinal inflammation in EED and 
investigate if the reported relationship between microbiota diversity and intestinal 
inflammation is a result of gut microbiota dysbiosis or vice versa. The study did 
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not find profound bacterial compositional differences between fecal samples with 
and without indications of EED, however, the study reported a finding that is 
consistent with a recent study in Malawian children. The genus Succinivibrio, 
which was reported by another study to be reduced in EED, was associated with 
composite EED scores. This bacterium has been associated with fiber-
degradation and has recently been shown to be more abundant in children 
consuming a diet rich in fiber in low-income settings. Future studies need to 
investigate the role of this bacterium in EED. Such future studies could also 
explore the role of metabolites produced by such bacteria in preventing EED in 
children. Large-scale studies, conducted in multiple low-income settings, would 
be valuable in defining thresholds for the biomarkers of EED in children most at 
risk of developing this condition. 
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7. Effect of azithromycin on fecal microbiota 
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7.1.1 Introduction 
 
The use of antibiotics has been shown to have growth-promoting effects in 
animals and humans. Early animal studies comparing animals given prophylactic 
antibiotics in their feed versus untreated animals reported growth-promoting 
effects of antibiotics100-102. Infants exposed to antibiotics in the first year of life 
have been reported to have higher chances of being overweight later in childhood 
compared to unexposed infants215. Prophylactic antibiotics and antibiotics given 
for infection have also been shown to promote weight gain in pre-pubertal 
children living in low-income countries103,104 but the mechanism through which 
this happens is not known. One explanation for the effect of antibiotics on growth 
could be due to their ability to clear enteric pathogens or modulate the intestinal 
microbiota105,106. 
 
The impact of antibiotics on enteropathogens is well documented and the impact 
of antibiotics on the gut microbiota composition and development in mice and 
humans has been described. A study by Nobel and colleagues showed that beta-
lactams or macrolides altered intestinal microbiota composition and delayed 
microbiota maturation in mice216. In that study, mice were treated with beta-
lactams or macrolides during the second, fourth and fifth week of life and fecal 
samples were collected in between the treatments from the treated mice and their 
controls to determine short-term effects of antibiotics on the intestinal microbiota. 
The study reported reduction in alpha diversity a week after the initial treatment 
and a reduction in the abundance of Bacteroidetes after the third treatment in 
mice that were treated with beta-lactams or macrolides compared to their 
controls. Also, a comparison of overall gut microbiota composition between 
antibiotic-treated mice and their controls showed significant differences in 
microbiota composition between the two groups.  
 
Other studies have also documented a reduction in gut microbiota diversity and 
changes in gut microbiota composition in the human population as a short-term 
effect of antibiotics on the gut microbiota. A study that examined microbiota 
diversity and composition in adults before and immediately after a 7-day course 
of antibiotic treatment reported a significant reduction in microbiota diversity and 
a shift from Faecalibacterium to Bacteroides as the most dominant genus217.  A 
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recent study that investigated the short-term effects of antibiotics on the gut 
microbiota of infants reported a reduction in alpha diversity and changes in 
microbiota composition after antibiotic treatment218. Here, the intestinal 
microbiota, of children randomized to a 3-day course of azithromycin or placebo, 
was characterized at baseline and 14 days after treatment. The study showed a 
decrease in microbiota richness and a decrease in the relative abundance of 
Proteobacteria and Verrucomicrobia in fecal samples of treated children 
compared with the control group. Taken together, the above findings indicate 
short-term effects of antibiotics on gut microbiota diversity.  
 
The long-term impact of antibiotics on the gut microbiota is not well established 
as available evidence is mixed. A study by Korpela et al. (detailed previously in 
chapter 1.8) showed that the antimicrobial effect of macrolides on the fecal 
microbiota in early childhood is long-term127. Here, a reduction in microbial 
richness in fecal samples from treated children compared to control samples was 
detected 12-24 months after treatment. Also, a significant decrease in the relative 
abundance of Actinobacteria and increased abundance of Bacteroidetes and 
Proteobacteria in fecal samples from children who had used macrolide antibiotics 
within 6 months of sample donation compared to controls was reported. However, 
another study by Wei et al. did not find any long-term differences in gut microbiota 
diversity between antibiotic-treated and untreated children219. Here, children 
aged 12-36 months were prescribed a 3-day course of azithromycin or placebo 
and the gut microbiota was characterized in fecal samples collected from each 
child at 4 years of age. The study reported no significant differences in alpha 
diversity (measured by observed richness and Shannon index) between the 
treatment and placebo groups. Additionally, there were no OTUs that differed 
significantly between groups. These inconsistent findings mean the long-term 
effects of macrolides on the gut microbiota are unclear.  
 
Azithromycin is a broad-spectrum, macrolide antibiotic characterized by a long 
intra- and extra-cellular half-life. Its use is indicated in the treatment of atypical 
pneumonia, skin and soft tissue infections and sexually transmitted infections110. 
Community-wide mass azithromycin treatment is a core pillar of the WHO-
recommended approach to control ocular infection with the intracellular bacterium 
Chlamydia trachomatis, the causative agent of trachoma111. Studies conducted 
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in trachoma endemic areas provide evidence that mass azithromycin treatment 
also reduces child morbidity and mortality113-117. 
 
The current study assessed the long-term impact of azithromycin treatment on 
the fecal microbiota of Malawian children. The study investigated the impact of 
up to 2 or 4 biannual azithromycin treatments on the diversity and composition of 
intestinal microbiota.  
7.1.2 Study design and analyses 
 
This study utilized demographic data and fecal samples collected by the 
MORDOR-Malawi morbidity study, described in detail in chapter 3. Briefly, 
MORDOR-Malawi morbidity randomized children in communities to azithromycin 
treatment or placebo at baseline and collected fecal samples cross-sectionally at 
baseline (n=709), 12 months post 2 biannual azithromycin administration (n=689) 
and 24 months post 4 biannual azithromycin administrations (n=873) to 
investigate the effect of carriage of antimicrobial resistant bacteria. A subset of 
fecal samples from 103 children, who were sampled, by chance, at two-time 
points were selected for the present study to investigate the long-term effect of 
azithromycin treatment on the gut microbiota.  
 
Fecal samples were processed as described in chapters 3 (sections 3.1.8.4 and 
3.1.8.7) and 6. V4-16S rRNA gene sequencing was conducted and Shannon (H) 
and Simpson (D) diversity indices were calculated from the OTUs to indicate 
alpha diversity. Differences in alpha diversity distribution between groups were 
tested using parametric (Student’s t-test or ANOVA) or non-parametric tests 
(Wilcoxon-rank or Kruskal-Wallis tests). Weighted and unweighted UniFrac 
distance matrices were calculated to determine the bacterial phylogenetic 
distance between samples and were used to compare bacteria community 
compositional differences between groups in PERMANOVA analysis.  
7.2 Results 
7.2.1 Participant characteristics 
 
From the children who participated in baseline fecal sampling, 54 also 
participated in sampling at 12 months. The results from these samples are 
referred to as the “baseline-12-month dataset”. Fifty-five children participated in 
Page | 151 
 
baseline sampling and sampling at 24 months and their results are referred to as 
the “baseline-24-month dataset”. Within the baseline-12-month dataset, 30 
children received placebo while 24 received azithromycin treatment. Within the 
baseline-24-month dataset, 30 children received placebo while 25 received 
azithromycin treatment. Baseline characteristics of all children in the azithromycin 
and placebo arms are shown in Table 7.2.1. For the baseline-12-month dataset, 
age, sex and Simpson diversity index were comparable between azithromycin 
and placebo arms but taxa relative abundance and Shannon diversity index were 
higher at baseline in azithromycin-treated children compared to those in the 
placebo arm. For the baseline-24-months dataset, all characteristics (age, sex, 
taxa relative abundance and alpha diversity) were comparable between 
azithromycin and placebo groups. 
Table 7.2.1 Baseline characteristics of participants for the 
baseline-12months and baseline-24 months datasets. 
  Treatment arm 
Participant characteristics Azithromycin Placebo 
Baseline-12 months dataset 
Number of participants 24 30 
Child male sex N (%) 14 (58.3%) 15 (50%) 
Mean (SD) age, months 27 (14) 24.3 (15.4) 
Median (25th ,75th quartile) taxa relative 
abundance 
0.65 
(0.54,0.77) 
0.56 
(0.49,0.64) 
Median (25th ,75th quartile) Shannon 
diversity index 
2.4 (1.9,2.5) 2 (1.6,2.2) 
Median (25th ,75th quartile) Simpson 
diversity index 
0.87 
(0.78,0.89) 
0.81 
(0.73,0.85) 
Baseline-24 months dataset 
Number of participants 25 30 
Child male sex N (%) 13 (52%) 16 (53.3%) 
Mean (SD) age, months 18.3 (10.6) 19 (10.8) 
Median (25th ,75th quartile) taxa relative 
abundance 
0.58 
(0.51,0.66) 
0.52 
(0.45,0.65) 
Mean (SD) Shannon diversity index 1.85 (0.47) 1.93 (0.55) 
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Median (25th ,75th quartile) Simpson 
diversity index 
0.78 
(0.67,0.83) 
0.8 (0.74,0.84) 
 
7.2.2 Up to 4 biannual azithromycin treatments did not have any long-term 
effect on fecal microbiota diversity 
 
The baseline-12-month dataset was used to explore the effect of up-to 2 rounds 
of azithromycin on fecal microbiota diversity. Out of the 24 fecal samples 
originating from the 12-month survey in the azithromycin arm, 13 were from 
children who received 2 rounds of azithromycin, 10 from children who received 1 
round and 1 sample from a child who did not receive any azithromycin. At 12 
months, a comparison of fecal microbiota diversity between azithromycin and 
placebo arms showed no differences in alpha diversity, measured by Shannon 
diversity index [median (25th, 75th quartile) of 2.15 (2,2.42) vs 2.22 (1.7,2.37), 
Wilcoxon’s test P=0.71] and Simpson diversity index [median (25th, 75th quartile) 
of 0.83 (0.78,0.87) vs 0.81 (0.78,0.87), Wilcoxon’s test P=0.72). Similarly, there 
were no differences in Shannon diversity (Wilcoxon’s test P=0.88) or Simpson 
diversity (Wilcoxon’s test P=0.99) distribution between baseline and 12-month 
fecal samples in the azithromycin arm regardless of the number of treatment 
rounds received.  
 
To assess the effect of up to 4 rounds of biannual azithromycin treatment on fecal 
microbiota diversity, the baseline-24-month dataset was used. Out of the 25 fecal 
samples originating from the 24-months survey in the azithromycin arm, 9 were 
from children who received 4 rounds of azithromycin treatment, 4 from children 
who received 3 rounds, 6 from children who received 2 rounds, 3 from children 
who received 1 round and 3 from children who did not receive treatment. 
Comparison of fecal microbiota diversity between azithromycin and placebo arms 
at 24 months showed no differences in Shannon diversity [mean (SD) of 2.2 
(0.47) vs 2.2 (0.4), Student’s t-test P=0.97] and Simpson diversity [median (25th, 
75th quartile) of 0.82 (0.78,0.87) vs 0.83 (0.77,0.88), Wilcoxon’s test P=0.91). 
Comparison of Simpson diversity index distribution between baseline and 24-
month fecal samples in the azithromycin group showed no differences between 
the two time-points. Shannon diversity tended to be higher in the 24-month fecal 
samples compared to baseline samples [mean (SD) of 2.2 (0.46) vs 1.97 (0.36), 
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Student’s t-test P=0.057)], which was not significant after adjusting for age and 
sex (linear regression, P=0.192).  
7.2.3 Azithromycin treatment was associated with changes in fecal microbiota 
composition at 24-months follow-up 
 
At 12 months, PERMANOVA analysis using unweighted (R2 =0.01, F=0.69, 
P=0.85) and weighted (R2 =0.01, F=0.47, P=0.89) UniFrac distances detected no 
differences in overall fecal microbiota composition between azithromycin-treated 
children and children who received placebo. Similarly, there were no differences 
in microbiota composition between the baseline and 12-month fecal samples in 
the azithromycin group based on weighted (R2 =0.03, F=1.39, P=0.21) and 
unweighted (R2 =0.03, F=1.35, P=0.14) UniFrac distances nor were there 
differences in microbiota composition by number of azithromycin treatments 
received by the 12-month fecal collection (PERMANOVA based on weighted 
UniFrac, R2 =0.05, F=1.01, P=0.42 and PERMANOVA based on weighted 
UniFrac, R2 =0.03, F=0.75, P=0.76). Relative abundance showed increasing 
trends in Prevotella and Ruminococcaceae at 12 months compared to baseline 
and reduced trends of Streptococcus and Bacteroides at 12 months compared to 
baseline (Figure 7.2.3.1). At 24 months, PERMANOVA analysis did not detect 
any differences in overall fecal microbiota composition between azithromycin and 
placebo groups based on weighted (R2 =0.005, F=0.24, P=0.97) and unweighted 
(R2 =0.015, F=0.79, P=0.73) UniFrac distances and comparison of microbiota 
composition by number of treatment rounds within the azithromycin arm showed 
no effect based on weighted UniFrac distances (PERMANOVA, R2 =0.24, 
F=1.54, P=0.095) and unweighted UniFrac distances (PERMANOVA, R2 =0.07, 
F=0.83, P=0.81). However, a comparison of fecal microbiota composition 
between baseline and 24-month fecal samples within the azithromycin group 
showed significant differences based on unweighted UniFrac distances 
(PERMANOVA, R2 =0.1, F=5.09, P=0.001 and PCoA, Figure 7.2.3.2 A) and 
weighted (PERMANOVA, R2 =0.1, F=5.1, P=0.001 and PCoA, Figure 7.2.3.2 B).  
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Figure 7.2.3.1 Relative abundance of genera in baseline and 12-month fecal 
samples within the azithromycin group. Only shows the 9 most abundant genera are 
shown. The remaining genera were grouped as “Other”. 
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Figure 7.2.3.2 Overall fecal microbiota composition differences between baseline 
and 24-month fecal samples in the azithromycin arm.  (A) PCoA plot of unweighted 
UniFrac distances and (B) PCoA plot of weighted UniFrac distances. In both A and B, 
PCo1 explained the most variation and baseline fecal samples clustered in the negative 
space of PCo1 while 24-months fecal samples clustered in the positive space of PCo1. 
 
Taxa relative abundances of fecal samples collected at baseline and 24 months, 
within the azithromycin and placebo groups, were compared and visualized using 
stacked bar plots at phylum and genus levels. Crude comparisons of taxa relative 
abundance at the phylum level showed a higher relative abundance of 
Bacteroidetes in the 24-month fecal samples compared to baseline samples 
[median (25th,75th quartile) of 0.38 (0.31,0.45) at 24 months vs 0.21 (0.08,0.40) 
at baseline, Wilcoxon P=0.004] while Actinobacteria was shown to be more 
abundant in fecal samples collected at baseline in both the azithromycin [median 
(25th ,75th quartile) of 0.08 (0,0.47) at baseline vs 0.01 (0,0.02) at 24 months, 
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Wilcoxon P=0.014] and placebo groups [median (25th ,75th quartile) of 0.14 
(0,0.31) at baseline vs 0.0001 (0.00,0.01) at 24 months, Wilcoxon P=0.001] 
(Figures 7.2.3.3 A and 7.2.3.4 A). At the genus level, Bacteroides was more 
abundant at baseline compared to 24 months in the placebo group (Figure 
7.2.3.4 B). Bifidobacterium and Streptococcus were shown to be more abundant 
in fecal samples collected at baseline compared to 24-month fecal samples while 
genera Prevotella and Ruminococcaceae were more abundant in fecal samples 
collected at 24 months compared to baseline fecal samples in both treatment 
groups (Figures 7.2.3.3 B and 7.2.3.4 B). Age and sex-adjusted generalized 
linear mixed models (with the participant as a random effect) were then used to 
assess the longitudinal differences in the relative abundance of individual genera 
in fecal samples of children who received azithromycin or placebo. The analyses 
showed no significant differences in the relative abundance of Bifidobacterium, 
Streptococcus, Ruminococcus, and Ruminococcaceae between baseline and 24 
months in both treatment arms, however, the interaction between time of sample 
collection and azithromycin treatment was associated with 60% decreased odds 
of Streptococcus abundance at 24 months (odds ratio of 0.4, P=0.008) compared 
to baseline in the azithromycin arm. Additionally, azithromycin treatment was 
associated with 30% increased odds of relative abundance of Prevotella at 24 
months (odds ratio of 1.3, P=0.05) compared to baseline within the azithromycin 
arm. Adding time of sample collection as an interaction term did not make any 
significant difference. Age and sex-adjusted generalized linear mixed models 
(with the participant as a random effect) showed no longitudinal differences in the 
placebo arm. 
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Figure 7.2.3.3 Relative abundance of phyla (A) and genera (B) in baseline and 24-
month fecal samples within the azithromycin group. Figure 7.2.3.3B only shows the 
9 most abundant genera. The remaining genera were grouped as “Other”. 
 
 
 
 
Figure 7.2.3.4 Relative abundance of phyla (A) and genera (B) in baseline and 24-
month fecal samples within the placebo group. Figure 7.2.3.4B only shows the 9 
most abundant genera. The remaining genera were grouped as “Other”. 
 
7.3 Discussion 
 
Page | 158 
 
This study assessed the long-term impact of mass azithromycin treatment on the 
intestinal microbiota. There were no differences in gut microbiota diversity or 
composition between azithromycin and placebo arms at 12 or 24 months. 
However, age and sex-adjusted longitudinal assessments of the gut microbiota 
within the azithromycin arm showed marginal differences in gut microbiota 
composition between baseline and 24-months samples. A higher abundance of 
Prevotella and a lower abundance of Streptococcus were observed at 24-months 
follow-up compared to baseline samples in the azithromycin arm suggesting long-
term azithromycin-related changes in gut microbiota composition. Age and sex-
adjusted longitudinal assessments in the placebo arm did not show any 
significant differences. 
7.3.1 Azithromycin treatment was associated with changes in gut microbiota 
composition at 24-months follow-up 
 
The present study assessed the impact of up to four biannual azithromycin 
administrations on intestinal microbiota diversity and composition. This study did 
not find any effect of up to four biannual azithromycin treatments on microbiota 
diversity, which is consistent with data by Wei et al.219, although the follow-up 
period in the present study was shorter. This study did however find weak 
associations between azithromycin treatment and microbiota composition. 
Azithromycin treatment was weakly associated with increased abundance of 
Prevotella at 24-months follow-up compared to baseline within the azithromycin 
arm while no differences were detected in the placebo arm. While this finding has 
not previously been reported, it is consistent with a recent study that investigated 
the effect of azithromycin on gut microbiota composition and reported an 
increased abundance of Bacteroidetes, the phylum to which Prevotella belongs, 
in children who received macrolides within 6 months preceding samples 
collection compared to untreated controls. Prevotella is a gram-negative 
commensal bacterium found on the mucosal sites of the respiratory tract, the gut, 
and the oral cavity. Reduced abundance of this bacterium has been associated 
with Crohn’s disease in pediatric patients220. Therefore, increased abundance of 
Prevotella at 24-months following azithromycin treatment suggests that long-term 
azithromycin treatment potentially increases the abundance of a bacterium 
beneficial to the gut. Azithromycin treatment was also associated with reduced 
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abundance of Streptococcus at 24-months follow-up compared to baseline when 
the time of sample collection, within the same individual, was considered. The 
reduction in Streptococcus abundance at 24-months follow-up suggests time-
dependent antimicrobial effects of azithromycin. 
One of the limitations of this study was availability of fewer fecal samples 
compared to the total number of children enrolled by MORDOR-Malawi morbidity 
at baseline. The fecal samples included in the analyses were selected based on 
the availability of corresponding baseline and 12 months or baseline and 24-
month fecal samples, which might have been prone to selection bias as a smaller 
number of children at baseline participated in fecal sampling compared to the 
total number of children enrolled.  
7.3.2 Conclusion and future work 
 
This study did not find any long-term impact of up to four biannual azithromycin 
treatments on alpha diversity, however, longitudinal assessment of the gut 
microbiota showed weak long-term associations between azithromycin treatment 
and the abundance of defined taxa that had not been demonstrated before; 
increased relative abundance of Prevotella and reduced relative abundance of 
Streptococcus were associated with azithromycin treatment. The association 
between azithromycin treatment and relative abundance of Prevotella is 
consistent with a previous study showing an increase in abundance of the phylum 
Bacteroidetes, to which Prevotella belongs. Future studies could determine 
whether the increased abundance of Bacteroidetes or Prevotella spp. after long-
term exposure to azithromycin is a result of selective macrolide resistance and if 
there are any subsequent effects on gut health.  
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8. Discussion 
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8.1 No evidence of association between fecal biomarkers of EED and 
growth outcomes in rural Malawian children 
 
In this study, biomarkers of intestinal inflammation (NEO and MPO) and protein-
losing enteropathy or intestinal permeability (AAT) were quantified in fecal 
samples and their associations with growth outcomes were assessed. Two-thirds 
of the children had raised NEO levels and one-third of the children had raised 
fecal MPO concentration. Intestinal permeability or protein-losing enteropathy, 
measured by fecal AAT, was prevalent in approximately 16% of children. The 
biomarkers showed no correlation between themselves and all decreased with 
increasing age. Additionally, children who resided in Namwera had higher levels 
of AAT and MPO compared to children who were resident in Mangochi, Monkey 
Bay, Mankanjira or Chilipa. None of the biomarkers, assessed individually or 
combined, showed a relationship with poor growth outcomes. The differences in 
the proportion of children with raised NEO and children with raised MPO, both of 
which are markers of intestinal inflammation, in addition to lack of correlation 
between biomarkers of intestinal inflammation and intestinal permeability, 
suggests that intestinal inflammation in EED is triggered by independent 
mechanisms and that intestinal inflammation does not always lead to intestinal 
permeability. The lack of a relationship between intestinal inflammation or 
permeability and growth outcomes may suggest that the impact of EED on growth 
impairment is not pronounced in this population. 
8.1.1 Intestinal inflammation in EED is triggered by independent mechanisms 
and does not correlate with intestinal permeability 
 
Elevated levels of fecal NEO or MPO indicate intestinal inflammation, which is 
one of the key features of EED. This study detected a larger proportion of children 
who had raised fecal levels of NEO compared to MPO, indicating variation in pro-
inflammatory responses. NEO is a low molecular weight molecule belonging to 
the chemical group known as pteridines. It is synthesized and released upon 
stimulation of macrophages and dendritic cells with IFN-γ. Thus, elevated levels 
of NEO in the fecal samples indicate increased activity of macrophages and 
dendritic cells, which are part of the mononuclear phagocyte system. Both 
macrophages and dendritic cells are classical antigen-presenting cells; they 
present antigens to major histocompatibility (MHC) molecules thereby activating 
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naïve T cells221. Additionally, macrophages play a key role in clearing apoptotic 
cells, cellular debris and pathogens. The prominence of intestinal inflammation 
indicated by NEO might suggest macrophages and dendritic cells are the primary 
innate immune response in EED in this setting, which is consistent with the 
chronic T cell infiltration observed in EED in other populations3. Conversely MPO, 
which is another biomarker of intestinal inflammation, was elevated in only one-
third of the children. The differences in the proportion of children with higher fecal 
levels of MPO and NEO suggest to the candidate that intestinal inflammation in 
EED is triggered by independent mechanisms. 
  
In serum, AAT makes up the majority of serine protease inhibitors and protects 
tissues from protease damage during inflammation. AAT is synthesized primarily 
in the liver but also to a smaller extent in intestinal macrophages, monocytes, and 
intestinal epithelial cells. Since AAT is relatively resilient to enzymatic digestion, 
its increased levels in fecal samples indicate intestinal protein loss and increased 
mucosal permeability. In this thesis, the proportion of children with raised AAT 
was low suggesting a low proportion of children with a leaky gut. The lack of 
correlation between fecal markers of intestinal inflammation (NEO or MPO) and 
AAT suggests that intestinal inflammation in EED does not always result in 
intestinal permeability.  
8.1.2 No evidence of intestinal inflammation and permeability as prominent 
mediators of growth failure in rural Malawian children 
 
Intestinal inflammation and permeability are some of the key features of EED and 
there is evidence to support associations between fecal markers of intestinal 
inflammation or permeability and growth faltering in some populations53,54,57, 
however, conflicting evidence also exists. George et al. and Campbell et al. did 
not find significant relationships between biomarkers of EED and child growth in 
low-income settings56,163, findings that are similar to data reported in this thesis.  
 
The inconsistent data on the relationship between biomarkers of EED and child 
growth can partially be attributed to differences in study designs. Most of the 
studies that have reported associations between the biomarkers of intestinal 
inflammation or permeability and growth were longitudinal studies conducted in 
children less than 2 years of age and had relatively large sample 
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sizes53,57,161compared to the present study and to other studies that have not 
found these associations56,163. Nonetheless, a study conducted in North-Eastern 
Brazilian children that had a sample size smaller than the present study (n=375) 
reported associations between fecal markers of intestinal inflammation or 
permeability and linear growth in children aged 6 to 26 months54. That study found 
that high fecal levels of MPO and AAT were associated with a reduction in HAZ 
score of 0.15 at 6-months follow-up. Although the associations between the two 
biomarkers and HAZ score were statistically significant, a reduction in HAZ score 
by 0.15 translates to a reduction in height by approximately 0.5 cm222, which is 
marginal. Thus, larger sample sizes may still be a prerequisite to detect significant 
evidence of a relationship between fecal biomarkers of EED and child growth. 
  
Available evidence indicates that the relationship between intestinal inflammation 
or permeability and child growth is plausible53,54. However, EED might not be the 
primary determinant of growth failure in Malawian children given that associations 
between intestinal inflammation or permeability and growth impairment have 
been demonstrated in populations where growth indicators are better compared 
to Malawi 54,131,223. The lack of a link between intestinal inflammation or 
permeability and growth outcomes in Malawian children might also be attributed 
to the presence of other predominant factors that affect child growth such as poor 
maternal nutritional status during pregnancy, diarrheal diseases and poor socio-
economic status224-226, which might mask the effect of intestinal inflammation or 
permeability on growth outcomes.  
8.2 Intestinal bacterial carriage and associations with fecal markers of 
intestinal inflammation or permeability and growth outcomes 
 
Intestinal carriage of Akkermensia muciniphila, Bifidobacterium longum, Dorea 
formicigenerans, and Faecalibacterium prausnitzii in rural Malawian children was 
described using qPCR assay. The associations between intestinal carriage of 
these bacteria and biomarkers of intestinal inflammation and permeability or 
growth were also explored. F. prausnitzii and D. formicigenerans were found to 
be the most prevalent of the bacteria assayed while B. longum was the least 
prevalent bacterium. A. muciniphila was carried by almost half of the children 
studied. Comparisons of bacterial carriage by age, sex, and area of residence 
showed significant differences. Intestinal carriage of B. longum or D. 
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formicigenerans was associated with biomarkers of intestinal inflammation and 
permeability. Additionally, intestinal carriage or relative abundance of B. longum 
or D. formicigenerans were associated with ponderal growth.  
8.2.1 Intestinal carriage of F. prausnitzii and A. muciniphila was not 
associated with fecal biomarkers of intestinal inflammation and 
permeability or growth outcomes 
 
F. prausnitzii is one of the most common intestinal bacteria whose abundance 
has been shown to increase with age176,177. F. prausnitzii has also been identified 
as one of the most important age discriminatory bacterium in low-income 
settings76,168. This thesis found a high prevalence of F. prausnitzii. Additionally, 
prevalence of F. prausnitzii showed a trend that increased with increasing age 
confirming previously reported trends177. However, F. prausnitzii carriage did not 
have any significant effect on biomarkers of EED or growth outcomes.  
 
This study also found carriage of A. muciniphila in almost half of the fecal samples 
tested. A. muciniphila is a recently discovered gram-negative bacterium that 
produces several enzymes that degrade mucin (mucous lining of the gut) 
subsequently providing carbon and nitrogen to other intestinal bacteria178. A. 
muciniphila is said to colonize the intestinal tract early in life and almost reaches 
the level observed in healthy adults within the first year of life, representing 
approximately 1 to 3% of the total microbiota179. The abundance of A. muciniphila 
has been strongly associated with markers of lipid metabolism and negatively 
associated with inflammation in adipose tissue in a mouse model 174 while in adult 
humans, the presence of A. muciniphila has shown an inverse association with 
body weight175,227,228. A study that was conducted to understand the physiological 
roles of A. muciniphila in obesity reported an increase in the expression of 
markers of antimicrobial peptides in A. muciniphila-treated mice indicating 
potential antimicrobial effects229. In the present study, A. muciniphila carriage was 
observed in almost half of the children but was not associated with fecal 
biomarkers of intestinal inflammation, permeability or child growth, therefore, the 
significance of A. muciniphila carriage in this population needs to be further 
investigated.  
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8.2.2 Area of residence was associated with intestinal inflammation or 
permeability and prevalence of A. muciniphila carriage 
 
This thesis found associations between geographic location and fecal levels of 
AAT and MPO. Fecal samples of children from Namwera had higher levels of 
AAT and MPO compared to the other 4 geographic locations. The higher levels 
of fecal biomarkers shown in children from Namwera could be explained by 
geographical and / or climatic factors that subsequently contribute to poor 
sanitation and hygiene. Namwera lies at a higher altitude compared to Mangochi, 
Monkey Bay, Makanjira and Chilipa and generally experiences more rainfall 
compared to the other 4 locations230,231. Higher rainfall allows rapid spread of 
enteropathogens232 whose carriage in children from similar settings has been 
associated with raised AAT, MPO and NEO57. 
 
This thesis also found differences in the prevalence of A. muciniphila carriage by 
geographic location. A smaller proportion of children who resided in Mangochi 
carried A. muciniphila compared to children from the other 4 locations. Mangochi 
is a peri-urban setting compared to the other 4 rural locations. Children in 
Mangochi might have had access to cleaner water and improved sanitation 
compared to the rest of the children. Nonetheless, this thesis did not assess the 
socio-economic status of these children as such, the candidate can only postulate 
that socio-economic status affects intestinal carriage of A. muciniphila. 
8.2.3 Unexpected association between fecal carriage of B. longum and raised 
fecal markers of EED or lower WAZ scores in Malawian children 
 
In this thesis, B. longum was the least prevalent intestinal bacterium of the four 
assayed and its carriage was primarily found in fecal samples of children aged 
between 1 and 12 months. This supports data from previous studies that 
indicated early colonization of B. longum in the human gut 64,68,181. Since B. 
longum is more abundant during the first 18 months of human life181, the lower 
proportion of fecal samples positive for B. longum, in comparison to other studies, 
likely reflects the small number of young infants who were included in this study. 
Less than one-third of the children included in this study were ≤12 months old. B. 
longum carriage was also associated with elevated levels of fecal AAT, MPO, 
Page | 166 
 
and NEO. Correspondingly, fecal levels of AAT, MPO, and NEO were elevated 
in children aged between 1 and 12 months compared to older children in this 
thesis. The higher abundance of B. longum in younger infants has been attributed 
to breastfeeding; B.  longum is said to be present in human breast-milk182,183. 
Additionally, breastfeeding has been associated with high fecal levels of AAT and 
MPO in low-income settings161. Therefore, the association between B.  longum 
carriage and fecal levels of AAT, MPO, and NEO could be due to residual 
confounding by breastfeeding and not necessarily an effect of B.  longum 
carriage. Breastfeeding status was not assessed in this thesis. Adjusting for age 
in the analyses should have mitigated for confounding by breastfeeding given the 
association between age and breastfeeding. However, age stratified analysis on 
the associations between B. longum carriage and the biomarkers showed 
significant associations for the age groups less than 2 years highlighting a 
potential effect of breastfeeding; most children of this age group consume 
breastmilk in this population131. 
 
Intestinal carriage of B. longum was associated with lower WAZ scores while the 
increased relative abundance of B. longum was associated with better WHZ 
scores. The relationship between B. longum carriage and lower WAZ score is 
surprising considering that B. longum is widely associated with good health. To 
date, there is no available data indicating the relationship between the presence 
or absence of B. longum in the gut and ponderal growth in humans. Considering 
that there was a positive relationship between the relative abundance of B. 
longum and WHZ scores, the candidate suggests that analyses focusing on just 
absence or presence of bacteria can yield different results from analyses that 
take into account bacteria load. Moreover, Subramanian et al. found a lower 
relative abundance of the genus Bifidobacterium in Bangladeshi children with 
poor WHZ compared to children with better WHZ168, which is consistent with the 
relationship between the relative abundance of B. longum and WHZ reported in 
this thesis. These results, therefore, suggest a potential role of B. longum in 
ponderal growth and offers insight on the discrepancies different analyses might 
have. The lack of firm evidence on the effects of B. longum carriage or relative 
abundance on growth in the human population leaves room for uncertainty as 
such the association between B. longum carriage and WAZ should not be ignored 
but rather investigated further. 
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8.2.4 Intestinal carriage of D. formicigenerans is potentially associated with a 
healthy gastrointestinal tract 
 
D. formicigenerans was reported as the second most prevalent bacterium of the 
bacteria tested in this thesis and its carriage was higher in older children than 
younger children. D. formicigenerans is a gram-positive obligate anaerobic 
bacterium that is known to produce large amounts of formic acid from 
carbohydrate fermentation233. Formic acid is one of the organic acids whose 
supplementation in poultry feeds has been associated with beneficial effects on 
poultry performance, immunity and gut health via reduction of intestinal bacterial 
infections234,235. The high prevalence of D. formicigenerans carriage in rural 
Malawian children and its association with normal fecal levels of AAT, MPO, and 
NEO indicate the potential of this bacterium to have anti-inflammatory effects in 
the human gut and also suggests other beneficial effects this bacterium might 
have on gastrointestinal health.  
8.3 The gut microbiota of children with signs of EED differs from that 
of children without these signs 
 
The gut microbiota in children with and without signs of EED was characterized 
through sequencing of the bacterial 16SrRNA gene and quantification of the 
biomarkers of EED in fecal samples. There was no association between gut 
microbiota diversity and AAT or MPO nor was there a relationship between gut 
microbiota diversity and composite EED score. However, there was a negative 
association between fecal microbiota diversity and fecal concentration of NEO. 
Comparison of bacterial community composition between normal and elevated 
biomarker concentration showed no significant differences, but significant 
differences were found between low and high composite EED score. These 
results highlight the potential role of the gut microbiota in EED development. 
  
8.3.1 Increase in microbiota diversity is associated with reduced intestinal 
inflammation 
 
To date, there is no data available supporting the relationship between fecal 
microbiota diversity and intestinal inflammation in EED. However, available 
evidence from IBD studies suggests an association between intestinal 
inflammation and reduced intestinal microbiota diversity213,236,237, which is similar 
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to what has been reported in this thesis. These results, therefore, show 
consistency in the relationship between increased fecal microbiota diversity and 
reduced intestinal inflammation suggesting a potential role of the gut microbiota 
in modulating inflammatory responses. In this thesis, an increase in gut 
microbiota diversity was associated with low levels of NEO, which suggests that 
high microbiota diversity modulates innate immune responses by downregulating 
macrophage or dendritic cell activity.  
 
Findings from this thesis support existence of a link between gut microbiota 
diversity and intestinal inflammation that has also been reported in IBD studies. 
However, EED and IBD are different conditions and therefore the mechanisms 
behind such a link should be different for the two conditions. In IBD, there has 
been a debate regarding what comes first between changes in gut microbiota 
diversity or intestinal inflammation. Sepehri and colleagues suggested that the 
reduction in microbiota diversity is a consequence of intestinal inflammation 
triggered by enteropathogens238. This suggestion would, therefore, indicate that 
gut microbiota diversity increases in the absence of enteropathogens.    
8.3.2 The intestinal bacterial community composition in children with low and 
high composite EED scores is different 
 
There is limited data indicating associations between intestinal bacterial 
community structure and EED. Recently, Ordiz et al. found differences in 
intestinal bacterial composition between children with increased and normal 
levels of intestinal permeability measured by the L:M ratio test59. At phylum level, 
Proteobacteria was significantly reduced in children with increased intestinal 
permeability compared to children with normal levels while prevalence of genera 
Megasphaera, Mitsuokella, and Sutterella was higher in children with increased 
intestinal permeability compared to children with normal levels. 
Succinivibrio, Klebsiella, and Clostridium_XI were less prevalent in children with 
increased intestinal permeability compared to children with normal levels. 
Similarly, this thesis found an association between higher abundance of 
Succinivibrio and low composite EED score. To date there are no other studies 
that have characterized the gut microbiota in EED using the composite EED 
score. The consistency in the association between Succinivibrio abundance and 
EED indicates the potential role of Succinivibrio in improving EED.  
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Succinivibrio is a gram-negative anaerobic commensal of the human colon that 
is normally present in low abundance239,240. Succinivibrio is a genus of phylum 
Proteobacteria and has two species, Succinivibrio amylolytica, and Succinivibrio 
dextrinosolvens. The abundance of these species differs depending on the diet. 
S. amylolytica is found in high abundance in the rumen of livestock that are fed 
diets consisting of hay and grain while S. dextrinosolvens is found in higher 
abundance in the rumen of livestock fed a starch-rich diet or other diets that 
include large quantities of fermentable carbohydrates241,242. Succinivibrio has not 
been extensively studied but its higher abundance in the bovine rumen has been 
associated with fiber-degradation214. Interestingly, high abundance of this 
bacterium has been shown in the fecal microbiota of rural African children, 
consuming a diet rich in fiber and non-animal protein88 emphasizing the role of 
this bacterium in fiber degradation. Fiber degradation by anaerobic bacteria 
produces SCFAs whose supplementation in poultry feeds has been associated 
with a reduction of intestinal bacterial infections234,235. Drawing from this, the 
candidate hypothesizes that the higher abundance of Succinivibrio in the gut 
inhibits colonization by enteropathogens thereby improving signs of EED. Thus, 
Succinivibrio is potentially beneficial to gut health.  
8.4 Long-term treatment with azithromycin was weakly associated 
with Prevotella abundance 
 
This study assessed the long-term impact of azithromycin treatment on the fecal 
microbiota of Malawian children. Azithromycin treatment did not have an impact 
on gut microbiota diversity, however, there was a higher abundance of Prevotella 
at 24-months in azithromycin recipients indicating long-term effects of 
azithromycin treatment on the gut microbiota composition. 
 
Prevotella is a gram-negative commensal bacterium found on the mucosal sites 
of the respiratory tract, the gut, and the oral cavity. The genus Prevotella is a 
member of phylum Bacteroidetes, which includes other clinically relevant genera 
such as Bacteroides and Porphyromonas. Although emerging evidence from 
murine studies has implicated Prevotella copri in experimental colitis243, reduced 
relative abundance of Prevotella has been reported in pediatric Crohn's disease 
in humans220. Drawing from the latter finding, together with the findings of this 
thesis, the candidate suggests that the increase in the abundance of Prevotella 
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following long-term azithromycin treatment is potentially beneficial to human gut 
health. Interestingly, these findings are not consistent with findings by Korpela 
et.al. who reported increased abundance of phylum Bacteroidetes, to which 
Prevotella belongs, in children who had used macrolide antibiotics within 6 
months of sample donation but found no impact in children who had used the 
antibiotics longer than 6 months127. This inconsistency suggests that either the 
long-term impact of azithromycin treatment on phyla and genera are different or 
that the long-term effect of azithromycin treatment on gut microbiota composition 
varies depending on other factors, such as geography and socio-economic 
status. The study by Korpela et al. was conducted in a high-income European 
setting.  
8.5 Limitations 
8.5.1 Reference values for normal or raised fecal biomarkers of EED in low-
income settings and the composite EED score 
 
Reference values of fecal AAT, MPO, and NEO in low-income settings have yet 
not been established, as such the adoption of Western values was the only 
available option. However, the available Western reference values reported in the 
literature for some of the fecal biomarkers have been determined from adult IBD 
studies244. IBD is strikingly a different condition from EED and fecal levels of these 
markers in adults might be different from children as trends of these markers have 
been shown to decrease with increasing age161. Also, the trends of these 
biomarkers in Western populations might vary from populations in low-income 
settings. Therefore, the adoption of the Western reference values in this study 
might have undermined or exaggerated the magnitude of intestinal inflammation 
or permeability reported in this thesis. However, this thesis did not find 
associations between the uncategorized concentration values and growth 
suggesting that the use of these reference values might not have adversely 
affected the association between categorized fecal biomarkers of EED and child 
growth in this thesis.  
 
This study also used the composite EED score to indicate EED in chapters 4, 5 
and 6. Despite the significant associations the composite EED score has shown 
with growth in the previous studies53,56, the use of the composite EED score has 
yet to be validated. Therefore, the associations between fecal microbiota and 
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composite EED score reported by this study might not be a true reflection of what 
occurs in EED. However, the observation that high abundance of Succinivibrio 
was associated with low EED score in this thesis is consistent with findings from 
a recent Malawian study that found a higher abundance of Succinivibrio in 
children with normal levels of intestinal permeability59. This conformity somewhat 
underscores the validity of the composite EED.  
 
8.5.2 Use of commercial kits to describe the intestinal bacterial carriage 
 
Chapter 5 described intestinal carriage of B. longum, D. formicigenerans, A. 
muciniphila, F. prausnitzii and explored their associations with growth or fecal 
biomarkers of EED. Use of commercial qPCR kits to describe the prevalence of 
bacterial carriage limited the number of bacterial targets studied, as primers and 
probes for other targets that could have been included in the study were not 
commercially available. Clostridium butyricum for example is one bacterium that 
has been associated with growth in a mouse model and its inclusion in the study 
would have been valuable, but its qPCR assay was not commercially available. 
Nevertheless, using the few targets that were available, this study showed 
associations between individual bacteria and biomarkers of EED or child growth 
suggesting that commercial assays can be conveniently used to study intestinal 
bacteria in settings where bacterial 16S rRNA gene sequencing platforms cannot 
be easily accessed. 
 
The lack of standards in the available commercial qPCR kits made absolute 
quantification of each bacterium impossible. Absolute bacteria quantification 
would allow comparative analyses of total number of bacteria versus absence or 
presence of bacteria. However, the use of the published bacterial quantification 
PCR assay allowed relative quantification of each bacterium and offered insight 
into the differences that may be present in an analysis that is centered on the 
relative number of bacteria versus analysis that focuses solely on the presence 
or prevalence of the bacterium. 
8.5.3 Lack of data on risk factors for EED 
 
This study opportunistically utilized fecal samples from a study that was designed 
to investigate the impact of azithromycin on childhood morbidity and as such did 
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not have data on other factors that influence fecal levels of AAT, MPO and 
intestinal bacterial colonization such as data on breastfeeding status, access to 
water, sanitation and hygiene. Human breast milk has been associated with high 
levels of fecal AAT and MPO161 and a higher abundance of Bifidobacterium191. 
The relationship between breastfeeding and higher levels of fecal MPO or AAT 
or high abundance of Bifidobacterium can be attributed to the presence of the 
biomarkers164 or Bifidobacterium in the human breast milk182,183. The higher 
levels of AAT, MPO, and NEO observed in younger children compared to older 
children in this thesis indicate that breastfeeding might have contributed to the 
higher levels of fecal AAT, MPO and NEO observed in young children since most 
Malawian children, like children in other populations, consume maternal breast 
milk together with other complementary foods into the second year of life131. 
Therefore, the absence of data on the breastfeeding status of the children 
included in this study might have led to residual confounding resulting in the 
unusual associations between intestinal carriage of B. longum and raised AAT, 
MPO or NEO. Adjusting for breastfeeding status in analyses involving fecal levels 
of AAT, MPO and NEO has been previously recommended161. However, given 
the clear association between breastfeeding and age, adjusting for age in the 
analyses should have mitigated for potential confounding by breastfeeding 
status.  
 
Access to potable drinking water, living in poor sanitary conditions and 
consumption of unhygienic foods are some of the suggested risk factors for 
EED94. A recent study in South-Western Uganda reported an association 
between unsafe drinking water and EED in young children. Children from 
households with unsafe drinking water had higher levels of intestinal permeability 
compared to children from households with safe drinking water245.  Another study 
that assessed the relationship between environmental contamination and EED in 
rural Bangladeshi children reported associations14. Here, children from clean 
households had lower levels of intestinal permeability and microbial translocation 
compared to children from contaminated household environment. Additionally, 
children from clean households had a lower prevalence of parasites tested 
compared to children from contaminated household environment. Parasites, 
which are some of the suggested exposures in EED etiology, have been 
associated with biomarkers of EED and growth faltering in low income settings57. 
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The lack of data on access to safe drinking water, improved sanitation and 
hygienic practices limited a more informative analysis that could have been 
conducted to better explore some of the associations reported in this study.  
8.5.4 Use of 16S rRNA gene sequencing 
 
One challenge in 16S rRNA gene sequencing approach is the presence of 
contaminants introduced either during sample collection or during processing in 
the laboratory. It is usually recommended as good practice to include reagent-
only controls during 16S rRNA gene sequencing processes as a way to check 
reagent contamination. In this thesis, the extraction controls for each batch of 
DNA isolation reagents used and environmental controls were included during 
the isolation of DNA from the samples. Non-template controls were also included 
during library preparation. The controls were sequenced together with the 
samples and bacterial sequences were detected in the controls. The presence of 
bacterial sequences in the controls is not surprising as commercial reagents 
(extraction kits, primers, and polymerases) are known to contain microbial DNA 
contaminants, which vary in amounts from one batch to another246 and common 
laboratory contaminants have been reported to be present in processed 
samples247. To date, there is no consensus on how to deal with sequences 
identified as environmental or reagent contaminants. Some authors suggest 
subtracting the “contaminant” sequences, but this is not appropriate as some of 
the OTUs found in the controls can genuinely be found in samples, therefore, 
their removal can affect the interpretation of the data.  
To reduce the impact of potential contaminants on fecal microbiota diversity and 
composition, samples with >1000 total reads were retained and from these, only 
bacterial OTUs identified to the genus level, with sequences more than 0.005% 
of the total number of sequences143 and a frequency of more than 0.01% in any 
sample were kept. Additionally, OTU data was rarefied to 1000 reads with 1000 
permutations before calculating diversity indices and determining bacterial 
community differences between samples or was normalized by cumulative sum 
scaling (CSS) before performing univariate analysis with individual taxa144,145. 
Another challenge with partial-full length 16S rRNA gene sequencing is that its 
resolution is generally limited to the genus level making it impossible to perform 
comprehensive microbiota analyses at the species level, which would be more 
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informative. Additionally, 16S rRNA gene sequencing as used here targets a 
limited number of variable segments of the 16S gene that are present in bacteria 
and archaea. As such, even full length 16S rRNA gene sequencing is not 
representative of all constituents of the microbiota such as viruses, protozoa and 
fungi. Whole genome shotgun sequencing is an alternative sequencing approach 
that has greater taxonomic resolution, and the ability to infer functional profiling 
and cross-domain coverage, however, this sequencing approach is more 
expensive and requires greater computational power and analysis. 
8.5.5 Study design 
 
This PhD project utilized a platform provided by the MORDOR-Malawi study, 
which was designed to test hypotheses different from this PhD thesis. The fecal 
samples, demographic and anthropometric data available to this PhD project, 
through the MORDOR-Malawi platform, were collected cross-sectionally. Some 
of the challenges with cross-sectional studies are that they do not help with 
evaluating cause and effect and, the timing of a sampling is not assured to be 
representative. Nonetheless, this thesis reported associations some of which are 
consistent with findings reported by longitudinal studies.  
As this PhD thesis used fecal samples originally collected for other purposes, the 
sample volumes remaining to this PhD project were not always sufficient to carry 
out all the desired tests. As such, some samples were tested for all the 
biomarkers while other samples were only tested for one or two biomarkers giving 
rise to missing data. Missing data can introduce bias, make data handling and 
analysis more difficult, and can reduce power. One way of alleviating problems 
caused by missing data is conducting data imputation. However, data imputation 
can reduce variance and distort relationships between variables, and was not 
done for this PhD thesis. Another limitation that arose from the opportunistic use 
of MORDOR-Malawi fecal samples and data was the smaller sample sizes 
available for various objectives. Smaller sample sizes might have lowered the 
statistical power to establish associations between biomarkers and growth 
outcomes, or to detect pronounced differences in intestinal microbiota between 
treatment groups. 
8.6 Future work 
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8.6.1 Understanding the significance of D. formicigenerans, Succinivibrio, and 
Prevotella in gut health 
 
Future studies should explore the significance of intestinal carriage of D. 
formicigenerans, Succinivibrio and Prevotella and other potentially beneficial 
bacteria such as Bifidobacterium in humans. The studies should aim to 
demonstrate whether intestinal carriage of these bacteria protects against 
colonization by enteropathogens thereby reducing intestinal inflammation or 
permeability. PCR assays that can test a panel of up to 40 enteropathogens in a 
single sample and individual PCR assays for some of the putatively beneficial 
bacteria are commercially available, therefore, conducting such studies should 
not be very challenging. Such studies would uncover potential probiotic 
candidates for EED therapy in addition to providing knowledge on the specific 
enteropathogens that need to be targeted by EED interventions. 
 
In vitro and in vivo studies can also be used to understand the specific 
mechanisms through which the abundance of D. formicigenerans, Succinivibrio 
and Prevotella influence gut health. These bacteria are commonly found in the 
colon of populations consuming a plant-rich diet, a good source of fiber.  Fiber-
degradation by anaerobic bacteria in the colon produces SCFAs. Previous 
studies of probiotics and studies of organic acid supplementation in animals have 
utilized colonic or epithelial cell-lines to understand the effect of certain bacteria 
on intestinal inflammatory responses or gut health in general. Future studies 
could therefore isolate strains of D. formicigenerans, Succinivibrio, Prevotella, 
Bifidobacterium and culture these isolates in colonic or epithelial cell-lines 
colonized with enteropathogens to explore whether the metabolites produced 
from fiber-degradation promote gut integrity by preventing enteropathogen 
colonization via direct killing of enteropathogens or by out-competing pathogenic 
bacteria for nutrients. Such studies could also demonstrate if different strains of 
the beneficial bacteria have varying effects on gut health.  
8.6.2 Establishing reference values for fecal AAT, MPO, and NEO in low-
income settings 
 
To develop reference values for biomarkers of EED, studies would need to recruit 
children from different geographic regions representing low-income settings. 
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Recently, a multi-site study was implemented to investigate associations between 
EED and growth in infants from low-income settings of South Asia, Latin America, 
and Sub-Saharan Africa248. This study measured fecal levels of AAT, MPO, and 
NEO. The data collected by this study, therefore, presents an opportunity to 
develop reference values for fecal AAT, MPO, and NEO in children living in low-
income settings. 
8.6.3 Validity of the composite EED score 
 
The composite EED score has been previously shown to predict linear growth 
deficits in infants53. This thesis found an association between low composite EED 
score and higher abundance of Succinivibrio, which is consistent with recent 
findings that used different biomarkers of EED59 underscoring the potential of the 
composite EED score to indicate EED disease activity. Nevertheless, the use of 
this score in EED has not been properly validated. Therefore, future studies 
should aim to validate the composite EED score using “gold standard” tests. 
Endoscopy or biopsy would be the ideal tests to use to validate this score, 
however, these tests are invasive as such cannot be implemented in 
asymptomatic participants. L:M ratio tests, which have correlated well with 
histopathologic changes in EED, could therefore be used as an alternative to 
validate the use of this score. Studies should also assess if the composite score 
is optimal with only the three biomarkers (NEO, MPO, and AAT) or if markers of 
other processes of EED can be incorporated in the score. Alpha-1 acid 
glycoprotein (AGP) is a marker of systemic inflammation that has been strongly 
associated with growth faltering in low-income settings57 as such its incorporation 
into the composite EED score could improve the utility of the score.   
8.7 Summary 
Almost two-thirds of rural Malawian children had elevated NEO, while MPO was 
raised in one-third of the children and AAT was elevated in less than one third of 
the children making it the least elevated biomarker, of those tested, in this 
population. Consistent with previous findings, biomarker levels were significantly 
higher in younger children compared to older children. There was no association 
between biomarkers of EED (individually or as a composite score) and growth 
impairment suggesting that EED is not the main driver of growth impairment in 
this population.  
Page | 177 
 
 
F. prausnitzii and D. formicigenerans were found to be the most prevalent 
bacteria, of those assayed for, in children; F. prausnitzii was present in almost all 
fecal samples while D. formicigenerans was present in over two-thirds of the fecal 
samples tested. Both bacteria were more prevalent in older children compared to 
younger children, which is similar to previous findings. In contrast, B. longum was 
present in just over one-third of the fecal samples making it the least prevalent 
bacteria assayed. Additionally, intestinal carriage of B. longum differed by age; 
higher prevalence of the bacterium was observed in younger children compared 
to older children. Intestinal carriage and relative abundance of B. longum were 
associated with elevated individual biomarker concentration and high composite 
EED scores, which is unusual. Additionally, intestinal carriage of B. longum was 
associated with lower WAZ while increased relative abundance of this bacterium 
correlated with an increase in WHZ suggesting a potential role of individual 
bacteria in ponderal growth in humans. Intestinal carriage of D. formicigenerans 
was associated with normal biomarker concentration suggesting a beneficial role 
of this bacterium in gut health.  
Fecal microbiota diversity was weakly associated with reduced fecal 
concentration of NEO indicating a link between increased fecal microbiota 
diversity and reduced intestinal inflammation. There were significant differences 
in fecal microbiota composition between low and high composite EED scores 
suggesting perturbations in overall gut microbiota composition in EED. 
Azithromycin treatment was not associated with fecal microbiota diversity, but 
was weakly associated with relative abundance of Prevotella at 24-months follow-
up suggesting potential long-lasting effects of azithromycin on the abundance of 
defined bacterial taxa but not overall microbiota diversity. 
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